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General introduction
Rheumatoid arthritis (RA) is a quite common autoimmune disease, also affecting pregnant 
women. The impact of RA during pregnancy on mother and child is largely unknown. 
This introduction will first provide knowledge on RA in general, around pregnancy and 
during lactation. Next, a description will be given on the developmental origins of health 
and disease (DOHaD) hypothesis, which contributes to the explanation of the impact of 
RA during pregnancy on the child. Furthermore, the role of cortisol and epigenetics (in 
particular DNA methylation) within this hypothesis will be summarized. This will be followed 
by a description of the designs of the studies. Finally, the aims of this thesis will be described 
as well as its outline. 
1.1 RHEUMATOID ARTHRITIS 
RA is a disease characterized by a chronic, systemic inflammation and the presence of the 
autoantibodies1, affecting synovial membranes of joints, which can lead to significant joint 
destruction2. The prevalence of RA ranges from 0.5 to 2%, mostly affecting women between 
40 and 50 years2, yet also often during fertile age3. 
It is being thought that the development of RA is a complex interaction between a high-
risk genetic profile in combination with environmental exposures (e.g. cigarette smoking4) 
and epigenetic changes5. Although RA is predominantly an articular disease, approximately 
50% of the patients develop some kind of “extra articular manifestations” (EAMs) associated 
with the disease2, 6. EAMs include involvement of the skin, eyes, cardiovascular system, lungs, 
and nervous system2. The presence of the RA related autoantibodies rheumatoid factor (RF) 
and anti-citrullinated protein antibody (ACPA) is associated with more progressive joint 
damage and more severe EAM7. 
1.2 PREGNANCY AND RA
1.2.1 Fertility
Multiple studies have shown that fertility in female patients with RA is impaired8-12. Women 
with RA have a prolonged time to pregnancy (TTP), have a smaller family size and are more 
likely to receive fertility treatment12, 13. In the past, it had been hypothesized that impaired 
fertility in RA is due to a smaller ovarian reserve14, which might already be present before 
diagnosis. At diagnosis, the levels of anti-Müllerian hormone (AMH), a biomarker for ovarian 
reserve, are not different in premenopausal in women with RA versus healthy controls15. 
However, AMH levels in patients with RA decline more rapidly over time compared to 
healthy controls, indicating that RA might have a negative impact on the ovarian reserve16.
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A longer TTP in female patients with RA has been associated with older age, nulliparity, 
higher RA disease activity, and the use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 
and prednisone (>7.5 mg/day) before conception12.
1.2.2 The effect of pregnancy on RA
In 1938, Hench17 was the first who described the spontaneous improvement of RA during 
pregnancy and the flare postpartum. Since then, research on pregnancy and RA increased 
in popularity, however there are still limited numbers of prospective cohort studies within 
this field of research. Multiple retrospective8, 18-25 and some prospective studies26-31 reported 
the pregnancy related improvement of RA disease activity and the postpartum flare. Initially, 
higher improvement rates around 90% were reported, but in the more recent prospective 
studies these rates were around 50%32. Discrepancies between studies are probably 
caused by differences in study design, patient selection, and definitions of improvement32. 
Especially patients who do not express the autoantibodies RF and ACPA are more likely 
to improve during pregnancy33. Although RA disease activity decreases in approximately 
half of the patients, the mean improvement is limited, and only a small number of patients 
achieves remission during pregnancy30, 31. 
The pregnancy-associated improvement of RA and the flare of the disease activity 
postpartum is thought to be the result of multiple immunological and hormonal changes34. 
One of the theories behind this phenomenon is the shift of T helper (Th) cells from a 
pro-inflammatory Th1 to an anti-inflammatory Th2 profile during pregnancy35. Another 
theory is the influence of female sex hormones on RA disease activity, since pregnancy is 
associated with changes in estrogen and progesterone levels36, 37, RA is more prevalent in 
women compared to men38, and oral contraceptives have a protective effect on the onset 
of rheumatoid arthritis39. 
1.2.3 The effect of RA on pregnancy and outcome
RA is thought to impair pregnancy outcome, although not to that extend that has e.g. been 
described for Systemic Lupus Erythematosus(SLE)40. 
Some studies41, 42, but not all43, have shown that the risk of preeclampsia is slightly 
increased in RA. In addition, women with RA have an increased risk of a cesarean section, 
especially if the disease activity is higher32, 43. Furthermore, the risk of preterm delivery is 
increased in female patients with RA41, 42, especially if they have higher RA disease activity 
during pregnancy44. Also, the use of prednisone during pregnancy is associated with a 
shorter gestational age43. 
Fortunately, female patients with RA do not have an increased risk of offsprings with 
congenital malformations or perinatal death41, 45, and the risk of a miscarriage is comparable 
with the general population46. 
Children born to women with higher RA disease activity have a lower birth weight, 
although still within the normal range, even when correcting for gestational age43, 47. Those 
children also show rapid catch-up growth in weight, defined as a weight gain standard 
deviation score (SDS) of >0.5 during the first 3 months in infants with a weight gain of >0.67 
SDS in the first year of their life43, 47. The effect of RA on pregnancy outcome might have 
lifelong consequences for the offspring, since a lower birth weight in combination with 
rapid catch-up growth in weight is associated with future metabolic and cardiovascular 
disease48, 49. 
1.2.4 Lactation and RA
In the World Health Organization’s (WHO’s) infant feeding recommendation it is advised 
that infants should be exclusively breastfed for the first 6 months of life in order to achieve 
optimal growth, development and health. After those 6 months, breastfeeding should be 
continued for up to two years of age or beyond50. These recommendations are based on 
the fact that breast milk, which is a completely personalized nutrition source, has multiple 
beneficial effects for mother and child51. Breastfed children have a lower risk of Sudden 
Infant Death Syndrome(SIDS)52, infectious diseases53, diabetes53, obesity, high cholesterol or 
high blood pressure in adulthood54, 55. In addition, breast milk might be able to modulate 
imprinting events during the first months of life in terms of development of the immune 
system and susceptibility to mainly immune-mediated diseases, resulting in long-term 
effects for the offspring51. Besides the numerous benefits in general, breastfeeding is 
associated with additional beneficial effects for premature infants in terms of a decreased 
risk of sepsis, meningitis and retinopathy, and improved neurodevelopmental outcomes53. 
There have not been many studies on lactation in female patients with RA. It’s not 
known if women with RA breastfeed their offsprings more or less often compared to 
healthy mothers. In addition, only one prospective study56 has focused on the postpartum 
flare in relation with lactation. They showed that first-time breastfeeding RA patients had 
higher disease activity within 6 months postpartum, even after correcting for treatment, 
compared to patients with RA who had breastfed before and patients with RA who were 
not breastfeeding56. Given the previous conflicting results on breastfeeding and the onset 
of RA, more studies are required to draw any firm conclusions on the relationship between 
breastfeeding and the risk of a postpartum flare. 
1.2.5 Treatment of RA during pregnancy and lactation
Treatment of RA during pregnancy is challenging. On one hand disease activity needs to 
be suppressed in order to improve health and to achieve better outcomes for mother and 
child. On the other hand medication with possible harmful side effects for the offspring, like 
methotrexate and leflunomide, must be avoided during pregnancy57-59. More knowledge 
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on long-term effects of high disease activity and medication use is necessary in order to 
find a balance between accepting higher disease activity versus intensifying treatment. 
Until the first decade of this century it was assumed that RA improved during pregnancy, 
therefore and because of fear for side effects, rheumatologist mostly tried to avoid 
medication as much as possible, but when this was not feasible, treatment was restricted to 
sulfasalazine, prednisone and hydroxychloroquine57. 
The use of Tumor Necrosis Factor (TNF) inhibitors in RA has increased in the last years, 
also during pregnancy. Most safety data are on the use of the TNF inhibitors infliximab and 
adalimumab during early pregnancy. Use during first and second trimester is not associated 
with an increased risk of miscarriages or congenital malformations60. 
At the time the study in this thesis was performed, the use of hydroxychloroquine, 
sulfasalazine, azathioprine, prednisone, and most NSAIDs were considered compatible with 
lactation57. 
1.3 THE DEVELOPMENTAL ORIGINS OF HEALTH AND DISEASE 
Environmental conditions during early life, such as before conception, during pregnancy 
and in infancy may have lifelong consequences61, 62. According to the DOHaD hypothesis, 
first described by Barker63, after intrauterine growth restriction due to (relative) 
undernourishment during pregnancy, either direct (e.g. maternal malnutrition) or indirect 
through placental malfunction (e.g. maternal disease), a child is biologically programmed 
to improve its chances of survival on a low caloric intake48, 64. If, however, after birth the 
nutrient availability is abundant64, the child will show rapid catch-up growth for weight49. 
The combination of lower birth weight with a rapid catch-up growth for weight is associated 
with an impaired glucose tolerance64, a higher fat percentage49 and therefore an increased 
risk for cardiovascular65 and metabolic diseases66 in adulthood. Fetal growth restriction and 
adult onset disease are thought to be linked by epigenetic processes64, 67, 68. The long-term 
consequences of a lower birth weight are irrespective of the cause of this lower birth weight. 
In the Dutch Hunger Winter study, exposure to famine during pregnancy and its long-
term health consequences on the offspring have been explored69, 70. In this study, exposure 
to famine during any stage of gestation was associated with glucose intolerance70, 71. Women 
who were undernourished during mid- to late gestation had offsprings with significantly 
lower weight at birth72, and higher blood pressure in later life70. Babies born to mothers who 
were exposed to famine only during early gestation had normal birth weights. However, 
they had higher rates of obesity and cardiovascular and metabolic disease in adulthood70, 
72. These results demonstrate that the programming of adulthood obesity by intrauterine 
adverse conditions is not always accompanied by lower birth weight72. Notably, in the 
Dutch Hunger Winter study, exposure to famine was restricted to a certain time-period of 
pregnancy, whereas in other studies, exposures are often present from preconception until 
birth. 
Within the DOHaD hypothesis, the placental 11beta-hydroxysteriod dehydrogenase type 2 
(11βHSD2) enzyme plays a key role. Normally, in the placenta 11βHSD2 inactivates maternal 
cortisol73-75, however 10-20% still reaches the fetus76-78. Cortisone can be considered an 
inactive metabolite of cortisol. Reverse metabolism from cortisone to cortisol occurs 
continuously79. Multiple maternal stress factors during pregnancy, like maternal smoking or 
alcohol use, psychological stress, famine/malnutrition, maternal disease, and the presence 
of pro-inflammatory cytokines are known to modulate the expression of 11βHSD2 (Figure 
1).78, 80, 81. In addition, the capacity of 11βHSD2 may be exceeded by the administration of 
glucocorticoids76, 77. Subtle changes in 11βHSD2 activity during pregnancy, resulting in a 
relative deficiency of 11βHSD2, may lead to large glucocorticoid effects on the fetus. 
Figure 1. Factors that influence fetal cortisol concentrations. In (A) the normal physiological situation 
is shown. (B) illustrates the increased cortisol concentrations that reach the fetus because of decreased 
expression of the 11βHSD2 enzyme due to external factors . In (C) is shown that the administration 
of prednisone to the mother results in increased fetal glucocorticosteroids concentrations, namely 
cortisol and prednisolone when both exceed the capacity of 11βHSD2. 
11βHSD2: 11beta-hydroxysteriod dehydrogenase type 2
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1.4 CORTISOL AND PREGNANCY
1.4.1 Glucocorticoids and cortisol 
Cortisol, a glucocorticoid hormone, is the final product of activation of the hypothalamic-
pituitary-adrenal (HPA axis) and regulates among others the glucose and fat metabolism, 
the immune system, and the electrolyte balance82-84. Cortisol is also known as the stress 
hormone because it’s released in higher doses under stressful conditions85, 86. Chronically 
elevated levels of this hormone are associated with an increased risk of cardiovascular and 
metabolic disease87. In the placenta the 11βHSD2 enzyme inactivates maternal cortisol by 
converting it to the inactive form cortisone. In normal situations, maternal cortisol rises 
during pregnancy along with a rise in placental 11βHSD288. Towards the end of pregnancy 
the levels of 11βHSD2 drop, ensuring that the fetus is exposed to sufficient levels of cortisol, 
which are important for e.g. maturation of the fetal lungs88. 
Prednisone is a synthetic glucocorticoid pro-drug that is converted to the active form 
prednisolone in the liver, which supresses the HPA axis activity of the patient89, 90. The 
11βHSD2 enzyme also inactivates prednisolone73-75. Factors known to influence the activity 
of this enzyme, as mentioned in paragraph 1.3 (e.g. maternal smoking, malnutrition, maternal 
disease and pro-inflammatory cytokines) and the administration of glucocorticoids, may 
lead to higher cortisol (and cortisone) concentrations in the offspring, which in turn may 
result in negative effects on the development of the fetal HPA axis48, 89, 91, 92.
Exposure to higher cortisol concentrations in utero are associated with a lower birth 
weight and higher cortisol concentrations in the offsprings due to dysregulation of the fetal 
HPA axis91, 93. In addition, antenatal prednisone exposure in children born to female patients 
with RA is associated with higher daytime cortisol levels81.
1.4.2 Long-term cortisol and cortisone analysis
Suitable matrices to test acute or short-term changes in cortisol include saliva, serum and 
urine. However, due to the circadian rhythm, pulsatile secretion, daily variation and reactivity to 
acute (transient) stress, none of these are useful for long-term cortisol analysis85, 94. Measuring 
cortisol and cortisone in hair is a relatively new, reliable and non-invasive method for long-term 
cortisol analysis95-99. Because hair grows approximately 1 cm per month, a hair sample of 1 cm 
is thought to reflect the mean exposure of free cortisol in 1 month89, 94. Additionally, sampling 
of hair that is taken from the posterior vertex is the most optimal, because the intra-individual 
variation is smallest at that site95, 98. Hair growth patterns vary across different regions of the 
scalp and the posterior vertex region shows the most uniform growth rates100. The mechanism 
of cortisol incorporation into hair is not fully understood. It is assumed that unbound cortisol 
passively diffuses from capillaries into the cells of the hair follicle and becomes deposited 
within the hair shaft73, 95, 99. Another possible mechanism is the incorporation of cortisol 
from sweat or sebum secretions into the hair shaft101. There is a wide consensus that the 
first proximal 6 cm of hair can reliably reflect cortisol concentrations in the last 6 months. 
Exogenous environmental factors, such as frequent hair washing and cosmetic treatments 
decrease cortisol levels in the more distal segments of the hair. Theoretically, the older (distal) 
hair segments are more damaged due to environmental factors and cortisol could escape 
from these damaged hair segments especially during the washing procedures87, 95, 102. 
1.5 EPIGENETICS
Many diseases have a genetic background. The human genome consists of deoxyribonucleic 
acid (DNA), where genetic information is stored. Nucleotides, the building blocks of DNA, 
are composed of a nucleobase (cytosine (C), guanine (G), adenine (A), or thymine (T)), a 
sugar molecule and a phosphate group. 
Genetic variations can be divided into DNA sequence variations, structural/chromosomal 
variations and epigenetic variations. In majority, common variations in DNA sequence are 
caused by single nucleobase substitutions (mutations), that can cause altered protein 
transcription (Figure 2). The term single nucleotide polymorphism (SNP) is used to describe 
mutations that occur relatively frequent in the population. Structural variations affect larger 
segments of DNA or whole chromosomes. 
Epigenetic variations are stable, tissue-specific, environmentally influenced, sometimes 
reversible and to some extent heritable changes in a chromosome without alterations in the 
underlying DNA nucleotide sequence, that can result in altered gene expression103. These 
changes include DNA methylation, posttranslational histone modifications (e.g. acetylation, 
methylation, ubiquitination, phosphorylation) and non-coding microRNAs103. Epigenetic 
regulations are involved in determining gene functions and activities104. 
Although different autoimmune diseases have diverse epidemiology or symptoms, 
they usually have a common origin. Genetic predisposition is involved in the etiology 
and pathology of autoimmune disorders105. Twin studies showed that the contribution of 
genetics to RA is approximately 65%106. However, monozygotic twins, who share an identical 
genetic profile, have a low concordance rate of 12.3% in RA107. Discordance in the onset of 
autoimmune diseases in monozygotic twins suggests that factors other than genetics also 
have a predisposing influence105, 107. The environment plays a large role in determining an 
individual’s phenotype through epigenetic mechanisms107. 
Epigenetics may be seen as a bridge in the gap between genetics and environment 
and can partially explain the discordance of some diseases in monozygotic twins107. 
Epigenetic modifications are believed to be the underlying mechanisms of biological fetal 
programming69, 108-112 explaining the developmental origins of disease. 
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Figure 2. Examples of single nucleobase substitutions, resulting in silent, nonsense and missense 
mutations. Silent mutations are substitutions that result in coding for the same amino acid. Nonsense 
mutations are substitutions that result in coding for a stop codon and missense mutations are 
substitutions that result in coding for another amino acid. 
1.5.1 DNA methylation
Among all the epigenetic mechanisms, DNA methylation is most extensively studied, but 
still not completely understood113. In DNA methylation the DNA sequence is not changed. 
Methylation mostly occurs at the 5’ position on cytosine bases, where a methyl group is 
added to a cytosine converting it to a methyl-cytosine (Figure 3). DNA methyltransferase 
enzymes are responsible for the establishment and maintenance of methylation105, 114. 
This process usually occurs in regions of clustered Cytosine-phosphate-Guanine (CpG) 
dinucleotides, known as CpG islands (CGIs)114, 115. CGIs are mostly found proximal to promoters 
of housekeeping genes115. Changes in DNA methylation include hypermethylation and 
hypomethylation of CGIs114, 115, and the effects these changes on the expression of genes 
depends on the location. Overall, hypermethylated regions block the accessibility of 
transcriptional factors and thereby inhibit gene transcription105. In contrast, regions with 
hypomethylation are accessible for transcription, resulting in enhanced transcription116. 
As mentioned before, during fetal development internal and external factors might have 
critical influences for long-term health. After fertilization, DNA methylation marks from the 
parents are erased by a process of almost full demethylation, with the exception of some 
imprinted genes117. Subsequently, re-establishment of DNA methylation marks occurs with 
de novo methylation, mostly in the first weeks of pregnancy117. In this period, several factors 
like maternal disease68 or malnutrition69, 110, smoking118, folate depletion109 can influence 
DNA methylation of the offspring in utero, resulting in differential expression of genes and 
creating possible long-term adverse effects for the child119. 
Figure 3. DNA methylation of a cytosine. DNA methylation does not alter the DNA nucleobase 
sequence. C illustrates an unmethylated and C* a methylated cytosine. 
1.6 DESIGN OF THE STUDIES
1.6.1 PARA-study
The Pregnancy-induced Amelioration of Rheumatoid Arthritis (PARA) study is a large 
nationwide prospective cohort study conducted in the Netherlands31. The aims were to 
prospectively study the effects of pregnancy on RA and vice versa, including the pregnancy 
outcome. In the PARA-study female patients with RA who fulfilled the 1987 revised criteria 
of the American College of Rheumatology120 and had a wish to conceive or were already 
pregnant were included from 2002 to 200831. Patients were seen at preconception (if 
possible), 3 times during pregnancy and 3 times postpartum in a home-visit. During every 
visit data on mother (e.g. disease activity and medication use) and child (e.g. gestational 
age, birthweight) was collected31. For calculating RA disease activity the Disease Activity 
Score in 28 joints using C-Reactive Protein (DAS28-CRP(3)) was used121. 
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1.6.2 FEPRA-study
A few years after participation in the PARA-study, mothers were asked to participate with 
their children in a follow-up study, the FEtal Programming in Rheumatoid Arthritis (FEPRA) 
study122. Growth charts and information on growth of the children were collected from 
birth and onwards. After reaching the age of 5, 108 children and their parents visited 
the Erasmus Medical Center (MC) Sophia Children’s Hospital in Rotterdam. During this 
visit, anthropometric measurements (e.g. weight, height, blood pressure, waist and hip 
circumference and skin folds) and a Dual-Energy X-ray Absorptiometry (DXA)-scan were 
performed. In addition, saliva samples to measure cortisol and fasting blood samples to 
measure glucose and lipid levels, and to measure DNA methylation were collected122.
1.6.3 HAIR-study
In 2014 the HAIR-study was conducted to study the long-term effects of antenatal 
prednisone exposure in children, aged 5-16 years, born to women with an autoimmune 
disease (primarily RA). Children with antenatal prednisone exposure were compared to 
children without antenatal exposure, all born to women with an autoimmune disorder. First, 
participants of the PARA-study were contacted for inclusion. Second, siblings of participants 
of the PARA-study were included. Finally, children born to women with an autoimmune 
disease from the outpatient clinic at the department of Rheumatology in the Erasmus MC 
were included. Participants were visited at home, where a tuft of hair from the children and 
data from children (weight, height, blood pressure, waist and hip circumference, skin folds) 
and their parents (weight, height, blood pressure) were collected. 
1.7 AIMS AND OUTLINE OF THIS THESIS
In this thesis we have focused more in depth on the impact of RA during pregnancy on 
mother and child. Children born to women with RA have a less fortunate start compared 
to children born to women from the general population. They have a higher risk of lower 
birth weight with a rapid catch-up growth, both risk factors for future diseases. High RA 
disease activity and prednisone use have been shown to be associated with less favorable 
pregnancy outcomes. 
Therefore, one of the main aims of the current study was to identify clinical factors at the 
beginning of pregnancy that could predict women who are more and women who are less 
likely to improve during pregnancy. Identifying those patients will help in clinical practice 
and in future studies to select patients in whom medication may be tapered, continued or 
intensified. 
Another aim was to identify the possible long-term consequences of RA, RA disease 
activity and prednisone use on the offsprings, regarding DNA methylation and long-
term cortisol and cortisone concentrations. Identifying these consequences will help to 
determine the impact of maternal disease on the later-life health of the offspring. 
In addition, since infants with a low birth weight would benefit the most from breastmilk, 
studying lactation in this group of patients, and determining factors associated with 
discontinuation of breastfeeding is important. If we can identify influenceable reasons that 
prevent women with RA from breastfeeding, we might be able to increase the percentage 
and duration of lactation in female patients with RA. 
Chapter 1 introduces the topics described in this thesis. In Chapter 2 multiple aspects on 
RA and pregnancy, from fertilization to outcome, are reviewed. Chapter 3 illustrates RA 
disease activity in two subsequent pregnancies to determine whether the course of the RA 
disease activity in a first pregnancy (during pregnancy and after delivery) is comparable with 
the disease course in a second pregnancy. The objective of Chapter 4 was to determine a 
combination of clinical factors at the beginning of pregnancy, associated with low disease 
activity and remission of RA in the third trimester during pregnancy. Also to identify women 
who are more and less likely to improve during pregnancy. Chapter 5 investigates whether 
children born to women with RA have a different DNA methylation profile compared to 
children born to women from the general population and whether these differences are 
associated with RA disease activity or medication use. Chapter 6 focusses on the long-
term consequences of antenatal prednisone exposure and RA disease activity to investigate 
whether these are associated with chronically elevated cortisol and cortisone levels in 
children born to women with RA. In addition, whether these are associated with a high-risk 
profile for metabolic and cardiovascular disease. Chapter 7 demonstrates the differences in 
frequency and duration of breastfeeding of the offspring in female patients with RA versus 
the general population. Additionally, it demonstrates which clinical factors in the third 
trimester are associated with discontinuation of breastfeeding within 12 weeks. In Chapter 8
we discuss the relevance and clinical implications of the results we’ve found. In Chapter 9, 
an English summary and in Chapter 10 a Dutch summary of the dissertation is provided. 
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ABSTRACT 
Fertility is impaired in female patients with rheumatoid arthritis (RA), which is related to 
disease activity and the use of certain medication. During pregnancy, disease activity 
usually improves, but less than previously thought. Especially in women with high disease 
activity, the pregnancy outcome is also impaired. All of this underscores the importance of 
strict control of disease activity in patients with RA who wish to conceive. 
Management of RA disease activity during pregnancy might be a challenge as the 
treatment options are limited. Evidence is accumulating that tumor necrosis factor (TNF) 
blockers can be safely used during pregnancy, particularly during the first trimester and the 
beginning of the second trimester. 
Far less is known about the problems faced by male RA patients who wish to conceive, in 
terms of not only fertility and pregnancy outcome, but also the safety of medication. 
In this paper, the fertility issues in patients with RA, the pregnancy-associated 
improvement of RA, the pregnancy outcomes, including the long-term effects on the 
offspring, and treatment options, including those during lactation and for male patients 
wishing to conceive, will be reviewed. 
CASE REPORT
Mrs. A, a 41-year-old patient with rheumatoid arthritis (RA), visited the specialized outpatient 
clinic of the Department of Rheumatology for consultation on her wish to conceive. Her 
medical history revealed diabetes mellitus type 1 since the age of 25. At the age of 33, 
she was diagnosed with a rheumatoid factor (RF)- and anti-citrullinated protein antibody 
(ACPA)-positive, erosive RA. She and her partner had been trying to conceive for more than 
7 years, but this had not resulted in a live birth. The fertility work-up did not reveal any 
cause for the couple’s subfertility. In their attempts to conceive, the couple had undergone 
intrauterine insemination (IUI) 6 times and an in vitro fertilization (IVF) procedure twice. 
In both IVF procedures, the embryos could be transferred into the uterine cavity. During 
her attempts to conceive, the patient was treated with sulfasalazine and etanercept, but 
she reported active RA during this period. At the age of 40, she spontaneously became 
pregnant when being treated with methotrexate (MTX) and etanercept. Unfortunately, this 
resulted in a miscarriage at week 7 of gestation. 
At the first consultation, the patient still showed active RA (Disease Activity in 28 joints (DAS28) 
3.5; 5 swollen joints) despite treatment with etanercept and MTX. MTX and etanercept were 
stopped, and the patient was started on 400 mg of infliximab (5 mg/ kg bodyweight) every 
6 weeks, 1000 mg of sulfasalazine twice daily, and 400 mg of hydroxychloroquine once 
daily. Four months thereafter, the RA was in clinical remission (DAS28 2.6; 1 swollen joint); 
after careful consideration and gynecological consultation, IUI was restarted, as the couple 
decided not to undergo IVF anymore. The second IUI attempt resulted in a successful 
pregnancy. At week 20 of gestation, infliximab was stopped and 200 mg of certolizumab 
every second week was started. The patient gave birth to a healthy baby girl at week 38.0 
of gestation. Both infliximab and certolizumab could not be detected in the cord blood. 
Throughout pregnancy, the RA remained in remission and the diabetes was well controlled. 
Ten weeks after delivery, the patient experienced a flare of her arthritis for which MTX was 
added to the combination therapy of certolizumab, sulfasalazine, and hydroxychloroquine. 
At the following visit, 3 months later, the RA was again in clinical remission. 
FERTILITY IN PATIENTS WITH RA
Conceiving a child is a major life event, and most adults try to have a child during their 
reproductive life span. However, the literature suggests that achieving this goal might be 
more difficult for women with RA. 
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Several studies indicate that family size is diminished in women with RA 1-6 . Some studies 2, 
6 , but not all 5 , indicate that this smaller family size is already present before the actual 
diagnosis of RA. Apart from a smaller family size in women with RA, such patients experience 
more difficulties in conceiving, as indicated by a longer time to pregnancy (TTP). In a study 
performed in the Danish National Birth Cohort, it was shown that 25% of patients with RA 
took more than a year to conceive compared with 15.6% of controls 7 . As only women who 
gave birth were included in this birth cohort, the actual data might be more concerning, 
as data on women who do not conceive at all were not incorporated. Clowse et al. 8  
reported that 36% of patients with RA had difficulties in conceiving at least once during 
their reproductive life span. In the Pregnancy-induced Amelioration of Rheumatoid Arthritis 
(PARA) study, a prospective Dutch cohort study on RA and pregnancy 9 , it was shown that 
42% of patients with RA did not conceive within 1 year or at all during the follow-up 
period of that study. For comparison, in the general population, the median prevalence of 
subfertility defined as TTP of > 12 months is 9%, with a range of 3.5-24.2 % depending on 
the geographic area 10, 11 . 
Several factors might be associated with the reported smaller family size and the longer 
TTP in female patients with RA. As impaired fertility might already be present before the 
diagnosis of RA 2, 6  and as earlier menopause has been reported in patients with RA 2, 6 , it has 
been postulated that these patients have a smaller ovarian reserve, which is already present 
before the onset of the disease and could account both for the impaired fertility and for the 
earlier menopause 12 . To test this hypothesis, the levels of serum anti-Müllerian hormone 
(AMH) (the most reliable biomarker for ovarian reserve) were tested in 72 premenopausal 
women (age range 18-42 years) with early RA. No differences were observed between 
patients with RA and healthy controls, making it unlikely that the observed impaired fertility, 
already present at time of diagnosis, is related to a diminished ovarian reserve 13 . Personal 
choices, due to RA related concerns, have been shown to be at least partially responsible 
for the smaller family size 8 , but it cannot account for the observed impaired fertility. 
Inflammation, as reflected by disease activity, has been shown to be associated with TTP. In 
women with active disease (DAS28 > 5.1) TTP exceeded 1 year in 67% of women, whereas 
this was only 30% in women in remission (DAS28 < 2.6) 9 . The use of nonsteroidal anti-
inflammatory drugs (NSAIDs) has been associated with increased TTP 9 , most likely through 
inhibition of the production of prostaglandins. Prostaglandins are involved in ovulation and 
implantation 12 . In addition, prednisone in a dose exceeding 7.5 mg daily has been associated 
with prolonged TTP 9 . The effect of prednisone might be related to a transient suppression of 
the hypothalamic-pituitary-ovarian axis by glucocorticoids or by a direct effect on ovarian 
function or on the endometrium 14, 15 . Finally, mainly based on studies in oncology and in 
animal models, it has been suggested that prior treatment with MTX is associated with 
impaired fertility 12 . However, in a prospective cohort study on RA and fertility, prior MTX 
treatment did not affect TTP 9 . Furthermore, short-term MTX treatment had no impact on 
the ovarian reserve in patients patients with RA 13 . Finally, is has been hypothesized that the 
impaired fertility in patients with RA is a result of a lower intercourse frequency 12 . Although 
a high prevalence of sexual dysfunction has been described in mainly postmenopausal RA 
patients 12 , it is unclear whether any conclusions can be drawn from these studies on the 
intercourse frequency of young patients with RA who actively wish to conceive. 
In conclusion, the doctor must be aware of the impaired fertility and consider various 
contributing factors, when consulting an RA patient who wishes to conceive.
RA DISEASE COURSE DURING AND AFTER PREGNANCY
Determination of the RA disease activity during pregnancy
As disease activity is associated with TTP as well as pregnancy outcome in patients with 
RA, accurately determining RA disease activity in pregnancy is important. However, this 
is difficult as several measures of determining disease activity or its components are 
influenced by pregnancy. For example, the erythrocyte sedimentation rate (ESR) is elevated 
in pregnant women due to increased circulating fibrinogen, plasma expansion and 
decreased hemoglobin concentration 16 . The ESR rises during pregnancy from 10 mm/hour 
in the first trimester to 33 mm/hour in the third trimester, and it declines postpartum to 
<20mm/hour 17 . Therefore, variants of the disease activity score (DAS) that include the ESR 
are not preferred as scoring methods in pregnancy 17, 18 . Pregnancy might also influence the 
visual analogue scale (VAS) of global health, which is incorporated in the DAS 19 . These are 
some of the reasons for investigating validated alternative DAS scoring methods. Given that 
C-reactive protein (CRP) is only slightly influenced by pregnancy, RA disease activity during 
gestation can be most reliably determined with a DAS incorporating a swollen and tender 
joint count and a CRP, but without considering of the VAS scores 17, 20 . The Clinical Disease 
Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) have not been validated 
for use in pregnancy and have not been used in pregnancy studies. 
RA disease course during pregnancy 
Pregnancy is the most studied physiological condition in which RA remits spontaneously 18, 
21 . This phenomenon was first described by Hench in 1938 22 . In this retrospective study, 
improvement was observed in 90% of the 34 included pregnancies. Following this, multiple 
retrospective studies between 1950 and 1989 confirmed his initial observation with 
improvement rates in pregnant RA patients ranging from 54 to 95% 1, 23-30 , (Table 1). Besides 
retrospective studies, a few small prospective studies 18, 31, 32  within that period of time 
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reported improvement in 71-86% of the patients. In 1993, Nelson et al. 33  showed remission 
in 39% and improvement in 21% of the 18 prospectively and 39 retrospectively followed 
pregnancies. 
After this period, multiple larger prospective studies were conducted. Barrett et al. 21  
prospectively studied 140 pregnant patients with RA in the UK to ascertain the influence 
of pregnancy on RA disease activity. Patients were followed up from the third trimester of 
their pregnancy until 6 months postpartum. In this study, the disease activity was assessed 
by clinical examination of inflamed joints and a VAS and Health Assessment Questionnaire 
(HAQ) scoring system. Data were collected at the third trimester of pregnancy and 1 and 
6 months postpartum. The main disadvantage of this study is that the evaluation started 
at the third trimester, and therefore disease activity in the first and second trimester 
was retrospectively assessed by self-report. In this study, in total 65% of the patients 
retrospectively reported a decrease in pain and swelling during pregnancy. However, only 
16% reached complete remission in the third trimester, defined as no swollen joints and 
receiving no antirheumatic therapy 21 . From 2002 until 2008, de Man et al. 34  conducted 
the PARA-study, a nationwide prospective cohort study within the Netherlands, to gain 
insight into the influence of pregnancy on the disease activity and the impact of RA and 
medication use on the pregnancy outcome. In this study, disease activity was objectively 
assessed with the validated DAS28-CRP(3) scoring system. The patients were followed 
up from preconception (if possible) up to 26 weeks postpartum. The results of the PARA-
study showed that 48% of the 52 patients with an initial DAS28-CRP(3) ≥ 3.2 improved 
during pregnancy, based on the European League Against Rheumatism (EULAR) response 
criteria (good and moderate response combined). Improvement occurred although certain 
medications such as the contraindicated DMARDs were discontinued in all women wishing 
to conceive. When all patients, including those who were already in remission at the time of 
conception, were analyzed together, the mean DAS28 decreased from the preconception 
visit to third trimester by 0.4 (from 3.8 to 3.4) with a more pronounced decrease in patients 
with a moderate to high disease activity in the first trimester. Nevertheless, the percentage 
of patients with moderate to high disease activity (DAS28 ≥ 3.2) in the third trimester was 
approximately 50%. Furthermore, in the third trimester, in total 27% of the patients were in 
remission compared with 11% before conception, according to a DAS28 < 2.6 34 .
The differences in improvement rates between earlier and more recent studies can 
be explained by differences in study design (retrospective vs. prospective studies) and in 
patients selection; in some earlier studies, only patients with active disease were included. 
Also various definitions of improvement and remission may contribute to differences in study 
outcome. In addition, increased numbers of patients with RA enter their pregnancy with low 
disease activity as treatment regiments have been intensified over the past decades. 
Table 1. Studies on the effect of pregnancy in women with rheumatoid arthritis
Study Study type Number of patients 
(pregnancies)
Improvement during 
pregnancy, %
Deterioration 
postpartum, %
Hench 22 Retrospective 20 (34) 90 90
Lewis-Faning 23 Retrospective 22 95 81
Torrent 24 Retrospective 15 80 -
Oka 25 Retrospective 93 (114) 75 84
Hargreaves 1 Retrospective 10 (11) 91 91
Smith 31 Prospective 12 75 -
Betson 26 Retrospective 24 54 -
Morris 27 Retrospective 17 82 -
Neely 28 Retrospective 20 63 -
Ostensen 29 Retrospective 31 (49) 75 62
Ostensen 18 Prospective 10 90 100
Unger 32 Prospective 14 71 -
Klipple 30 Retrospective 93 (114) 77 >90
Nelson 33 Partial retrospective
and prospective 
41 (57, retrospective 
=18, prospective=39)
60 (remission 39%) -
Barrett 21 Prospective 140 65 (remission 16%) 62-77
De Man 34 Prospective 84 total, 52 with initial 
DAS28-CRP(3) ≥3.2
48 (remission 27%) 39
De Man 35 Prospective 118 39 and 75 (depending 
on the presence of 
autoantibodies)
34 and 42 (depending 
on the presence of 
autoantibodies)
RA disease course post-partum
After delivery, there is an increased risk of a flare in disease activity. Postpartum exacerbations 
were also described by Hench 22  in 90% of the 34 pregnancies. Other retrospective studies 
report percentages of patients with a flare between 62% and 90% 25, 29, 30 (Table 1). In the 
prospective study from Barrett et al. 21 , 66% of the women reported an increase in joint swelling 
and 77% in pain at 6 months postpartum. Furthermore, in this study, 62% of the women had 
more affected joints postpartum than in the third trimester. The median number of affected 
joints increased from 8 during pregnancy to 10 at 6 months postpartum 21 . 
De Man et al. 34  reported that 39% of patients experienced a flare after delivery, despite 
restarting medication. Interestingly, also after miscarriage, one-third of patients experience 
a flare of their disease activity. In a recent study on a sample of 21 patient with RA, Brouwer 
et al. 36  showed that in 33% the disease flares between the preconception period and 3 
months after a miscarriage. 
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In conclusion, it must be noted that RA improves less and in fewer patients during pregnancy 
than is generally perceived. Therefore, when patients with RA conceive successfully, 
medication must be continued and only tapered with caution. In addition, after delivery 
and even during lactation, continuation of appropriate medication might be necessary to 
prevent a flare of RA disease activity. 
OUTCOMES 
Pregnancy Outcomes 
In large cohort studies, it has been found that pregnancy outcome in patients with RA is, in 
general, less favorable than in the normal healthy population 37-40 , although not to the same 
extend as that reported for systemic lupus erythematosus (SLE) for example. Differences 
from the general population are often small; therefore, it is unclear whether the found 
differences have clinical implications for the individual patient. Notably, none of the studies 
on pregnancy outcome in female RA patients found increased risks of major congenital 
malformations or perinatal death 41, 42 . 
An overview of studies on RA and pregnancy outcome is shown in Table 2. 
Miscarriage
Brouwer et al. 36  recently reported that the risk of a miscarriage in women with RA (17%) 
is comparable to that in the general population (11-22%). However, they do note that 
the miscarriage rate in patients with RA might be an underestimation. They explain that, 
among other reasons, the patients in their cohorts had planned pregnancies and therefore 
did not use any medication, for example, MTX, which is associated with an increased risk of 
miscarriages, and that there were fewer smokers and more patients with higher education 
levels in this cohort than in the general population 36 . 
Preeclampsia
Preeclampsia is a relatively uncommon pregnancy complication. Wolfberg et al. 41  showed 
an increased risk of preeclampsia in 114 women with rheumatic disease (e.g. RA and SLE) 
compared with unaffected women (8.8% vs. 2.3%). In a large combined Swedish and Danish 
prevalence study from 1994 to 2006 on 1199 women with RA and a first-time singleton birth 
registered in population-based healthcare databases, Norgaard et al. 38  showed that the risk 
of preeclampsia increased slightly from 3.4% in unaffected women to 5.0% in women with 
RA. Some studies 43  did not report an increase in preeclampsia during pregnancy in patients 
with RA, but this is most likely the result of a lack of power.
Mode of delivery
In a cohort of 243 women from the Washington State birth records, Reed et al. 42  found 
that women with RA had increased risks of a primary cesarean section (34% versus 19.5% 
in the control group). The main reasons for cesarean section in the RA population were 
cephalopelvic disproportion, dysfunctional labor, and fetal distress in 32%, 31%, and 18% 
respectively. These percentages were not significantly different from women without RA 42 . 
In the previously mentioned study by Norgaard et al. 38 , patients with RA had more cesarean 
deliveries (26.0% versus 16.5% in unaffected controls). However they did not report the 
indications for cesarean sections. In the study by de Man et al. 43 , cesarean sections were 
performed more often in the group with DAS28-CRP(3) ≥ 3.2 (22% versus 10% in the 
group with DAS28-CRP(3) < 3.2) and an increased number of patients with RA needed an 
instrumental vaginal delivery (17% vs. 10% in the reference group), but the latter was not 
associated with disease activity. Cesarean sections were indicated in the majority of the 
patients due to breech delivery and failure of labor progression 43 . Data on cesarean delivery 
should be interpreted with caution, as indication to perform a cesarean section may vary 
for different countries. 
Preterm delivery
The definition of preterm delivery in these studies is a birth before 37 weeks of gestation. In 
the previously mentioned study by Wolfberg et al. 41  and Norgaard et al. 38  the risk of preterm 
delivery was increased in women with RA compared with healthy controls (15.2% vs. 7.8% 
and 9.2% vs. 6.2%, respectively). Other studies 37, 42  report comparable risk percentages. In a 
recent prospective cohort study on 440 pregnant women with RA within the Organization 
of Teratology Information Specialists Autoimmune Diseases in Pregnancy Project, Bharti et 
al. 40  showed that high disease severity (as defined by a HAQ Disability Index (HAQ-DI) > 0.5) 
is associated with preterm delivery (20% vs. 12% in mild disease). In the PARA-study by de 
Man et al. 43 , the use of prednisone was associated with shorter gestational age (< 37 weeks) 
of the offspring at delivery.
Small-for-gestational-age infants
As shown in table 2 multiple studies 37-41  report an increased risk of small-for-gestational-
age (SGA) infants ranging from +/
- 
3% in unaffected women to +/
- 
10% in women with RA. 
Some studies defined SGA as a birth weight more than 2 standard deviations below the 
mean for infants of similar gestational age 38, 43 , and others as a birth weight lower than 
the 10th percentile adjusted for the gestational age 37, 39, 40 . De Man et al. 43  demonstrated 
that an increase in RA disease activity during pregnancy is independently associated with 
lower birth weight in the offspring, although still within the normal range. In this study, the 
incidence of SGA infants was 3.3% 43 . 
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Long-term effects on the offspring
Lower birth weight (even within the normal range) has been associated with an increased 
risk of cardiovascular and metabolic disease in adulthood 48, 49 . This effect is even more 
prominent if the children display rapid catch-up growth in weight during their first year of 
life. De Steenwinkel et al. 50  examined growth charts of 167 children born to women with RA. 
Of these children, 28% expressed rapid catch-up growth in weight, which was associated 
with maternal disease activity. A selection of 108 of these children was again evaluated at 
around 7 51 . At that age, these children did not have a high-risk profile in anthropometric 
measures, such as an increased blood pressure or altered body composition compared with 
children born to healthy mothers. 
Maternal use of prednisone during pregnancy has been associated with slightly higher 
daytime cortisol levels in children of age 7 51 . The clinical consequence of this is not clear, as 
this observation was not associated with clinical signs of a higher cortisol level.
In conclusion, pregnancy outcome in patients with RA is only slightly impaired, but it is 
not of clinical relevance to the individual patient, especially when disease activity is well 
controlled. This is reassuring for patients with RA wishing to conceive in terms of the impact 
of (well-controlled) RA on pregnancy outcome. 
PATHOGENIC MECHANISM UNDERLYING THE IMPROVEMENT OF RA 
DURING PREGNANCY AND THE FLARE AFTER DELIVERY
The pregnancy-associated improvement and postpartum exacerbation of RA might be the 
result of multiple hormonal and immunological changes during pregnancy and the gradual 
return of these changes to prepregnancy values after delivery 52 . Although multiple factors 
have been investigated, the exact mechanisms behind these phenomena remain unknown. 
Hormones in pregnancy and RA
Pregnancy is associated with changes in cortisol, estrogen and progesterone levels. 
Cortisol was initially believed to be associated with the improvement of disease activity 
during pregnancy in women with RA, due to its anti-inflammatory effects 53, 54 . Cortisol 
concentrations rise during pregnancy up to the third trimester and decrease after delivery 54-
56 . However, no clear associations were found between cortisol levels and the improvement 
of RA during pregnancy 54, 57, 58 . 
As RA is more prevalent in women 59 , sex hormones (estrogen and progesterone) were 
thought to play a role in the pathogenesis and therefore also in the improvement of RA 
during pregnancy, due to their effects on the immune system 52, 60-64 . In contrast to cortisol, 
the individual influence of the levels of sex hormones on disease activity has not been 
studied directly in cohorts of female RA patients. 
Autoantibodies
Besides being biomarkers for RA, the RA-associated ACPA and RF are considered to 
play a role in the pathogenesis of RA as well. Levels of ACPA and RF do not seem to be 
influenced by pregnancy in autoantibody-positive patients 35, 65 . However, de Man et al. 35  did 
demonstrate that, during pregnancy, patients without autoantibodies (negative for both 
ACPA and RF) are more likely to improve than are patients positive for either or both (75% 
vs. 39%, p = 0.01). In addition, in a small cohort study by Forger et al. 65 , patients with active 
disease (DAS28-CRP(3) ≥ 3.2) before and during pregnancy had higher ACPA levels than did 
patients with low disease activity (DAS28-CRP(3) < 3.2). 
Glycosylation
Glycosylation is the process of attachment of sugar molecules. Among others, its important 
functions include protein folding and receptor binding 66 , occurring in roughly 50% of 
proteins. 
Glycosylation studies in patients with RA have mainly focused on the glycosylation of the 
fragment crystallizable (Fc) region of immunoglobulin G (IgG). In this respect, glycosylation 
is divided into galactosylation, sialylation, fucosylation, mannosylation, and the presence of 
bisecting N-acetylglucosamine (GlcNAc) 67, 68 . Nonpregnant patients with RA have a lower 
percentage of galactosylated IgG molecules than women without RA do, which is found to 
be correlated with increased disease activity 69  and with a more progressive disease course 70 . 
During pregnancy the percentages of galactosylated IgG molecules increase. This increase 
is associated with the improvement of RA disease activity during pregnancy 67, 71, 72 . The 
correlations that Alavi et al. 72  found in a small study with 23 patients were confirmed by van 
de Geijn et al. 67  in a larger cohort study. 
As each galactose residue can bind one sialic acid residue, IgG molecules lacking a 
terminal galactose also lack terminal sialic acid residues 67, 71 . However, Bondt et al. 71  showed 
that the association between increased galactosylation and pregnancy-related RA disease 
improvement is independent of sialylation. 
To date, glycosylation of the Fc region has been studied most extensively 67 , regarding 
the improvement of RA during pregnancy. Nevertheless, both the Fc region and the Fab 
region of immunoglobulins can be glycosylated. In addition, Ruhaak et al. 66  report changes 
in the glycosylation of other proteins during pregnancy. This could indicate changes in 
other molecules that play a role in the pathogenesis of RA could also be responsible for the 
improvement of RA during pregnancy. 
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Human leukocyte antigen disparity
To induce tolerance against the semi-allogenic fetus, the maternal immune system is 
suppressed during pregnancy 73 . It has been hypothesized that the more mother and fetus 
differ genetically, the more the immune system needs to be suppressed and therefore the 
more autoimmune diseases like RA should improve 74 . 
In line with this hypothesis, it has been reported that a high degree of maternal-
fetal human leukocyte antigen (HLA) class II disparity in the DRB1, DQA and DQB alleles 
is associated with improvement of RA disease activity during pregnancy 33, 75, 76 . However, 
another study failed to reconfirm these data 77 . 
T cells in RA and pregnancy 
During pregnancy, an increase in regulatory T cells (Tregs) and a shift in T helper (Th) cells 
producing pro-inflammatory type 1 cytokines (Th1) to a profile with Th cells producing 
anti-inflammatory type 2 cytokines (Th2) can be observed 78, 79 . These shifts are thought 
necessary to prevent maternal rejection of the semi-allogenic fetus 80 . In parallel with these 
shifts, an improvement of RA during pregnancy has been described 78, 79 . 
Other factors in the improvement of RA
An increase during pregnancy in the anti-inflammatory cytokines interleukin-1 receptor 
antagonist (IL1Ra) and soluble tumor necrosis factor receptors (sTNFR) have been implicated 
in the improvement of RA during pregnancy, among other factors 81 . Furthermore, a 
decrease in neutrophil function has been hypothesized to, at least partially, underlie the 
improvement of RA during pregnancy 82 . Further, the levels of mannose-binding lectin 
(MBL) were hypothesized to be related to a favorable RA disease course during pregnancy 83 . 
However, in a cohort of 216 patients, van de Geijn et al. 84  found no associations between 
MBL and changes in RA disease activity during the gestational period . 
Post-partum deterioration of RA
As mentioned before, patients with RA are at an increased risk of a flare in disease activity 
after delivery. As changes in hormone levels and alterations in the immune system are 
considered to be responsible for the pregnancy-related improvement of RA, the postpartum 
flares can be explained by the return of the immune system to the preconception state 64 . 
Another theory on the postpartum deterioration involves the high levels of prolactin in 
breastfeeding women. Prolactin, a peptide hormone, has pro-inflammatory effects such 
as enhanced B-cell generation, cell proliferation, development of antigen-presenting cells, 
immunoglobulin production and upregulation of Th1 type cytokines (IL-1, IL-6, and IL-12) 85 . 
In their prospective cohort from late pregnancy and onwards, Barrett et al. 86  reported that 
breastfeeding is associated with increased disease activity at 6 months postpartum based 
on tender and swollen joint counts, CRP levels, and self-reported symptoms of pain and 
swelling. Although this could be an effect of prolactin, the results need to be interpreted 
with caution, as women who breastfed probably do not use medication and are therefore 
more prone to deteriorate during the lactation period 64, 86 . 
In conclusion, most likely, the improvement of RA during pregnancy can be attributed 
not only to one underlying mechanism but also to changes in several factors, which 
together cause subtle changes in the maternal immune response resulting in tolerance 
towards the fetus and a decrease in RA disease activity. 
MEDICATION AND PREGNANCY
Disease-modifying antirheumatic drugs that can be prescribed during 
pregnancy
Of the traditional disease-modifying antirheumatic drugs (DMARDs), sulfasalazine (SSZ) and 
hydroxychloroquine are most frequently used during pregnancy in RA, due to their known 
efficacy in RA and proven safety during pregnancy. 
Several studies have shown that SSZ can be used safely during pregnancy, although SSZ 
crosses the placenta 87 . As some case reports have noted the occurrence of aplastic anaemia 
and neutropenia in children born to women who used > 2 g SSZ daily, it is recommended 
not to exceed this dose in pregnant women 88, 89 . SSZ inhibits the gastrointestinal and cellular 
uptake of folate; therefore, folate supplementation should be prescribed throughout the 
entire pregnancy. Only trace amounts of uncleaved SSZ have been found in breast milk, 
but sulphapyridine (a metabolite of SSZ) levels can be found in breast milk at 30-60% of 
maternal serum levels. Nevertheless breastfeeding is considered safe in the in the healthy, 
full-term infant. In case of dysmaturity, prematurity, hyperbilirubinemia, ill-health, or infants 
with a glucose-6-phosphate dehydrogenase deficiency, breastfeeding when using SSZ 
should be avoided 87 . 
Hydroxychloroquine crosses the placenta, but no increase in congenital malformations 
was reported in several hundreds of pregnancies at the recommended daily dose of 200-
400 mg. Moreover, long-term follow up studies of children did not reveal visual, hearing, or 
developmental abnormalities 87 . Hydroxychloroquine can only be detected in trace amounts 
in breastmilk and is therefore considered compatible with breastfeeding 87 .
Of the less frequently prescribed DMARDs, both azathioprine and cyclosporine are 
considered safe during pregnancy, but they are hardly prescribed in RA pregnancies due to 
a less favourable balance between efficacy and safety 87 .
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DMARDs that should be avoided during pregnancy
As MTX is known to be teratogenic and to induce miscarriages, it should be avoided during 
pregnancy 87, 90 . In general, it is advised to stop MTX 3 months before a planned pregnancy 91 ; 
however, recent evidence suggests that a shorter period might also be appropriate 90 . 
MTX can be detected in small amounts in breastmilk and should be stopped because of a 
theoretical risk 87 .
Leflunomide is a known teratogen in animal studies. Human data are less clear, with 
some studies reporting no excess of congenital malformations after first-trimester exposure 
to leflunomide followed by a washout procedure with cholestyramine for enhanced 
elimination from the body. Nevertheless, according to expert opinion, leflunomide should 
be discontinued before a pregnancy and a wash out procedure should be performed until 
the levels are undetectable 87 . 
Nonsteroidal anti-inflammatory drugs 
First- and second-trimester exposure to NSAIDs is not teratogenic. However, the use of 
NSAIDs has been associated with an increase in miscarriages and a prolonged TTP 9, 87 . After 
week 20 of gestation, all NSAIDs can impair renal function and cause constriction of the 
ductus arteriosus. The latter risk increases with gestational age. Therefore, and as NSAID 
are known to impair labor, all NSAIDs should be discontinued before the 32nd gestational 
week. NSAIDs can only be detected in low concentrations in breastmilk and are therefore 
considered compatible with breastfeeding. Data on the safety of cyclooxygenase (COX) 
inhibitors during pregnancy are scarce; therefore, it is sometimes recommended to switch 
to nonselective COX inhibitors during pregnancy 87 . Nonselective COX inhibitors can be 
combined with omeprazole during pregnancy 92 .
Glucocorticosteroids
Non-fluorinated glucocorticoids, such as prednisone, are metabolized by the placenta; 
therefore, no more than 10% of the drug reaches the fetus. Although the association 
between the use of prednisone during pregnancy and an increase of oral clefts is 
controversial, the use of prednisone is not considered to be teratogenic in general 87, 93 . 
During pregnancy, glucocorticoids may exert the same side effects as outside of pregnancy, 
which might be more damaging during pregnancy, like insulin resistance. Furthermore, of 
relevance for pregnancy, the use of corticosteroids has been associated with intrauterine 
growth restriction, shorter gestational age 43 , premature rupture of the membranes, and 
longer TTP 9, 87, 93 .
Fluorinated glucocorticosteroids are not inactivated by the placenta. Their use during 
pregnancy should be restricted to fetal indications, for example, the induction of fetal lung 
maturation 87 . 
TNF inhibitors and pregnancy
Increasingly more data are available on the use of TNF inhibitors during pregnancy. As the 
majority of reports involved unplanned pregnancies initially, most data concern exposure 
during the first trimester of pregnancy. More recent reports include intentional treatment 
of pregnant women until the end of pregnancy. These reports mainly involve women with 
inflammatory bowel disease (IBD), as adequate control of maternal disease activity in IBD 
might even be more important than in women with arthritis. Most data are on infliximab 
and adalimumab, as these were the first TNF inhibitors registered for both arthritis and IBD. 
Data on the use of etanercept and certolizumab during pregnancy are increasing, whereas 
pregnancy data on golimumab are still limited 94-96 . 
The use of TNF inhibitors has not been associated with congenital abnormalities or 
adverse pregnancy outcome 94, 95 . However, very recently a prospective study from the 
European Network of Teratology Information Services on 495 pregnancies that were 
exposed to TNF inhibitors during first trimester and 1532 pregnancies from healthy 
pregnant women revealed a small increase in major birth defects (5% vs. 1,5%; OR 2.2 95% 
CI 1.0-4.8). These results are not easy to interpret since no distinct pattern of malformations 
could be identified which would be expected for typical teratogens. In addition, the rate of 
1.5% major birth defects in the comparison cohort is lower than the prevalence of all non-
chromosomal anomalies of 2.2% recorded by EUROCAT 97 . 
TNF inhibitors that contain an Fc part of an IgG molecule are actively transported from the 
maternal to the fetal circulation starting at around week 18 of gestation 98 . This transport 
is mediated through binding of the Fc part to the fetal Fc receptor. Both infliximab and 
adalimumab bind to this receptor with high affinity. After third-trimester exposure, the 
serum levels of infliximab and adalimumab are up to 3 times higher in the newborn than 
in the mother. Serum levels only gradually reduce over time, and they can still be detected 
in the newborn 6 months after birth 99 . The limited data suggest that placental transport 
might not be a major concern for etanercept 100, 101 . For golimumab no data are available. 
Certolizumab has a pegylated Fab prime component; hence, it is not actively transported 
over the placenta as it lacks an Fc tail. After third-trimester exposure to certolizumab, only 
trace amounts can be detected in the fetal circulation 99 . 
Small studies indicate no increase of infections during the first year of life of newborns after 
intrauterine exposure to TNF inhibitors, normal response to vaccination, and developmental 
milestones achieved in a timely manner 96 . In contrast to these reassuring data, a small case 
series describes the presence of transient severe neutropenia, subsequently complicated 
by skin infections, in 4 newborns after intrauterine exposure to infliximab (including the 
third trimester) 102 . Furthermore, in view of the death of a 4.5-month-old female infant who 
developed disseminated Bacillus Calmette-Guérin (BCG) following BCG vaccination at 3 
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months of age, live vaccines should be considered with caution. Her mother had been treated 
for Crohn’s disease throughout her pregnancy with infliximab 103 . It is therefore advised that, 
after intrauterine exposure to TNF inhibitors (with the exception of certolizumab), all live 
vaccines should be postponed to 6 months of age 94 . 
THE MALE PERSPECTIVE
There are no well executed studies available on the fertility of male patients with RA and 
the impact of their disease on the pregnancy outcome of their partners. Lower testosterone 
levels have been described in male patients with RA than in healthy controls 104 , but whether 
this also results in less fertility is not known. In addition, little is known on the effects of 
antirheumatic drugs and medication. 
Treatment with SSZ has been associated with oligospermia, reduced sperm motility, an 
increased proportion of abnormal forms, and infertility. Spermatogenesis usually recovers 
2 months after withdrawal of the drug 105 . An expert publication advised discontinued 
MTX in men 3 months before a planned pregnancy, although it also states the lack of an 
underlying literature basis 91 . Recent studies on a total of 162 pregnancies suggest that 
paternal exposure to low-dose MTX at time of conception is not associated with an excess 
risk of birth defects 106, 107 . In general, low-dose MTX treatment is not considered to be 
associated with oligospermia, motility, concentration, and morphology in semen, although 
oligospermia and reversible sterility have been observed in case reports 108 . Theoretically, 
glucocorticosteroids may impair male fertility 109 , but clinical studies are lacking. One study 
suggests that the chronic use of NSAIDs may also impair sperm quality 110 . The previous 
literature, based on relatively small patient numbers, suggested that TNF inhibitors may 
negatively impact sperm quality 111, 112 . More recent data show that TNF inhibitors do not 
have a negative impact on the quality of semen or male fertility, nor do they increase 
the risk of adverse pregnancy outcome 113-115 . In vitro studies suggest that chloroquine 
may negatively impair sperm motility. No clinical data are available on chloroquine and 
hydroxychloroquine 108 .
PRACTICAL APPROACH TO RA PATIENTS WHO WISH TO CONCEIVE
The female patient
RA patients who wish to conceive should consult both a rheumatologist and a gynecologist 
in a timely manner. Given the restrictions of pregnancy, medication should be adjusted 
in time and one should strive for low disease activity or remission whenever possible. In 
general, all our RA patients hoping to conceive were prescribed SSZ and HCQ. If this did not 
result in low disease activity, prednisone preferably not higher than 7.5 mg daily and/or a 
TNF inhibitor was added. In patients already on a TNF inhibitor, the indication for the TNF 
inhibitor is reevaluated, but most often continued, as discontinuation TNF inhibitors usually 
results in high disease activity. Women with RA might be physically impaired; in such cases, 
a pregnancy might have a higher impact on those women than on other patients. This 
should be anticipated. A frequent concern of women with RA is that their children have 
a considerable risk of developing this disease as well. In this respect, our patients may be 
assured: although there is some increased relative risk, given the relatively low prevalence 
of RA of 1%, the absolute risk is still low. 
In general the following check list can be used:
- Age of patient
- Social context (social roles and work)
- Number and course of previous pregnancies. What was the time to pregnancy in 
previous pregnancies? Did the couple require assisted reproductive techniques? 
Were previous pregnancies of the same partner?
- How is her menstrual cycle? When using oral contraceptives: how was her menstrual 
cycle before starting the oral contraceptives.
- Family history. Any genetically determined diseases in her family?
- Regarding her partner: does he have a chronic illness; does he use medication, 
alcohol, or drugs, or does he smoke? Medical history, diseases that might affect 
fertility (cryptorchidism?). Are there any genetically determined diseases in his family?
- Current medication, disease activity, extra-articular features?
- Functional impairment
- Smoking, alcohol, drugs
- Comorbidity
- Sexual problems
The male patient
In general, the same checklist can be used for male patients, with the relevant adaptations. 
In addition, low disease activity and preferably remission should be the goal when treating 
male patients. For this purpose, we prescribe a low dose of prednisone sometimes in 
combination with hydroxychloroquine or a TNF inhibitor. MTX seems to be a good option 
for male patients who wish to conceive; nevertheless we are still cautious in prescribing it 
in this particular situation. For some medications, like MTX and TNF inhibitors, no impact 
on sperm quality has been described at a group level, whereas an association between the 
prescription of a certain drug and impaired sperm quality has been suggested in case reports 
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or small studies 108, 111, 112 . In these particular cases, one may consider referring the patient for 
a sperm analysis. Except for using cyclophosphamide, we do not advise cryopreservation 
for male RA patients before the start of medication.
SUMMARY 
Fertility is impaired in female patients with RA; > 40% of patients with RA need > 1 year to 
conceive. Higher disease activity, the use of NSAIDs, and the use of prednisone > 7.5 mg 
daily are associated with a longer time to pregnancy in patients with RA. During pregnancy, 
disease activity usually improves, although less than previously thought; > 50% of pregnant 
patients with RA still experience moderate to high disease activity during the third trimester. 
The improvement of RA during pregnancy can be attributed to not just a single mechanism 
but most likely several different pathogenic mechanisms. 
Almost all pregnancy complications are slightly increased in patients with RA, especially 
if the disease is active. The clinical relevance for the individual patient is doubtful, especially 
if the disease is well controlled.
The challenges encountered by male patients with RA who wish to conceive have not 
been investigated as much. 
Although the use of medication is restricted during pregnancy, there are far more 
treatment options both for women and men than generally thought. Increasing evidence 
is available on the safe use of TNF inhibitors in both female and male RA patients who wish 
to conceive. 
As prolonged periods of uncontrolled disease activity are known to be harmful for the 
patient and given the known impact of high disease activity on fertility and pregnancy 
outcome, a treat-to-target approach is advocated in both in female and male RA patients 
wishing to conceive.
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ABSTRACT
Objectives. To determine whether disease activity in women with rheumatoid arthritis (RA) 
in 1 pregnancy is predictive for disease activity in a subsequent pregnancy. 
Methods. In the Pregnancy-induced Amelioration of Rheumatoid Arthritis study, there are 
prospective data on 27 patients who participated twice. Improvement and deterioration is 
determined by changes in the Disease Activity Score in 28 joints.
Results. Only 4 patients (14.8%) had comparable disease courses in both pregnancies, 
whereas treatment remained mostly similar. In contrast, a flare postpartum after the first 
pregnancy was predictive for a flare after the second pregnancy (p = 0.003).
Conclusions. RA disease course in following pregnancies cannot be predicted based upon 
previous pregnancies. However, a flare postpartum seems to predict subsequent flares. 
INTRODUCTION
Pregnancy is the only physiological condition in which rheumatoid arthritis (RA) remits 
spontaneously in about 50% of cases 1-3 . We previously reported in a prospective cohort 
study on pregnancy and RA that 48% of patients improved during pregnancy, based upon 
the Disease Activity Score in 28 joints (DAS28) according to the European League Against 
Rheumatism (EULAR) response criteria 3 . 
Some studies showed that improvement in the first pregnancy is predictive for 
improvement in the next pregnancy 1, 4 . However, in these studies, assessment of the RA 
disease activity in the first pregnancies was retrospective and self-reported by the women 1 . 
Understanding the influence of pregnancy and especially the effect of subsequent 
pregnancies may provide more insight into the pathophysiological mechanisms underlying 
RA. Further, increased knowledge on the disease course of RA during subsequent 
pregnancies might also provide valuable information for daily clinical practice. 
To our knowledge, the course of RA disease activity has not been prospectively studied 
during subsequent pregnancies and after delivery. The aim of our present study was to 
prospectively determine whether RA disease activity course is similar in subsequent 
pregnancies and after delivery and thereby to determine whether the disease activity 
course in following pregnancies can be predicted. 
MATERIALS AND METHODS 
Study population
Our study is embedded in the Pregnancy-induced Amelioration of Rheumatoid Arthritis 
(PARA) study, a nationwide prospective cohort study from the Netherlands 3 . From May 2002 
to August 2008, 475 patients in total who met the 1987 revised criteria of the American 
College of Rheumatology (ACR) 5  for RA were recruited by their rheumatologist, and from 
these, 369 were enrolled in the PARA-study. Women were eligible for inclusion if they had a 
pregnancy wish or were already pregnant (in their first trimester). The PARA-study is believed 
to be a good representation of the general Dutch pregnant RA population between 2002 
and 2008. During the study period, 205 women conceived at least once 6 . There were data 
available on 27 female patients with RA who had 2 successful pregnancies until delivery 
resulting in a live birth. 
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Data collection
Data on disease activity and medication use were collected before conception, if possible, at 
each trimester during pregnancy (8-12, 18-22 , and 28-32 weeks) and 3 times postpartum(6, 
12, and 26 weeks) 3 . 
Disease activity
DAS28 was calculated based upon the number of swollen joints, the number of tender 
joints, and the level of C-reactive protein (CRP) 7, 8 . 
Improvement and deterioration of the disease activity during pregnancy were calculated as 
differences in DAS28 between first and second, first and third or second and third trimester. 
Preconception DAS28 was not used in the analysis because this was only available in 6 
patients in both pregnancies. Improvement of the disease activity during pregnancy was 
defined as a decrease in DAS28 > 0.6 and deterioration as an increase in DAS28 > 0.6. 
Possible disease activity courses were categorized as improvement, deterioration, both 
improvement and deterioration, and no change. The limit of 0.6 was chosen since it is the 
lowest meaningful difference according to the EULAR response criteria 3, 9 . In contrast to the 
EULAR response criteria, an initial DAS28 of ≥ 3.2 was not a prerequisite. 
Flares postpartum were calculated as an increase in DAS28 between the third trimester and 
any of the three time points postpartum of > 0.6. 
Statistical analysis
For all subjects, descriptive statistics were calculated as numbers, percentages, means, 
and standard deviations (SD). A 2-sample Student t test was used to detect differences in 
mean disease activity scores. Binomial probability tests were used to analyze whether a flare 
after the first pregnancy was predictive for a subsequent pregnancy. P values < 0.05 were 
considered statistically significant. Statistical analysis were performed using STATA software 
version 13.1 for Windows. 
Ethics
Our study is in compliance with the Helsinki Declaration. The Medical Ethics Committee at 
the Erasmus Medical Center Rotterdam, the Netherlands, approved the PARA-study. 
RESULTS
Participants
Descriptive statistics of the study population are shown in table 1. In the first and second 
pregnancies, the mean maternal age was 31.2 years and 33.6 years respectively (p<0.007). 
Mean duration of RA was 6.5 years in the first pregnancy and 8.7 years in the second 
pregnancy group. In total, 70.4% of the patients were RF-positive, 55.6% were anti-cyclic 
citrullinated peptide (anti-CPP)-positive, and 74.1% had erosive RA. General characteristics 
of the selected patients were comparable with the other patients in the PARA-study (data 
not shown) 3 . 
Table 1. Descriptive statistics of study population. Values are n (%) unless otherwise specified. 
Characteristics First Pregnancy, 
N = 27 
Second Pregnancy, 
N = 27
Age, yrs, mean (SD)* 31.2 (3.6) 33.6 (3.4)
Smoking 3 (11.1) 2 (7.4)
RA duration, yrs, mean (SD) 6.5 (5.6) 8.7 (6.0)
DAS28-CRP(3) first trimester, mean (SD) 3.84 (1.11) 3.81 (1.22)
Patients with moderate and high disease activity, DAS28-
CRP(3) ≥ 3.2, at first trimester
19 (70.4) 17 (63.0)
Prednisone use during pregnancy 7 (25.9) 11 (40.7)
SSZ use during pregnancy 5 (18.5) 3 (11.1)
Both prednisone and SSZ use during pregnancy 1 (3.7) 2 (7.4)
No medication during pregnancy 14 (51.9) 11 (40.7)
In Total
RF-positive 19 (70.4)
Anti-CCP-positive 15 (55.6)
Erosion 20 (74.1)
MTX use ever 17 (63.0)
RA: rheumatoid arthritis; DAS 28: Disease Activity Score in 28 joints; CRP: C-reactive protein; SSZ: sulfasalazine; RF: 
rheumatoid factor; anti-CCP: anti-cyclic citrullinated peptide; MTX: methotrexate.
Disease activity during pregnancy
Mean DAS28 changed during first pregnancy from 3.84 (first trimester) to 3.52 (third trimester) 
to 3.75 (12 weeks postpartum) and finally 3.82 (26 weeks post-partum). The mean DAS28 
during second pregnancy at those timepoints was 3.81, 3.55, 3.74 and 3.41 respectively. In 
the first pregnancy, in total 37.0% of the patients improved, 22.2% deteriorated, 22.2% both 
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improved and deteriorated, and 18.5% had no change in disease activity. In the second 
pregnancy, these numbers were 37.0%, 18.5%,14.8%, and 25.9% respectively (Table 2). Only 
4 patients (14.8%) had a comparable disease activity course during their first and second 
pregnancy, represented by asterisks in table 2. 
Table 2. No. of patients in the disease course categories improvement, deterioration, both 
improvement and deterioration, and no change during first and second pregnancies. Values are n (%). 
Disease Activity 
during Pregnancy
Improvement
Second 
Pregnancy 
Deterioration
Second 
Pregnancy 
Improvement and 
Deterioration
Second Pregnancy
No Change
Second 
Pregnancy 
Total First 
Pregnancy
Improvement
First Pregnancy 
2 (7.4)* 3 (11.1) 2 (7.4) 3 (11.1) 10 (37.0)
Deterioration
First Pregnancy 
4 (14.8) 0 (0)* 0 (0) 2 (7.4) 6 (22.2)
Improvement and 
Deterioration 
First pregnancy 
2 (7.4) 2 (7.4) 1 (3.7)* 1 (3.7) 6 (22.2)
No change
First Pregnancy 
2 (7.4) 1 (3.7) 1 (3.7) 1 (3.7)* 5 (18.5)
Total 
Second Pregnancy 
10 (37.0) 6 (22.2) 4 (14.8) 7 (25.9) 27 (100)
* Similar disease courses in both pregnancies
Disease courses in the first and second pregnancies are shown in figure 1. 
Medication use during pregnancy
None of the pregnant women received methotrexate (MTX), biologicals, or 
hydroxychloroquine in the 3 months before conception or during pregnancy. Patients 
received prednisone, sulfasalazine (SSZ), both prednisone and SSZ, or no medication. In 
the first and second pregnancies, respectively 14 (51.9%) and 12 patients (44.4%) did not 
receive any medication. Treatment and also the medication doses were overall similar in 22 
patients (81.5%) in both pregnancies.
Flare postpartum
Twenty patients (74.1%) had a flare postpartum after their first pregnancy. In total, 17 
patients (63.0%) had a flare after both pregnancies. The occurrence of a flare postpartum 
after the first pregnancy was predictive for a flare after the second pregnancy (p = 0.003). 
Three patients (11.1%) had no flare after both pregnancies. Three patients (11.1%) had a flare 
after their first pregnancy and no flare after their second pregnancy. In 4 patients (14.8%), 
the RA flared postpartum after their second pregnancy while it did not flare after their first 
pregnancy. The mean time span between two subsequent pregnancies in patients with 
and without a flare after the first pregnancy was 924 and 727 days respectively (p = 0.07). Fi
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Medication use postpartum
Eleven patients (40.7%) restarted medication after both pregnancies, which they did 
not use during pregnancy, within 6 weeks after delivery. At 26 weeks, 18 (66.7%) and 22 
patients (81.5%) had started additional medication after their first and second pregnancies, 
respectively. From these, 10 (37.0%) started with MTX or a combination after their first 
pregnancy and 14 (51.9%) after their second pregnancy. Overall, treatment postpartum was 
different in 20 patients (74.1%). 
DISCUSSION 
To our knowledge, ours is the first prospective study that shows that the disease course in 
female patients with RA is different in subsequent pregnancies. In our present study, only 
14.8% of the patients had a comparable disease activity course while treatment in both 
pregnancies remained mostly similar. These findings are in contrast to previous studies that 
claimed that if the disease activity improves during a pregnancy, improvement is likely to 
occur in subsequent pregnancies as well 1, 4 . The most likely explanation for this discrepancy 
is the fact that in those studies, disease activity was retrospectively determined by self-
report. 
That the improvement rate in this study is lower (37%) than the 48% reported earlier in 
the PARA-study 3  is probably the result of using different definitions. In our current study, 
we chose not to define improvement according to the EULAR response criteria because 
this would lead to a loss of a considerable number of subjects, since the prerequisite of an 
initial DAS28 ≥ 3.2. With the EULAR response criteria, 15 out of 35 pregnancies (43%) were 
classified as improvement. This does not differ from the 48% reported earlier (p = 0.67). 
Seventeen patients (63.0%) had a flare postpartum after both pregnancies. The occurrence 
of a flare postpartum after the first pregnancy was predictive for a flare after the second 
pregnancy (p = 0.003), despite the differences in treatment between both pregnancies. 
Because we have shown that RA disease activity has a different course during subsequent 
pregnancies, it is tempting to speculate that fetal-related factors might be more important 
in the improvement of RA during pregnancy than pure maternal factors. The sex of the 
children was not associated in our current study with a certain disease activity course (data 
not shown). Previous studies have shown that incompatibility of human leukocyte antigen 
(HLA) class II between mother and child seems to positively influence RA disease activity 
during pregnancy 10-12 . The HLA-related mechanisms were not analyzed because that was 
beyond the purpose of our article. 
Finally, our study has some limitations. First, although in its kind it is a large (predominantly) 
descriptive study, a study on 27 subjects is still relatively small. Nevertheless, the analysis 
on postpartum flare reached statistical significance. Second, in the majority, no data on 
preconception DAS28 were available because some patients were included in their first 
trimester. However, we have previously reported no significant difference between 
preconception and first trimester DAS28 6 . 
Our study shows that we cannot predict the RA disease course in subsequent pregnancies 
based on the disease course in the first pregnancy. Each pregnant RA patient should be 
treated to achieve low disease activity without taking into account the disease course of 
a possible previous pregnancy. However, because the occurrence of flares after delivery in 
subsequent pregnancies seems to be related to previous flares, this phenomenon can be 
anticipated both by patients as well as their treating physicians. 
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Low disease activity and remission in rheumatoid arthritis
ABSTRACT 
Objectives. To identify a combination of clinical factors associated with low disease activity 
and remission in the third trimester during pregnancy in women with rheumatoid arthritis 
(RA). 
Methods. This study is embedded in the Pregnancy-induced Amelioration of Rheumatoid 
Arthritis (PARA) study, a prospective cohort study. There were data available on 190 
pregnancies from first trimester until delivery. Multivariate regression analyses were 
performed on the disease activity (Disease Activity Score in 28 joints[DAS28] using the 
C-Reactive Protein[CRP] level) in the third trimester. Independent covariates were the 
DAS28-CRP(3) in first trimester, prednisone and sulfasalazine use in the first trimester, parity, 
methotrexate use in past, autoantibody status, the presence of erosions, and RA disease 
duration.
Results. In multivariate regression models, the DAS28-CRP(3), use of prednisone in the first 
trimester and the presence of autoantibodies were negatively associated with low disease 
activity (DAS28-CRP(3) < 3.2) in the third trimester (P < 0.05), and the DAS28-CRP(3) and 
presence of autoantibodies were also associated with remission(DAS28-CRP(3) < 2.6) (P < 
0.001). Subgroup analysis revealed that the associations of prednisone use and presence 
of autoantibodies were only present in patients with moderate-to-high disease activity 
(DAS28-CRP(3) ≥ 3.2) in the first trimester. 
Conclusions. RA patients who have a low DAS28-CRP(3) in the first trimester (irrespective of 
autoantibody status or prednisone use) are likely to have low disease activity or remission in 
the third trimester. Also, women with higher disease activity who are not taking prednisone 
and who express no autoantibodies still have a fair chance of low disease activity in the last 
trimester. 
INTRODUCTION
Pregnancy is the only natural situation that results in spontaneous improvement of 
rheumatoid arthritis (RA) 1, 2 . The most recent prospective studies have shown that RA 
improves during pregnancy in 40-70% of the patients 1, 3-5 . However, only 16-27% of patients 
achieve remission, and approximately 50% still have active disease in the third trimester 1, 4 . 
The treatment of pregnant patients with RA is especially challenging. First, achieving and 
maintaining low disease activity throughout pregnancy is of interest for the welfare of the 
mother. Second, since several studies have shown that active maternal disease during 
pregnancy is negatively associated with pregnancy outcome, maintaining low disease 
activity is even more important 6, 7 .
Unfortunately not all antirheumatic drugs can be continued during pregnancy. Currently, 
mainly prednisone, sulfasalazine, hydroxychloroquine, and increasingly tumor necrosis 
factor (TNF) inhibitors 8, 9  are prescribed to pregnant RA patients. Furthermore, the use of 
a minimal amount of medication during pregnancy is preferred, to prevent drug-related 
side effects for mother and child. Therefore, and in view of the known improvement of 
RA during pregnancy, many physicians try to taper or to stop medication when a woman 
conceives. TNF inhibitors are often discontinued during the first weeks of pregnancy, since 
most safety data mainly concern first trimester exposure 8, 10 . In addition, TNF inhibitors with 
high affinity for the fetal fragment crystallizable (Fc)-receptor are actively transported to the 
fetus during the second and third trimester of pregnancy, which may result in fetal cord/ 
serum levels equal to or higher than maternal levels 9 . Expert opinion therefore advises to 
preferably discontinuing these agents before week 20 of gestation 11 . 
Moreover, an attempt is often made to stop or to taper the more traditional disease-
modifying antirheumatic drugs (DMARDs) during pregnancy. The rationale for doing so is 
that some side effects are mainly related to exposure later during pregnancy, e.g. prednisone 
has been associated with shorter gestational age 6 , gestational hypertension, gestational 
diabetes, and premature rupture of the membranes 12 , side effects that are most prominent 
during third-trimester exposure. Since lowering medication during pregnancy increases the 
risk of a flare of disease activity 13, 14 , it would be useful to identify those female RA patients in 
whom medication can be tapered safely in the first trimester of pregnancy. 
The aim of the current study was to determine which combination of clinical factors at 
the beginning of pregnancy was associated with low disease activity (Disease Activity Score 
in 28 joints[DAS28] using the C-Reactive Protein [CRP] level < 3.2) and remission (DAS28-
CRP(3) < 2.6) in the third trimester. There is evidence, from univariate analyses, that the 
presence of autoantibodies 5 , the initial DAS28-CRP(3) 4 , and the use of prednisone 15  are 
associated with RA disease activity during pregnancy. However, these factors have not yet 
been analyzed together in a multivariate model and were never studied in association with 
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other relevant clinical factors. In the current study, we performed multivariate analyses using 
these known factors and possible other factors, e.g., sulfasalazine use, parity of the mother, 
methotrexate (MTX) use in the past, the presence of erosions, and the duration of RA.
PATIENTS AND METHODS
Study population
This study is embedded in the Pregnancy-induced Amelioration of Rheumatoid Arthritis 
(PARA) study, a nationwide prospective cohort study from The Netherlands, conducted 
to gain insight into the influence of pregnancy on the RA disease activity 4 . Patients were 
eligible for inclusion if they fulfilled the American College of Rheumatology 1987 revised 
criteria for RA 16  and had a good understanding of the Dutch language. From 2002 to 2008, 
475 female RA patients who had a wish to conceive or were already pregnant (in their first 
trimester) were recruited by their rheumatologist, and from these, 369 were enrolled in the 
PARA-study. During the study period, 205 women conceived at least once. 
For the current analysis on identifying associated factors with RA disease activity during 
pregnancy, patients with a miscarriage (within 12 weeks) and patients with a missing 
DAS28-CRP(3) in the first or third trimester were excluded. After these exclusions, data 
on 190 pregnancies from 168 women remained available for the current analysis. In 110 
pregnancies, a preconception DAS28-CRP(3) was available. 
Data collection
In the PARA-study, data on disease activity and medication use were collected before 
conception if possible, each trimester during pregnancy (8-12 weeks , 18-22 weeks, and 
28-32 weeks) and 3 times postpartum (6 , 12 , and 26 weeks). The PARA-study has been 
described in detail previously 4 . Disease activity was measured with the DAS28-CRP(3) based 
on the number of swollen joints, the number of tender joints, and the CRP level, without 
consideration of the visual analogue scale (VAS) of global health 17, 18 . Improvement in disease 
activity was calculated as the difference between first and third trimester DAS28-CRP(3). 
Patient characteristics (duration of RA, erosion status, presence of Rheumatoid Factor[RF], 
and the presence of anti-citrullinated protein antibody[ACPA]) were obtained from the 
patient’s rheumatologist. RF and ACPA were also determined at study inclusion. A patient 
was considered to be positive for RF or ACPA when they were positive either at inclusion or 
in the past 4 . 
Statistical analysis
For all subjects, descriptive statistics were calculated as numbers, percentages, means, 
medians, standard deviation (SD) scores, and interquartile ranges (IQRs). The mean DAS28-
CRP(3) and the mean difference between DAS28-CRP(3) from first to third trimester and 
from preconception (if available) to third trimester was calculated. Paired t-tests were used 
to test the differences in disease activity scores. 
Two multivariate logistic regression models were built for the analyses of the 
dichotomized DAS28-CRP(3) in the third trimester (DAS28-CRP(3) ≥ or < 2.6 and DAS28-
CRP(3) ≥ or < 3.2) by step-wise forward selection of covariates with a P value less than 0.20 
in the univariate logistic regression analyses. After that, the full models were reduced by 
eliminating the covariates with a P value greater than or equal to 0.20 in the multivariate 
regression analyses (if present) to create the final models. 
The following independent covariates were analyzed in these models: the DAS28-
CRP(3) in the first trimester, prednisone use in the first trimester, sulfasalazine use in the first 
trimester, parity of the mother, MTX use in the past, autoantibody status (either one or both 
RF and ACPA positive versus both negative), the presence of erosions, and the duration of 
RA. The past use of MTX was included in our model as a marker for more severe RA, since 
in The Netherlands at the time of inclusion for this study, MTX was mainly prescribed to 
patients with more severe disease. The interaction terms between DAS28-CRP(3) in the first 
trimester, prednisone use in the first trimester and the presence of autoantibodies were also 
analyzed in the final regression models. A stratified analysis was performed if interaction 
terms were considered significant (P < 0.20). Correlations between the covariates were 
calculated with Pearson’s and Spearman’s rank tests. 
All of the above mentioned analyses were repeated in patients with a preconception 
DAS28-CRP(3) available. Instead of the DAS28-CRP(3) in the first trimester and prednisone and 
sulfasalazine use in the first trimester, the preconception DAS28-CRP(3) and preconception 
use of prednisone and sulfasalazine were used as independent covariates. 
P values less than or equal to 0.05 were considered statistically significant, except for 
interaction terms, where a P value less than 0.20 was considered significant. All statistical 
analysis were performed using STATA software version 14.1 for Windows. 
Ethics
This study is in compliance with the Helsinki Declaration, and the Medical Ethics Committee 
at the Erasmus Medical Center Rotterdam, The Netherlands, approved the PARA-study. 
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RESULTS
Participants
In total, data on 190 pregnancies from 168 women were used for the current analysis. 
Descriptive statistics of the study population are shown in table 1. The mean maternal age 
in the first trimester was 32.2 years and the median duration of RA was 4.8 years. In total, 
133 patients (70.0%) were RF positive, and 116 patients (61.1%) were ACPA positive. Of these 
patients, 143 (75.3%) were classified as either RF or ACPA positive, or positive for both, and 
47 (24.7%) as negative for both. Erosions were present in 118 patients (62.1%). 
RA disease activity during pregnancy
The mean ± SD DAS28-CRP(3) changed during pregnancy from 3.6 ± 1.2 in the first trimester 
to 3.3 ± 1.2 in the third trimester (P < 0.001) to 3.5 ± 1.1 at 12 weeks postpartum (P = 0.01), 
and finally 3.4 at 26 weeks postpartum (P = 0.03). In the third trimester, 50.0% of the patients 
had low disease activity (DAS28-CRP(3) < 3.2) compared to 40.5% in the first trimester (P 
= 0.02). The total number of patients in remission (DAS28-CRP(3) < 2.6) increased from 43 
(22.6%) in the first trimester to 58 (30.5%) in the third trimester (P = 0.03). 
In 110 pregnancies (57.9%) there was a preconception DAS28-CRP(3) available. In this 
subgroup, similar results for disease activity (but in this case from preconception to third 
trimester) as in the whole group were obtained. 
Medication use during pregnancy
In this study, the only antirheumatic medications prescribed during pregnancy were 
prednisone, sulfasalazine and hydroxychloroquine. Medication use remained overall 
similar throughout pregnancy. Prednisone, either with or without sulfasalazine and 
hydroxychloroquine, was used by 80 patients (42.1%) during at least 1 trimester of 
pregnancy. Seventy patients (36.8%) used prednisone in the first trimester, and 58 (30.5%) 
continued prednisone throughout the whole pregnancy. The median dose of prednisone 
was 7.5 mg/day (IQR 5.0 - 10) in every trimester during pregnancy. 
Sulfasalazine, either with or without prednisone and hydroxychloroquine, was used by 
62 patients (32.6%) during at least one trimester of pregnancy. A total of 57 patients (30.0%) 
used sulfasalazine in the first trimester, and 51 (26.8%) continued sulfasalazine throughout 
the entire pregnancy. The median dose of sulfasalazine remained 2,000 mg/day (IQR 1,500 
– 2,000) in every trimester during pregnancy. 
Hydroxychloroquine, either with or without prednisone and sulfasalazine, was used 
by 6 patients (3.2%) during at least 1 trimester of pregnancy. Five patients (2.6%) used 
hydroxychloroquine in the first trimester, and 4 (2.1%) continued hydroxychloroquine 
Table 1. Descriptive statistics of study population. Values are number (%) unless indicated otherwise. 
Baseline characteristics (n = 190)
Age of mother, 1st trimester, mean ± SD years 32.2 ± 3.7
Smoking during pregnancy 15 (7.9)
Duration of 1st trimester RA, median (IQR) years 4.8 (2.1 – 10.0)
RA-associated autoantibodies
RF positive 133 (70.0)
ACPA positive 116 (61.1)
Either RF or ACPA, or both positive 143 (75.3)
Presence of erosions 118 (62.1)
Parity 
Nulliparous 101 (53.2)
Multiparous 89 (46.8)
DAS28-CRP(3) 1st trimester, mean ± SD 3.6 ± 1.2
1st trimester DAS28-CRP(3)*: 
< 2.6 43 (22.6)
≥ 2.6 to < 3.2 34 (17.9)
≥ 3.2 to ≤ 5.1 95 (50.0)
> 5.1 18 (9.5)
Methotrexate use in the past 116 (61.1)
Biologic agent use in the past 33 (17.4)
Medication use during 1st trimester
Prednisone only 45 (23.7)
Sulfasalazine only 31 (16.3)
Both prednisone and sulfasalazine 24 (12.6)
Hydroxychloroquine (either alone or in combination) 5 (2.6)
No medication during 1st trimester 85 (44.7)
RA= rheumatoid arthritis; SD= standard deviation; IQR= interquartile range; RF= rheumatoid factor; ACPA= anti-
citrullinated protein antibody; DAS28-CRP(3) = Disease Activity Score in 28 joints using C-reactive protein levels. 
Disease activity groups are defined according to the European League Against Rheumatism criteria. * Disease 
activity groups are defined according to the European League Against Rheumatism criteria. 
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throughout the entire pregnancy. The median dose of hydroxychloroquine was 200 mg/
day (IQR 200 – 400) in the first and second trimester, and 300 mg/day (IQR 200-450) in the 
third trimester of pregnancy. 
In the first trimester, 85 patients (44.7%) did not use antirheumatic medication. From 
these, 74 patients (39.0%) did not use medication throughout the whole pregnancy. Of the 
11 patients who started using antirheumatic medication after the first trimester, 6 started 
using prednisone and 5 started using sulfasalazine. Five of the patients on prednisone started 
using it in the second trimester. The mean DAS28-CRP(3) of the patients using prednisone 
was 4.8 in the first and 4.6 in the third trimester. All patients who received prednisone had 
a DAS28-CRP(3) in the first, second, and third trimester above 3.2. In total, 116 patients 
(61.1%) used MTX and 33 (17.4%) used biological agents in the past. In all patients, MTX and 
biological agents were discontinued prior to conception.
Factors associated with low disease activity and remission in the third 
trimester
For clinical purposes the DAS28-CRP(3) in the third trimester was dichotomized for easier 
interpretation. In addition, the DAS28-CRP(3) in the first trimester was dichotomized to < 
3.2 or ≥ 3.2. In the multivariate model of low disease activity (DAS28-CRP(3) < 3.2) in the 
third trimester, moderate-to-high disease activity (DAS28-CRP(3) ≥ 3.2) in the first trimester, 
the presence of autoantibodies, and the use of prednisone during the first trimester were 
negatively associated with low disease activity in the third trimester (P < 0.001, 0.033, and 
0.024, respectively) (Table 2). In the final model, the interaction term between the DAS28-
CRP(3) in the first trimester and prednisone use in the first trimester was significant (P = 
0.094). 
In the multivariate logistic regression analysis of remission (DAS28-CRP(3) < 2.6) in the 
third trimester, only moderate-to-high disease activity (DAS28-CRP(3) ≥ 3.2) in the first 
trimester and the presence of autoantibodies were negatively associated with remission 
(DAS28-CRP(3) < 2.6) in the third trimester (P < 0.001 and P < 0.005, respectively) (Table 
2). Prednisone did not reach statistical significance (P = 0.089), but there was a trend for a 
negative association. In the final model, the interaction term between the DAS28-CRP(3) in 
the first trimester and the presence of autoantibodies was significant (P = 0.033).
In the subgroup analyses of patients for whom a preconception DAS28-CRP(3) was available 
(n = 110), similar results as in the whole group were obtained with the preconception 
variables (data not shown). 
Since 2 of the interaction terms were positive in these final models, subgroups based on 
the DAS28-CRP(3) (< 3.2 or ≥ 3.2) in the first trimester were created to perform a stratified 
analysis (Table 3). In patients with a low initial DAS28-CRP(3) (< 3.2) , neither prednisone use 
in the first trimester nor the presence of autoantibodies were associated with low disease 
activity or remission in the third trimester. In patients with a DAS28-CRP(3) ≥ 3.2 in the first 
trimester, prednisone use in the first trimester was negatively associated with low disease 
activity, and the absence of autoantibodies was associated with remission in the third 
trimester in the multivariate models (P = 0.007 and P = 0.001, respectively) (Table 3). 
Based on the results of the stratified analysis, patients were divided into groups to get 
more insight in the chance of low disease activity and remission in the third trimester (Table 
4). Since prednisone use in the first trimester was only associated with low disease activity 
and the presence of autoantibodies was only associated with remission in patients with an 
initial DAS28-CRP(3) ≥ 3.2, only these subgroups were created. 
In total, 95 patients achieved low disease activity (DAS28-CRP(3) < 3.2) in the third 
trimester (Table 4). From the 77 patients with a DAS28-CRP(3) < 3.2 in the first trimester, the 
majority (74.0%) had low disease activity in the third trimester as well. From the patients 
with an initial DAS28-CRP(3) ≥ 3.2, the chance for low disease activity was the highest in the 
subgroup which did not use prednisone in the first trimester (44.8%). 
In total, 58 patients achieved in remission (DAS28-CRP(3) < 2.6) in the third trimester 
(Table 4). From the 77 patients with a DAS28-CRP(3) < 3.2 in the first trimester, 45 (58.4%) 
were in remission in the third trimester. From the 91 patients who had a first trimester 
DAS28-CRP(3) ≥ 3.2 and autoantibodies present, only 5 (5.5%) achieved remission. In total 
8 of 22 patients (36.4%) of the patients with an initial DAS28-CRP(3) ≥ 3.2 but without 
autoantibodies achieved remission in the third trimester. 
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DISCUSSION
Almost all studies conducted so far on the subject of pregnancy in patients with RA have only 
focused on the occurrence of improvement rather than determining patient characteristics 
associated with disease activity. In this prospective study we showed that a low initial 
DAS28-CRP(3), and the absence of prednisone use and the absence of autoantibodies were 
associated with low RA disease activity in the third trimester. Other factors we thought to 
be associated with the disease course that were analyzed in this study (sulfasalazine use in 
the first trimester, parity of the mother, MTX use in the past, the presence of erosions, and 
the duration of RA) did not reach statistical significance. Of course there might be other, 
maybe genetic factors of mother and child that influence the improvement of RA during 
pregnancy 3, 19, 20 . However, this would not help us in the daily practice, since we do not have 
the genetic profile of every patient and her offspring. Additionally, research has recently 
shown that the disease course in a first pregnancy is not predictive for a subsequent 
pregnancy 21 . We considered the sex of the child as an influential factor, but this factor also 
did not reach statistical significance (data not shown). On the other hand, the sex is not 
known until approximately midgestation, and therefore is not useful in this context. 
The mean decrease in DAS28-CRP(3) of 0.3 that we found in our study is low, but the 
reason for this decrease is probably, as previously reported by de Man et al. 4 , due to the fact 
that a considerable number of patients already had low disease activity (40.5%) or were in 
remission (22.6%) in the first trimester. The decrease in DAS28-CRP(3) was the highest in 
patients with higher disease activity in the first trimester 4 , but these patients are still less 
likely, as shown in this study, to achieve low disease activity or remission.
It could be that prednisone was a proxy for disease activity since the mean DAS28-CRP(3) 
was the highest in patients who used prednisone during the first trimester (3.9 vs. 3.4). 
However, of the 18 patients who had high disease activity in the first trimester (DAS28-
CRP(3) > 5.1) 10 used prednisone and 8 did not use prednisone in the first trimester. From 
the 10 patients who used prednisone, in total 8 patients still had high disease activity in the 
third trimester. From the 8 patients with high disease activity who did not use prednisone in 
the first trimester, 4 still had high disease activity in the third trimester. Since these numbers 
are low, we cannot draw any firm conclusions. However, although speculative, we cannot 
rule out the idea that prednisone itself may inhibit mechanisms that lead to improvement 
of RA during pregnancy.
Many patients and physicians alike expect to be able to taper medication at the 
beginning of pregnancy in RA patients, since they rely on the spontaneous improvement 
of RA during pregnancy. Based on the results of our study, one may consider tapering 
medication in those patients who are already in remission or have low disease activity at 
the beginning of pregnancy, and maybe even in those with higher disease activity but 
not expressing autoantibodies and not taking prednisone. For those patients that still have 
moderate-to-high disease activity and are taking prednisone or express autoantibodies, we 
advise to continue medication, if possible, throughout pregnancy. Sound evidence-based 
recommendations on tapering medication can only be given based upon a controlled 
trial in which medication is tapered in a randomized manner. Given the restrictions of 
pregnancy, such a trial is very unlikely to be conducted. If such a trial does take place, the 
patient characteristics identified in this study could be used for patient stratification. 
Finally, our study has some limitations. First, none of the patients within this cohort used 
biological agents during pregnancy. It would be interesting to replicate the results of our 
current study in a cohort with patients who used biological agents during at least the first 
trimester of pregnancy. Second, in 42% of the patients there was no preconception DAS28-
CRP(3) available. Nevertheless, the regression analysis in the subgroup of 110 patients with 
a preconception DAS28-CRP(3) reached comparable statistical significant results to the 
whole group. Furthermore, there was no significant difference between preconception 
DAS28-CRP(3) and first trimester DAS28-CRP(3) in these patients (P = 0.43). Third, since 
rheumatologists in this study were free to change medication and dosages, lowering or 
discontinuation of prednisone after the first trimester could cause an increased DAS28-
CRP(3) in the third trimester, thereby resulting in an association between prednisone use 
during first trimester and more active disease during third trimester. However, our analysis 
showed that this was not the case in our patient group. In total, 12 patients who used 
prednisone in the first trimester did not use prednisone in the third trimester. From these, 
only 1 patient had low disease activity (DAS28-CRP(3) < 3.2) in the first trimester and ended 
with a higher DAS28-CRP(3) in the third trimester (DAS28-CRP(3) = 4.48). Furthermore, in 
total 14 patients used a lower prednisone dose in the third trimester compared to the 
first trimester. From these, only 2 had low disease activity (DAS28-CRP(3) < 3.2) in the first 
trimester and ended with a higher DAS28-CRP(3) in the third trimester (DAS28-CRP(3) 3.46 
and 3.70, respectively). These findings are not likely to have induced bias in the analyses, 
and therefore we assume that the negative association between prednisone use in the first 
trimester and the DAS28-CRP(3) in the third trimester is plausible. Fourth, dichotomizing the 
third trimester DAS28-CRP(3) to ≥ or < 2.6 and ≥ or < 3.2 resulted in slight loss of power in the 
association between prednisone use and remission, but there was a trend for significance 
(P = 0.08). Finally, for the current study we used all 190 pregnancies from 168 women in 
order to enlarge the power. To exclude possible selection bias in the obtained results, we 
performed a subgroup analysis, including only the first participation of the patients (n = 
168), and found similar results in all regression analyses (data not shown). 
In conclusion, our study shows that a low initial DAS28-CRP(3) (preconception or 
first trimester), the absence of autoantibodies and the absence of prednisone use at 
preconception or in the first trimester are associated with low disease activity in the 
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third trimester. These findings create more insight into the phenomenon of spontaneous 
improvement of RA during pregnancy and can be helpful in the daily care for our pregnant 
patients with RA. 
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ABSTRACT
Objectives. Adverse exposures during early life are associated with later-life health. DNA 
methylation may be an underlying mechanism. The main objective of this study was 
to determine whether the DNA methylation profile of children born to mothers with 
rheumatoid arthritis (RA) is different from that of children born to mothers from the general 
population. In addition, we aimed to determine whether any differences in methylation are 
associated with maternal RA disease activity or medication use during pregnancy. 
Methods. For this study, genome-wide DNA methylation was measured at CpG sites, 
using the Infinium Illumina Human-Methylation 450k BeadChip in 80 blood samples from 
children (mean age=6.8 years), born to mothers with RA. As controls, blood samples from 
354 children (mean age=6.0 years) from the population-based Generation R Study were 
used. Linear mixed models were performed to investigate differential methylation between 
the groups, corrected for relevant confounders. 
Results. A total of 147 CpGs were differentially methylated between blood samples of 
children born to mothers with RA and the control blood samples. The 5 most significantly 
associated CpGs were: cg06642177, cg08867893, cg06778273, cg07786668, and 
cg20116574. The differences in methylation were not associated with maternal RA disease 
activity or medication use during pregnancy
Conclusions. DNA methylation at 147 CpG sites differed between children born to mothers 
with RA and children born to mothers from the general population. It remains unknown 
whether the identified associations are causal and if so, whether they are caused by the 
disease or treatment. More research, including the replication of these results, is necessary 
in order to determine any relevance of these findings for the later-life health of children 
born to mothers with RA.
Adverse exposures in early life are associated with later-life health, which is referred to as the 
Developmental Origins of Health and Disease (DOHaD) hypothesis1-5. In the Dutch Hunger 
Winter study, exposure to famine during pregnancy has been shown to be associated with 
glucose intolerance, obesity, and cardiovascular and metabolic disease in adulthood6-9. 
The exact mechanisms underlying these associations are not completely understood. Epigenetic 
processes are thought to be one of the mechanisms underlying the associations of early-life 
exposures and later life health outcomes10, 11. Epigenetic changes are alterations to the DNA that 
do not affect the base pair order, but may influence gene expression. DNA methylation is the best 
studied and understood epigenetic modification12, 13, and has been shown to be associated with 
a number of adverse in utero exposures. Factors that have been demonstrated to be associated 
with fetal DNA methylation include maternal disease11 and malnutrition6, 8, 14, 15, smoking16, 
placental insufficiency 17, corticosteroids18, folate depletion19 and cytokines20. DNA methylation 
usually occurs at Cytosine-phosphate-Guanine (CpG) sites12, 13. The effect of hypermethylation and 
hypomethylation of a CpG, on the expression of genes, depends on the location of the CpGs21, 22. 
The most pronounced changes in DNA methylation occur during early pregnancy11, 14. 
During embryogenesis, there are 3 germ layers that form in the developing fetus: the 
ectoderm, the mesoderm, and the endoderm (e.g. buccal epithelial cells are derived from 
ectoderm, and blood from mesoderm). When DNA methylation is altered in early pregnancy, 
all the germ layers are affected23, 24. 
RA is a chronic inflammatory disorder, and may be considered as an adverse exposure 
during pregnancy25. Therefore, it is plausible that maternal RA may induce changes in fetal 
DNA methylation, and that it is related with the later-life health of the offspring. Interleukin 
(IL)-6, one of the pro-inflammatory cytokines present in patients with RA, is known to 
influence DNA methylation 20. RA treatment during pregnancy includes among others 
sulfasalazine (SSZ) and corticosteroids such as prednisone. SSZ is a known folate antagonist 
and could influence DNA methylation in this respect19. SSZ crosses the placenta and the 
developing child is exposed to almost similar levels of SSZ as the mother 26. Furthermore, 
corticosteroids might influence DNA methylation18. The active form of prednisone, 
prednisolone, is normally inactivated in the placenta27-29. However, until the gestational age 
of approximately 12 weeks, the phase in which a lot of DNA methylation changes happen, 
the placenta is not completely developed, and prednisolone diffuses passively to the fetus30. 
In the current study we investigated whether the DNA methylation profile of children 
born to mothers with RA was different from that of children born to mothers from the 
general population. Furthermore, we investigated whether the any differentially methylated 
CpGs were associated with RA disease activity or medication use during pregnancy, or 
with indicators of future metabolic and cardiovascular diseases. In addition, we examined 
whether these CpGs were associated with the expression of genes using expression 
quantitative trait methylation (eQTM) analysis. 
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METHODS
Study population
FEPRA-study
This study is embedded in the Pregnancy induced Amelioration of Rheumatoid Arthritis 
(PARA) study, a nationwide prospective cohort study from the Netherlands on pregnancy 
and RA31. From May 2002 to August 2008, 369 female RA patients who fulfilled the 1987 
revised criteria of the American College of Rheumatology32 and had a wish to conceive or 
were already pregnant, preferably in the first trimester, were enrolled in the PARA-study33, 
34. After participation in the PARA-study, 196 children and their parents were invited to 
participate in a follow-up study on fetal programming in RA, the FEPRA-study. For this study, 
108 children with a mean age of 6.8 years (SD=1.3) visited the Erasmus MC in Rotterdam. 
There were no statistical differences in baseline characteristics between the participating 
and non-participating group. The main reason for non-participation was the distance to 
the hospital (38%), or that parents felt that the investigations were too much of a burden 
for their child (30%). For the current study on epigenetics, the parents were contacted once 
more to obtain written informed consent to perform DNA methylation analysis in stored 
blood samples and to provide cheek swab samples from their children. Finally, parents of 85 
children gave consent to analyse the blood samples of their (European-ancestry) children. 
Furthermore, parents of 71 children provided cheek swabs from their children. From the 
parents of 23 children who did not provide informed consent, 20 (87.0%) could not be 
successfully contacted by phone or mail after multiple attempts. 
Generation R Study
The control group consisted of children with a mean age of 6.0 years (SD=0.4), included 
in the Generation R Study, a population-based prospective cohort study from pregnancy 
onwards in Rotterdam, the Netherlands. The Generation R Study has been described in 
detail previously35. Briefly, all pregnant women living in Rotterdam with a delivery date 
between April 2002 and January 2006 were invited to participate, and 9,778 mothers were 
enrolled in the study35. At the age of 6 years, DNA methylation was measured in a subgroup 
of 493 children of European ancestry. 
Data collection
FEPRA-study
In the PARA-study, RA patients were seen before pregnancy (if possible), three times during 
pregnancy and again three times after the birth of the child. At all time-points, data on 
mother (e.g. disease activity [with the Disease Activity Score in 28 joints using C-Reactive 
Protein levels (DAS28-CRP[3])], medication use, and pregnancy and outcome) and child 
(growth parameters) were collected 34. For the FEPRA-study, during the visit around the age 
of 7 years, data on blood pressure, growth and body composition including fat percentage 
and lean body mass of the children were measured. Also, blood, which is a mesoderm germ 
layer derivate, was drawn for the DNA methylation analysis 36. Cheek swabs were collected 
for the analysis of DNA methylation in buccal epithelial cells, which is an ectoderm germ 
layer derivate. 
Generation R Study
In the Generation R Study, mothers were seen three times during pregnancy. The children 
were followed from birth until childhood. Data collection in children and their mothers 
included among others, questionnaires (e.g. medical history, medication use including 
the use of corticosteroids during pregnancy), detailed physical examinations, and blood 
sampling35.
DNA methylation analysis
Genome-wide DNA methylation analysis
Genomic DNA was extracted from whole peripheral blood samples at the lab of the internal 
medicine of the Erasmus MC, and from the cheek swab samples at the rheumatology lab of 
the Erasmus MC. Bisulfite conversion of 500ng of genomic DNA was performed using the 
Zymo EZ-96 DNA Methylation Kit (Zymo Research Corporation, Irvine, CA, USA) according 
to the manufacturer’s protocol.
Genomic methylation profiling was performed using the Infinium Illumina 
HumanMethylation 450k BeadChip arrays (Illumina Inc., San Diego, USA) according to the 
manufacturer’s protocol. The Illumina array measures methylation status of 485,512 CpG 
sites in the gene and non-gene regions across the entire human genome. To prevent 
possible batch-effects, blood and cheek swab samples were measured in the same run.
Quality control and normalization
The data were pre-processed using the minfi package in R version 3.4.1 (www.r-project.org). 
Samples with incomplete or poor bisulfite conversion, extension, hybridization, or specificity 
were excluded37. In addition, samples with sex mismatch and samples with a call rate <95% 
were removed. This quality control (QC) was done separately for blood samples (Generation 
R and FEPRA) and for cheek swab samples (FEPRA). During QC, 5 blood and 14 cheek swab 
samples from the FEPRA-study were excluded, resulting in 80 and 57 samples respectively. 
From the Generation R blood samples, 27 were excluded due to corticosteroid use or RA 
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disease in the mother, and 32 were excluded during QC, resulting in 441 blood samples. 
In addition, in order to perform complete case analyses, 87 cases with missing data from 
the Generation R Study were excluded leaving 354 samples to analyse. The intensity values 
were then quantile normalized using the CPACOR workflow37. Methylation at each CpG was 
calculated as the beta-value [beta=intensity of the methylated allele (M)/(intensity of the 
unmethylated allele (U) + M + 100)], containing values from 0 to 1. Blood cell composition 
of the samples was estimated using the Houseman method with the Reinius reference set38, 
39. Probes with SNPs at single base extension, probes with improper binding, and CpGs on 
the X and Y chromosome were removed from the analysis40. From the initial 485,512 CpGs, 
32,057 were excluded during QC leaving 453,456 CpGs for analysis.
Statistical Analysis
Statistical Models
For all subjects, descriptive statistics were calculated as numbers, percentages, means, 
Standard Deviations (SDs), medians, and InterQuartile Ranges(IQRs) using stata version 
14.1 (https://www.stata.com/stata14/). Student t tests and chi-squared tests were used to 
compare the baseline characteristics of the FEPRA-study and Generation R Study. For these 
analyses, P-values <0.05 were considered statistically significant. 
Linear mixed models were performed to analyse differential methylation between the 
groups, using R. The first model was created to compare the blood samples from the FEPRA-
study with the blood samples of the Generation R Study to determine whether the DNA 
methylation profile of children born to mothers with RA was different from that of children 
born to mothers from the general population. This model was corrected for biological 
covariates (age, BMI standard deviation scores [SDS], adjusted for age and sex according 
to the Dutch reference values, using the Growth Analyser[version 4.0; Growth analyser BV, 
Rotterdam, the Netherlands, www.growthanalyser.org], sex, gestational age at delivery, 
maternal age, folic acid use during pregnancy, socioeconomic status [SES], maternal 
smoking, and white blood cell subtypes), technical covariates (technical batch effects 
[array ID & position on array], and 5 hidden confounders. Technical covariates were added 
as random effects in the models. The hidden confounders were calculated using the CATE 
package41, 42 while correcting for the group (RA vs non-RA offsprings), all biological covariates 
and technical covariates. This resulted in hidden confounders that were independent of all 
included covariates. The BACON package42 was used to correct for unobserved covariates 
in order to reduce test-statistic bias and inflation. The genomic inflation factor (λ)43 was 
calculated. After QC 453,456 CpGs remained for analysis. Therefore, a Bonferroni-adjusted 
P-value of 0.05/453,456=1.10*10-7 was used44. 
CpGs were annotated for nearby genes with the Genomic Regions Enrichment of 
Annotations Tool45. Bonferroni significant CpGs from the first analysis were then further 
analyzed within the blood samples of the FEPRA-study to explore if RA disease activity, 
prednisone use or SSZ use during pregnancy would explain the differences in methylation 
found in the first model. After that, 2 linear mixed models were created with the significant 
CpGs, to identify whether these were associated with the BMI SDS or the fat percentage SDS 
of the child, as indicators of future metabolic disease. These models were analysed in the 
80 blood samples of the FEPRA-study. CpGs with a P-value below 0.05/147=3.4*10-4 were 
considered statistically significant. 
The significant CpGs found in the first analysis were also analyzed in DNA derived 
from buccal epithelial cells, obtained by cheek swabs from the FEPRA-study, to explore if 
the differentially methylated CpGs were also differentially methylated in that germ layer 
derivate, as a kind of validation of the results. For this analysis, CpGs with a p-value below 
Bonferroni significance level of 3.4*10-4 were considered statistically significant. 
Genomic (median) methylation was also calculated from the beta values per sample in 
the blood samples of the FEPRA-study. This was compared with genomic methylation of 
the blood samples from the Generation R Study using a linear mixed model with the beta-
value as dependent variable and the covariates as previously mentioned in the first model 
(including RA exposure) as confounders. A p-value of <0.05 was considered statistically 
significant in this model. 
Expression quantitative trait methylation (eQTM) analysis 
EQTMs are sites at which DNA methylation is known to influence the expression of one or 
more genes46. To analyse whether any of the significant CpGs were linked to the expression 
of nearby genes, an eQTM analysis was performed. For the these analyses the online BIOS 
QTL browser (https://molgenis26.target.rug.nl/downloads/biosqtlbrowser/) was used40. 
Ethics
This study is in compliance with the Helsinki Declaration. Informed consent was obtained 
for all participants. The Medical Ethics Committee of Erasmus MC, University Medical Center 
Rotterdam, the Netherlands, approved the PARA-study (MEC-214.320/2002/117), FEPRA-
study (MEC-2009-441), and the Generation R Study (MEC198.782.2001.31) 
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RESULTS
Participants
The flow-chart of the study population is shown in figure 1. A total of 80 blood and 57 
cheek swab samples from the FEPRA-study (children born to mothers with RA), and 354 
blood samples from the Generation R Study (children born to mothers from the general 
population) remained for analysis. 
Descriptive statistics of the study population are presented in table 1. Overall, children 
born to mothers with RA were slightly older compared with children in the Generation R 
Study (6.8 years [SD 1.3] versus 6.0 years [SD 0.4], p<0.001). In the FEPRA-study 36 women 
(45%) did not start using folic acid before or in early pregnancy, while in the Generation 
R Study the vast majority of the women (92.7%) started using folic acid before or in early 
pregnancy (p<0.001). Approximately half of the women (47.5%) from the FEPRA-study 
had a high SES based on education level compared with 68.4% of the women from the 
Generation R Study (p<0.001). One woman (1.3%) from the FEPRA-study, and 86 women 
(24.3%) from the Generation R Study smoked periconceptionally or at any time during 
pregnancy (p<0.001). 
Figure 1. Flow-chart of the study population and exclusion of participants. 
Table 1. Descriptive statistics of study population 
FEPRA-study (n=80) Generation R Study (n=354)
Age child# (years), mean(SD) 6.8 (1.3)* 6.0 (0.4)*
BMI SDS child#, mean(SD) -0.14 (0.87)* 0.18 (0.74)*
Sex child
  Male, N(%)
  Female, N(%) 
46 (57.5)
34 (42.5)
176 (49.7)
178 (50.3)
Maternal age at delivery (years), mean(SD) 32.9 (3.9) 32.5 (4.0)
Gestational age (weeks), mean(SD) 39.5 (2.0)* 40.2 (1.5)*
Folic acid
  Start before pregnancy, N(%)
  Start in early pregnancy, N(%)
  No use, N(%)
25 (31.3)*
19 (23.8)*
36 (45.0)*
212 (59.9)*
116 (32.8)*
26 (7.3)*
SES based on education level
  Low, N(%)
  Middle, N(%)
  High, N(%)
9 (11.3)*
33 (41.3)*
38 (47.5)*
4 (1.1)*
108 (30.5)*
242 (68.4)*
Maternal smoking$, N(%) 1 (1.3)* 86 (24.3)*
DAS28-CRP-3 3rd trimester, mean(SD) 3.3 (1.1) - 
Use of medication ≥ 1 trimester
  Only prednisone use, N(%)
  Only sulfasalazine use, N(%)
  Combination, N(%) 
17 (21.3)
14 (17.5)
13 (16.3)
-
-
-
No medication use, N (%) 36 (45.0) -
Fat percentage SDS, mean(SD) 0.24 (0.97) -
BMI= Body Mass Index; SDS= Standard Deviation Score; SES= Socioeconomic Status; DAS28-CRP(3)= Disease 
Activity Score in 28 joints using C-reactive protein levels;
 #At time of the blood sampling; $During pregnancy. *P-values <0.001
DNA methylation in the FEPRA-study as compared to the Generation R Study
In the first linear mixed model blood samples from the FEPRA-study were compared with 
blood samples from the Generation R Study, corrected for the covariates mentioned in the 
methods. In total, 147 CpGs were significantly differentially methylated between children in 
the FEPRA-study and children in the Generation R Study (Figure 2). The QQ-plot is shown in 
figure 3. The genomic inflation factor (λ) was 1.06. 
In table 2 the 5 most significant CpGs, and the 5 CpGs with the largest effect sizes (within 
the significant CpGs) are described in detail. The complete list of significantly associated 
CpGs is provided as a supplemental file. A positive beta represents higher methylation levels 
in children born to mothers with RA. Methylation was higher in children born to mothers 
with RA (FEPRA-study) than in those from the general population at all 5 CpGs with the 
lowest P-values. Methylation at the 5 CpGs with the largest effect sizes was lower in children 
born to mothers with RA, with the exception of cg06656994.
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The median genomic methylation level was significantly lower, albeit with a very small 
difference, in children born to mothers from the FEPRA-study compared with children born 
to mothers from the Generation R Study (effect size= -0.0003, SE=0.0002, p-value 0.038). 
Figure 2. Results of the analysis of DNA methylation in children born to mother with RA (FEPRA-
study) compared with children born to women from the general population (Generation R Study). The 
chromosomes are depicted on the x-axis, and the -log p-value on the y-axis. The horizontal grey line 
represents the Bonferroni threshold for significance of p=1.10*10-7.
Figure 3. QQ-plot of observed versus expected p-values from the analysis of DNA methylation in 
children born to mother with RA (FEPRA-study) compared with children born to women from the 
general population (Generation R Study).
Table 2. The 5 most significant CpGs (white rows) and the 5 CpGs with the largest effect size (grey 
rows) from the linear mixed model: DNA methylation in blood samples from children born to mothers 
with RA (FEPRA-study) compared with children born to mothers from the general population 
(Generation R Study).
CpG Beta$ SE P-value Nearest gene (±bp) Chr Bp Location#
cg06642177 0.028 0.002 1.32*10-24 SLC2A12(-122529) 6 134496341 -
cg08867893 0.018 0.002 7.66*10-24 ZNF365(+221) 10 64134160 -
cg06778273 0.024 0.002 3.77*10-23 TNFRSF18(+4995) 1 1137117 -
cg07786668 0.026 0.002 7.11*10-23 ZFHX3(-10142) 16 73092391 -
cg20116574 0.019 0.002 5.91*10-19 NCOA5(+435) 20 44718168 Promoter
cg16930947 -0.050 0.008 3.22*10-11 - 8 88984447 -
cg01485645 -0.044 0.006 1.64*10-13 MLLT6(+303) 17 36862199 Promoter
cg12360123 -0.043 0.008 1.61*10-08 - 10 79984532 Enhancer
cg06656994 0.038 0.005 9.67*10-13 FAM163A(+903) 1 179713176 Enhancer
cg17483482 -0.037 0.006 4.62*10-10 - 1 117152162 -
bp=base pair; Chr= chromosome; SE= standard error
$ Beta represents the difference in DNA methylation at the given CpG site in children born to mothers with RA 
(FEPRA-study) as compared with children born to mothers from the general population (Generation R Study)
# Location in promoter, enhancer or unknown (-)
Association of the differences in DNA methylation with maternal RA disease 
activity and medication use during pregnancy and with indicators for future 
metabolic disease
None of the 147 CpGs were significantly associated with disease activity (DAS28-CRP(3)) or 
medication (prednisone or SSZ) use. In addition, none of the CpGs were associated with BMI 
SDS or fat percentage SDS in the children.
Analysis in buccal epithelial cells 
A total of 10 out of the 147 CpGs significantly associated with maternal RA in blood were 
also associated in buccal epithelial cells. From these, 4 were in the same direction as in 
blood, table 3. CpG cg11336323 was located in a promoter region. 
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Table 3. CpGs that were differentially methylated in the same direction in both blood and in buccal 
epithelial cells.
CpG Beta$ SE P-value Nearest gene (±bp) Chr Bp Location#
cg22998206 0.1029 0.022 4.40*10-06 - 12 49239429 - 
cg03654106 0.0727 0.016 9.50*10-06 - 19 49539527 - 
cg02613964 -0.058 0.014 7.57*10-05 - 3 44690321 - 
cg11336323 -0.092 0.024 1.63*10-04 - 19 41946040 Promoter
bp=base pair; Chr= chromosome; SE= standard error
$ Beta represents the difference in DNA methylation at the given CpG site in buccal epithelial cells from children 
born to mothers with RA (FEPRA-study) as compared with blood samples from children born to mothers from the 
general population (Generation R Study)
# Location in promoter, gene, enhancer or unknown (-)
Expression Quantitative Trait Methylation (eQTM) analysis 
Two CpGs, cg21384971 and cg11220663, were associated with expression of the COPZ2 
and ADD2 genes, respectively (Table 4). These two genes were also the nearest genes to 
those CpGs45. Both CpGs were hypermethylated in the children born to mothers with RA 
(FEPRA-study) as compared with children born to mothers from the general population 
(Generation R Study), and were associated with decreased expression of COPZ2 and ADD2 
in the BIOS eQTM lookup browser.
Table 4. Results from the eQTMs analysis using the 147 CpGs significantly different in children born to 
mothers with RA (FEPRA-study).
CpG Beta$ SE$ P-value$ Nearest genes Beta GN# SE GN# P-value GN# Genes GN# 
cg21384971 0.029 0.004 3.86*10-13 COPZ2 -0.073 0.039 1.79*10-06 COPZ2
cg11220663 0.023 0.003 1.68*10-11 ADD2 -0.121 0.039 3.32*10-06 ADD2
SE= standard error; GN= Genenetwork
$ The columns Beta, SE, P-value, and nearest genes represent the results from the analysis of DNA methylation in 
children born to mothers with RA (FEPRA-study) as compared with children born to mothers from the general 
population (Generation R Study)
# The columns Beta GN, SE GN, P-value GN, and Genes GN represent the results from the BIOS eQTM lookup 
browser.
The positive beta’s in column “Beta” represent hypermethylation, the negative beta’s in column “Beta GN” represent 
decreased gene expression
DISCUSSION 
This is the first study investigating the differences in DNA methylation of children born to 
mothers with RA compared with children born to mothers from the general population. In 
this unique study, all participants were followed prospectively from pregnancy onwards. 
Our study showed differential DNA methylation between the two groups. The differentially 
methylated CpG sites were not associated with disease activity (DAS28-CRP(3)) and/or 
medication (prednisone or SSZ) use, nor to BMI SDS and fat percentage SDS.
In total, 147 CpGs were significantly associated with maternal RA after adjustment for 
multiple biological and technical covariates, and hidden confounders. In addition, although 
the difference was relatively small, the median genomic methylation was significantly lower 
in children born to mothers with RA compared with children born to mothers from the 
general population. A decrease in genomic DNA methylation has been found in a variety of 
common age-related diseases47. Of the 5 most significant CpGs, interestingly, 2 (cg06642177 
and cg07786668) have been associated with myocardial infarction48. The most significant 
CpG, cg06642177, is located on chromosome 6 near the SLC2A12 gene49, associated with 
insulin sensitivity49, 50, heart failure and diabetes51 in animal models. Cg07786668, located 
on chromosome 16, is located in the ZFHX3 gene. ZFHX3 has been associated in multiple 
human studies with atrial fibrillation52-56, coronary heart disease57, and obesity in a Korean 
population58. Cg20116574, was annotated to the NCOA5, a protein coding gene, which has 
been associated with diabetes mellitus type 2 in animal models59, 60. 
From the remaining 142 CpGs, 1 (cg17218495), annotated to the SMARCA4 gene, has 
independently and significantly been associated with myocardial infarction48. The other 
significant CpGs from our study have not been associated with disease phenotypes. 
Out of the initial 147 significant CpGs, 10 were also significantly differentially methylated 
in buccal epithelial cells obtained by cheek swabs. From these, 4 were in the same direction 
as in blood. When DNA methylation is altered in more than one germ layer derivate, it is likely 
that these alterations occurred in early development23, 24. Unfortunately, in the Generation R 
Study, DNA methylation in buccal epithelial cells was not available. These 4 CpGs have not 
been associated with disease phenotypes in humans. 
Thus, some of the associated CpGs (cg06642177, cg07786668, and cg17218495) have 
been associated with cardiovascular disease in previous studies, while others are located 
in or near genes that are associated with cardiovascular or metabolic disease. Maternal 
RA during pregnancy, a chronic inflammatory disease, might be associated with later-life 
health and disease risk in the offspring. 
None of the significant CpGs were associated with RA disease activity or medication use 
during pregnancy. However, this may have been due to a lack of power, since these analyses 
were performed in the 80 samples of the children born to women with RA (FEPRA-study). 
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The same power problem also applied to the analysis of the CpGs with indicators for future 
metabolic and cardiovascular disease (BMI SDS and fat percentage). 
Our study has some limitations. First, although in its kind it is a large study, a study on DNA 
methylation including 80 subjects and 354 controls is still relatively small. A larger sample 
size would increase power and might result in increased distinctive capability regarding e.g. 
the relationship of altered methylation with RA disease activity or medication use. Despite 
the relative small sample size, a large number of CpGs reached Bonferroni significance. 
Correcting for biological and technical covariates, as well as hidden confounders, and using 
BACON resulted in a λ near 1, reflecting that there was no inflation. Second, we were not able 
to collect a new independent cohort of children born to mothers with RA to replicate the 
results. At the time our study was performed, there were no other comparable prospective 
studies available. Currently, European research groups are conducting new prospective 
cohort studies on the impact of RA on pregnancy and offspring. We encourage these 
research groups, possibly with international collaborations, to replicate our study. 
Thus, the results of this study may support follow-up research of children born to mothers 
with RA. Since follow-up research cannot cover all aspects of development of these children, 
it is important to make rational choices what aspects have to be studied. Based upon 
our data, we recommend that at least indicators for future cardiovascular and metabolic 
disease should be considered. The effects of RA disease activity and medication use on 
DNA methylation should be investigated in studies with larger sample sizes. Furthermore, in 
the last years the use of TNF inhibitors during pregnancy in patients with RA has increased. 
This often results in lower RA disease activity during pregnancy. Future research should 
also cover the effects of the use of TNF inhibitors on the differentially methylated CpGs in 
children born to mothers with RA. 
In conclusion, maternal RA during pregnancy is associated with differential DNA 
methylation in offspring. It remains unknown whether the identified associations are causal 
and if so, whether they are caused by the disease or treatment. Some of the differentially 
methylated CpGs or their nearby genes were associated with cardiovascular or metabolic 
disease. Maternal RA disease might have life-long consequences for the offspring. However, 
more research in this particular field must be undertaken in order to strengthen the 
relevance of our findings. 
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Supplemental table. The 147 significant CpGs from the linear mixed model: DNA methylation in 
blood samples from children born to mothers with RA(FEPRA-study) compared with children born to 
mothers from the general population(Generation R Study).
CpG Nearest gene  
(+/- base pairs)
Chr Base pairs Location Beta Standard error P-value
cg06642177 SLC2A12(-122529 6 134496341 - 0.027693315 0.002704662 1.32E-24
cg08867893 ZNF365(+221) 10 64134160 - 0.018410514 0.001828632 7.66E-24
cg06778273 TNFRSF18(+4995) 1 1137117 - 0.022857221 0.002306493 3.77E-23
cg07786668 ZFHX3(-10142) 16 73092391 - 0.02586352 0.002626713 7.11E-23
cg20116574 NCOA5(+435) 20 44718168 Promoter 0.018815575 0.002115599 5.91E-19
cg21160472 ATF3(+119) 1 212782112 Promoter 0.013379402 0.00166464 9.18E-16
cg09000178 CBFB(+294) 16 67063319 - 0.014919311 0.001866453 1.31E-15
cg01067849 WRNIP1(-102) 6 2765587 Promoter 0.010168425 0.001336479 2.78E-14
cg14119392 DICER1(-15866) 14 95623926 Promoter 0.009496235 0.001275776 9.81E-14
cg01485645 MLLT6(+303) 17 36862199 Promoter -0.044105009 0.005979805 1.64E-13
cg10196289 NSMAF(-196) 8 59572185 - 0.013826063 0.001891212 2.66E-13
cg13018448 ,CUTA(+600) 6 33385440 Promoter 0.035622707 0.004917127 4.34E-13
cg01402409 FRAS1(-614) 4 78978133 - 0.034187754 0.004758592 6.75E-13
cg17492326 ,ANXA13(-31076) 8 124780746 Promoter 0.013530835 0.001894369 9.15E-13
cg06656994 FAM163A(+903) 1 179713176 Enhancer 0.038178019 0.0053507 9.67E-13
cg13390975 BRIX1(+95) 5 34915890 Promoter 0.012727324 0.001788634 1.11E-12
cg17667988 PTBP1(-73) 19 797342 Promoter -0.033538136 0.004760613 1.86E-12
cg14810343 CXXC5(-127) 5 139028149 - 0.011939828 0.001706185 2.60E-12
cg17662034 RDH10(+706) 8 74207518 - 0.01366994 0.001961263 3.17E-12
cg22247188 H2AFY2(+1271) 10 71813603 - 0.020553561 0.002959855 3.81E-12
cg22998206 - 12 49239429 - 0.031783604 0.004590532 4.40E-12
cg00742472 HEATR5A(-149) 14 31889912 Promoter -0.036649507 0.005307146 5.00E-12
cg21423973 TYW1B(+121) 7 72298667 Promoter 0.034153776 0.004952153 5.32E-12
cg24334803 ZNF672(+281) 1 249132834 Promoter 0.032219477 0.00469291 6.62E-12
cg11014794 CPEB3(+51162) 10 93999688 - 0.020288544 0.002988909 1.14E-11
cg15591678 ZNF365(+216) 10 64134155 - 0.023828478 0.003516927 1.24E-11
cg08700690 RORA(+35122) 15 60884630 Promoter 0.009395729 0.001389406 1.36E-11
cg17218495 SMARCA4(+170) 19 11071743 Promoter 0.010408213 0.001546442 1.69E-11
cg18238491 SKA1(+73) 18 47901440 - 0.006920639 0.0010313 1.94E-11
cg00476896 - 17 60215463 - -0.029335846 0.004389098 2.33E-11
cg16930947 - 8 88984447 - -0.049809031 0.007505862 3.22E-11
cg01458961 PPP3CA(-822) 4 102269425 - 0.022397284 0.003379311 3.41E-11
cg22704520 TYW5(+31) 2 200820451 Promoter 0.015040524 0.002278848 4.11E-11
CpG Nearest gene  
(+/- base pairs)
Chr Base pairs Location Beta Standard error P-value
cg25863503 - 6 27799295 - 0.018114832 0.002760384 5.29E-11
cg23792383 KLF5(+171) 13 73633288 Promoter 0.009986606 0.001528091 6.35E-11
cg03847293 - 1 17734508 - -0.032462167 0.004970659 6.54E-11
cg08561325 AKIP1(+289) 11 8932965 Promoter 0.016285887 0.002494156 6.59E-11
cg12100751 HENMT1(+95) 1 109203672 Promoter 0.012782918 0.001960274 6.98E-11
cg18342832 - 7 99933797 Promoter 0.008837976 0.0013622 8.70E-11
cg21384971 COPZ2(+601) 17 46114574 - 0.029200877 0.004508859 9.40E-11
cg17607973 MEPCE(+179) 7 100027408 Promoter 0.012264221 0.001904559 1.20E-10
cg22512322 PSMD6(+47) 3 64009096 Promoter 0.010619257 0.001666666 1.87E-10
cg17255450 EVC2(-55) 4 5710372 - 0.016872706 0.002655126 2.09E-10
cg16041611 SRF(+785) 6 43139680 - 0.010561056 0.001664015 2.20E-10
cg11877270 SPRED2(+1048) 2 65658583 - 0.014862583 0.002349815 2.53E-10
cg25707994 DNAJB6(0) 7 157129685 Promoter 0.014060725 0.002226484 2.70E-10
cg03654106 - 19 49539527 - 0.026109337 0.004139079 2.83E-10
cg07479988 DHX57(-281) 2 39103277 Promoter 0.023103709 0.003673311 3.18E-10
cg21538902 ADO(+464) 10 64565003 Promoter 0.018717869 0.00297763 3.25E-10
cg19031844 ZNF536(+347411) 19 31210714 Enhancer 0.026178619 0.004168745 3.39E-10
cg06295548 - 4 146296778 - -0.021299828 0.003393384 3.45E-10
cg06117184 CKAP2L(+70) 2 113522207 Promoter 0.008425305 0.00134451 3.69E-10
cg04910183 CDC73(-75) 1 193090988 Promoter 0.010437417 0.001666679 3.79E-10
cg10181911 RPE(-268) 2 210867059 Promoter 0.035764362 0.005736336 4.53E-10
cg17483482 - 1 117152162 - -0.036832852 0.005910728 4.62E-10
cg02461956 NCAPD3(+509) 11 134093940 Promoter 0.01486645 0.002389714 4.94E-10
cg19656070 TAX1BP3(+18) 17 3571978 Promoter 0.01069978 0.001727363 5.85E-10
cg07283595 DHX33(+400) 17 5372003 Promoter 0.023494356 0.003797213 6.12E-10
cg25757017 OLR1(+18303) 12 10306462 Promoter, 
Enhancer
0.021080747 0.00341288 6.54E-10
cg02286335 ZWINT(-11) 10 58121068 Promoter 0.0149277 0.002433753 8.59E-10
cg15248577 ,SFMBT2(+3015) 10 7450456 Promoter 0.013766093 0.002252311 9.84E-10
cg14078059 GNS(-21459) 12 65174660 Enhancer 0.016388831 0.0026961 1.21E-09
cg04875007 RPS2(-21) 16 2014871 Promoter 0.012867742 0.002125921 1.42E-09
cg18764107 LBR(+169) 1 225615669 Promoter 0.012219992 0.002018668 1.42E-09
cg04759220 JMY(+660) 5 78532560 - 0.014868421 0.002458298 1.46E-09
cg08522087 ANKH(0) 5 14871910 - 0.007733637 0.00128734 1.88E-09
cg13579901 DCAF6(-280) 1 167905492 Promoter 0.022337576 0.003720867 1.93E-09
Supplemental table. Continued.
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CpG Nearest gene  
(+/- base pairs)
Chr Base pairs Location Beta Standard error P-value
cg02750935 PRELID2(-59) 5 145214981 Promoter, 
Enhancer
0.007716834 0.001285997 1.97E-09
cg05234169 CCDC59(-78) 12 82752252 Promoter 0.016282794 0.002714563 1.99E-09
cg05884522 NOL7(-44) 6 13615538 Promoter 0.01307324 0.00218602 2.23E-09
cg06091566 SAMD11(-523) 1 860621 - 0.026435441 0.004423976 2.29E-09
cg24079591 MARK3(-213) 14 103851511 Promoter 0.015991172 0.002680227 2.43E-09
cg11220663 ADD2(+7) 2 70994863 - 0.022700901 0.003806692 2.47E-09
cg12043722 CORO2B(-38066) 15 68870836 - 0.021346312 0.003589317 2.73E-09
cg07262328 CD44(+269) 11 35160709 Promoter 0.013942252 0.00235062 3.01E-09
cg16163324 RAD54L(-458) 1 46712932 Promoter 0.030437342 0.005137256 3.13E-09
cg23222745 - 6 27791912 - 0.016727733 0.002826838 3.27E-09
cg03243965 HSH2D(+9703) 19 16254516 Promoter 0.009874424 0.001670143 3.37E-09
cg06506598 ZFYVE16(+80028) 5 79783889 Promoter 0.024948733 0.004222809 3.46E-09
cg16370446 FAM200B(-43) 4 15683284 Promoter 0.010397718 0.001763573 3.73E-09
cg02547025 LBH(-97) 2 30454275 Promoter 0.008294564 0.001407597 3.80E-09
cg25335190 - 6 27791899 - 0.01905164 0.003241695 4.18E-09
cg22270384 ASNA1(-41) 19 12848240 Promoter 0.02699067 0.004627302 5.45E-09
cg21028463 MFSD11(+124) 17 74733682 Promoter 0.011167499 0.001916108 5.60E-09
cg15698851 TMEM66(+281) 8 29940391 Promoter 0.014332978 0.002463582 5.96E-09
cg15965583 ENSA(+172) 1 150601949 Promoter 0.025400177 0.004366307 5.98E-09
cg22100652 TRIM27(+57387) 6 28834404 Promoter -0.026777751 0.004614584 6.52E-09
cg08655589 SLC6A6(+46) 3 14444175 Promoter 0.014234875 0.002454671 6.67E-09
cg17834180 IKZF5(+94) 10 124768240 Promoter 0.015030674 0.002593684 6.83E-09
cg10101470 LRRC8D(-870) 1 90286633 Promoter 0.00739195 0.001276564 7.02E-09
cg21597684 HECW2(-42) 2 197457400 - 0.015548919 0.002685279 7.02E-09
cg19273746 B3GAT2(+700) 6 71666063 Promoter 0.023624873 0.004104604 8.63E-09
cg22870667 - 8 521182 Enhancer -0.027723903 0.004826716 9.26E-09
cg20718350 ASCL1(+819) 12 103352294 - 0.009430784 0.001644405 9.75E-09
cg18289490 SPATA2(+33) 20 48532070 Promoter 0.013736303 0.002396973 1.00E-08
cg20462855 HEY2(-370) 6 126070385 - 0.0072723 0.001269581 1.02E-08
cg20297566 TBC1D23(+267) 3 99979976 Promoter 0.031187463 0.005450513 1.05E-08
cg08709073 RGS7BP(-243) 5 63802184 - 0.018571888 0.003250119 1.10E-08
cg19080138 HERPUD2(+14) 7 35734733 Promoter 0.013942223 0.002443189 1.15E-08
cg26580332 - 8 143919495 - 0.018298842 0.003209963 1.19E-08
cg03713379 SLC12A2(+117789) 5 127537295 - 0.016365348 0.002875992 1.27E-08
CpG Nearest gene  
(+/- base pairs)
Chr Base pairs Location Beta Standard error P-value
cg18120578 E2F7(-24) 12 77459407 Promoter 0.014961422 0.002635655 1.37E-08
cg02994863 PGM1(-29613) 1 64059297 Promoter 0.013618631 0.002400823 1.41E-08
cg15408407 RPS15(+100) 19 1438438 Promoter 0.006751614 0.001191922 1.47E-08
cg21243939 SAMD4A(-1168) 14 55033137 - 0.015308476 0.002707084 1.56E-08
cg04041942 INTS9(-158) 8 28747613 Promoter 0.01474484 0.002608622 1.58E-08
cg12360123 - 10 79984532 Enhancer -0.043318426 0.007667128 1.61E-08
cg14229247 ANP32B(-373) 9 100745139 Promoter 0.005090587 0.000901141 1.61E-08
cg05944369 HMGB2(-673) 4 174255616 Promoter 0.017054023 0.003024432 1.71E-08
cg04335562 ZNF77(-56) 19 2945000 Promoter 0.023036961 0.004086777 1.73E-08
cg15012981 MAD2L2(+10644) 1 11741009 Promoter 0.005040813 0.000896171 1.86E-08
cg14225021 ITGB6(-69870) 2 161126482 Promoter, 
Enhancer
0.011800981 0.002102176 1.98E-08
cg09572053 C6orf1(-143622) 6 34360501 Promoter 0.006279856 0.001121122 2.13E-08
cg26646903 TBCCD1(-92) 3 186285208 Promoter 0.011590163 0.002084438 2.69E-08
cg13841783 - 6 32293117 - -0.030474363 0.00548179 2.71E-08
cg11706469 FGF8(+420) 10 103535362 - 0.027519708 0.004959609 2.88E-08
cg13425677 MAP3K1(+1215) 5 56112090 - 0.014548024 0.0026336 3.31E-08
cg15642758 HDGFRP3(-268) 15 83876612 Promoter 0.013003375 0.002354288 3.33E-08
cg06812693 RBPJ(+794) 4 26323246 - 0.020035197 0.003629075 3.38E-08
cg11336323 - 19 41946040 Promoter -0.03675832 0.00666397 3.47E-08
cg18913103 FBXW7(-1391) 4 153457599 Promoter 0.016671965 0.003022876 3.48E-08
cg10393416 PLK4(+86) 4 128802077 Promoter 0.011204472 0.002035668 3.71E-08
cg20692684 EPC1(-99070) 10 32735158 Promoter 0.013607155 0.002480731 4.13E-08
cg04551440 KATNAL1(-8) 13 30881194 Promoter 0.017295098 0.003153543 4.15E-08
cg04738301 NTN4(-21) 12 96184580 - 0.006624531 0.001210765 4.47E-08
cg01374398 SCAP(+493) 3 47516975 Promoter 0.02248462 0.004109964 4.48E-08
cg05740879 CDKN1C(+185152) 11 2721866 - -0.027389961 0.005036612 5.38E-08
cg09636406 RECQL5(+110) 17 73663134 Promoter 0.013516309 0.002488052 5.56E-08
cg10391895 ARL2(+112) 11 64781672 Promoter 0.016185438 0.002980622 5.63E-08
cg07361491 GATA6(+96) 18 19749535 - 0.011950742 0.002201116 5.65E-08
cg23055081 TRIM26(-21) 6 30181315 Promoter 0.019228906 0.003543944 5.77E-08
cg15040188 - 19 621137 - -0.025437993 0.004696691 6.09E-08
cg07226281 MAPK8IP3(+378) 16 1756622 Promoter 0.009645234 0.001783131 6.33E-08
cg17364044 PELI1(+378) 2 64371202 Promoter 0.012546186 0.00232473 6.78E-08
cg12260146 PDCD6IP(+196) 3 33840237 Promoter 0.030045517 0.005570297 6.90E-08
Supplemental table. Continued.Supplemental table. Continued.
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CpG Nearest gene  
(+/- base pairs)
Chr Base pairs Location Beta Standard error P-value
cg24906202 NEO1(+412) 15 73345212 - 0.013867409 0.002573678 7.12E-08
cg06803925 CENPL(+167) 1 173793126 Promoter 0.009030316 0.001677537 7.32E-08
cg16485682 GATA6(+101) 18 19749540 - 0.006185935 0.001149349 7.36E-08
cg23681311 MAPK1(+67) 22 22221878 Promoter 0.008424076 0.001567243 7.65E-08
cg23243902 SIDT2(-113) 11 117049849 - 0.022369089 0.004171023 8.19E-08
cg19906131 PANX1(+447) 11 93862516 - 0.011899087 0.002224471 8.84E-08
cg25668236 ST8SIA4(+2169) 5 100236841 - 0.010861389 0.002033066 9.17E-08
cg21475747 HNRNPAB(-58) 5 177631425 Promoter 0.012719026 0.00238298 9.43E-08
cg26021273 MNX1(-10742) 7 156814112 - 0.020861613 0.003918929 1.02E-07
cg05300158 SETD7(-127) 4 140477727 - 0.008149892 0.00153159 1.03E-07
cg02613964 - 3 44690321 Promoter -0.019188607 0.003608882 1.05E-07
cg04678743 COPG2(+106) 7 130353515 Promoter 0.011250205 0.00211627 1.06E-07
bp=base pair; Chr= chromosome; SE= standard error
$ Beta represents the difference in DNA methylation at the given CpG site in children born to mothers with 
RA(FEPRA-study) as compared with children born to mothers from the general population(Generation R Study)
# Location in promoter, enhancer or unknown(-)
Supplemental table. Continued.
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ABSTRACT 
Objectives. To identify whether children with antenatal prednisone exposure have 
chronically elevated cortisol and cortisone concentrations, an altered body composition, 
or higher blood pressure. In addition, to identify whether maternal rheumatoid arthritis 
disease(RA) activity is associated with these alterations. 
Methods. In this prospective study, 56 children(mean age=10.0 years) with, and 61 
children(mean age=9.6 years) without antenatal prednisone exposure, born to women with 
RA, were included. Hair cortisol and cortisone were analyzed using liquid chromatography–
tandem mass spectrometry. Linear regression models were built to analyze differences 
between the two groups, corrected for relevant covariates. Hair cortisol concentrations 
were also compared between the study population and an age-matched healthy reference 
group(N=150 children, mean age=9.8 years). 
Results. Hair cortisol and cortisone concentrations were similar in children with and 
without antenatal prednisone exposure(median cortisol 1.14pg/mg[IQR 0.67 -1.75] and 
1.15pg/mg[IQR 0.65 – 2.21], and median cortisone 6.76pg/mg[IQR 5.42 – 8.86] and 7.40pg/
mg[IQR 5.39 – 10.73], respectively).  Antenatal prednisone exposure and maternal RA 
disease activity were also not associated with body composition or blood pressure. Hair 
cortisol concentrations were not different in children born to mothers with RA compared 
with children from the reference group.
Conclusion. This, in its kind, large and unique long-term prospective study demonstrates 
that low-dose antenatal prednisone exposure and maternal RA disease activity are not 
associated with negative consequences in prepubertal childhood. The findings of this study 
are reassuring and support the assumption that low-dose maternal prednisone use during 
pregnancy is safe for the offspring, at least until the age of approximately 10 years. 
Ideally during pregnancy women would not use any medication, however sometimes it’s 
inevitable, like the use of corticosteroids in autoimmune disorders. In animal studies it has 
been shown that an excess of maternal glucocorticoids during pregnancy, for example 
administration of synthetic glucocorticoids, is associated with altered hypothalamic-
pituitary-adrenal (HPA) axis activity with higher plasma cortisol levels of the offspring, higher 
blood pressure,hyperglycemia, and visceral obesity in later life1-7.  
There are also several human studies demonstrating that adverse circumstances during 
pregnancy, that are related with cortisol concentrations in the mother (e.g. maternal stress8, 
maternal depression9-11, and maternal anxiety during pregnancy12-14), result in elevated 
cortisol concentrations and an altered cortisol response in the offspring. Chronically elevated 
cortisol levels are associated with an increased risk of abdominal obesity, hypertension, 
non-insulin dependent diabetes mellitus and cardiovascular disease15-20. 
Maternal cortisol rises throughout pregnancy, but normally only 10-20% reaches the 
fetus due to the oxidation of cortisol to cortisone by 11beta-hydroxysteriod dehydrogenase 
type II (11βHSD2) enzyme in the placenta21-23. Cortisone can be reverse metabolized into 
cortisol24. The 11βHSD2enzyme also converts the active prednisolone into its inactive 
metabolite prednisone25. Despite the presence of this enzyme, children born to mothers 
who use prednisone during pregnancy could be exposed to higher concentrations of 
corticosteroids in utero in at least three different ways. 
First, since the placenta is not fully developed before 12 weeks of gestation, in that period 
passive diffusion of prednisolone to the fetus takes place26. Second, the capacity of the 
11βHSD2 enzyme may be exceeded by  the external administration of corticosteroids26, 27, 
resulting in increased placental availability of prednisolone. Finally, the activity of 11βHSD2 is 
down-regulated by the pro-inflammatory cytokines Tumor Necrosis Factor (TNF), Interleukin 
(IL)-1 and IL-6, which are elevated in autoimmune disorders like Rheumatoid Arthritis (RA)26, 
28, resulting in decreased inactivation and increased availability of prednisolone. 
Exposure to higher corticosteroid concentrations in utero may influence the development 
of the fetal HPA axis, with reduced negative feedback due to  reduction in hippocampal 
glucocorticoid receptor expression2. As a result, this may lead to an overactive HPA axis, and 
elevated circulating glucocorticoids in the offspring2.
De Steenwinkel et al.26 reported that children born to mothers with RA who used 
prednisone during pregnancy had higher salivary cortisol levels at the age of approximately 
7 years, independent of RA disease activity of the mother during pregnancy26. However, 
there was no association with physical signs of higher cortisol levels. The main limitation 
of that study is that the analysis of cortisol was from a single day saliva sample collection, 
which is  a useful method to study acute HPA axis reactivity, but is not a good  reflection of 
long-term cortisol levels29, 30. 
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Since then, a  new method has become available to measure both long-term cortisol and 
cortisone concentrations in scalp hair31. Several studies have shown that this is a reliable, 
non-invasive method to measure endogenous cortisol and cortisone, in adults32-35, and in 
children30, 36, 37. Hair cortisol is a reflects long-term cortisol exposure30. It has been shown 
that obese children have higher hair cortisol concentrations compared with non-obese 
children24, 30. Furthermore, in a large population based cohort, hair cortisol concentrations 
were already associated with BMI and adverse body fat distribution in children at young age 
(mean age of 6 years)38. Also, children’s hair cortisol levels have been shown to be associated 
with stress at school entry37. 
Hair cortisol and cortisone analysis could provide more information about the long-term 
consequences of antenatal prednisone exposure. 
In the current study, we investigated whether children with antenatal prednisone 
exposure have signs of altered HPA axis activity, reflected by chronically elevated hair 
cortisol and cortisone concentrations, an altered body composition (risk factors for future 
cardiovascular and metabolic disease), or higher blood pressure compared with children 
without antenatal prednisone exposure. In addition, since pro-inflammatory cytokines may 
cause downregulation of 11bHSD followed by increased transfer of prednisolone to the 
fetus, we analysed the associations between maternal RA disease activity during pregnancy 
and the earlier mentioned outcome measures in childhood. 
METHODS
Study Population
In a previous study26 that showed that antenatal prednisone exposure is associated with 
elevated cortisol concentrations in saliva at the age of approximately 7 years, 42 children with 
and 63 children without prednisone exposure were included. Hair cortisol concentrations 
correlate with long-term salivary cortisol production measured over a one-month period32. 
Therefore, in order to acquire enough power in this prospective cohort study, we aimed 
to include comparable numbers of participants. In this study, a total of 56 children with 
(prednisone dose ≥5mg/day, during at least 2 trimesters of pregnancy) and 61 children 
without antenatal prednisone exposure born to women with RA , aged 5 to 15 years, were 
included between 2014 and 2018. 
First, children born to women who participated in the Pregnancy induced Amelioration 
of Rheumatoid Arthritis (PARA) study were included, a nationwide prospective cohort study 
on RA and pregnancy and onwards from the Netherlands39. The PARA-study has been 
described in detail elsewhere39. In the PARA-study, RA patients who met the 1987 revised 
American College of Rheumatology criteria40 with a wish to conceive or already pregnant, 
were enrolled between 2002 and 2008 (last visit in 2010). 
Second, siblings of the children born to PARA-participants were included (if their 
mother was already diagnosed with RA before pregnancy). Finally, after the inclusion 
was not sufficient, children born to women with RA who visited the outpatient clinic of 
the department of Rheumatology in the Erasmus MC Rotterdam, the Netherlands, were 
included to accomplish the intended number of inclusions. At this outpatient clinic, RA 
disease activity and medication use during pregnancy are properly recorded. 
In total, 97 children born the PARA-study participants, 14 siblings and 6 children born to 
women who visited the outpatient clinic were included. Exclusion criteria were: congenital 
abnormalities, chronic illness of the child, non-Caucasian ethnicity, scalp hair shorter than 
2 cm. 
Reference population
As a reference population, 252 healthy children born to women from the general population 
were used. These children had been recruited, as described in more detail elsewhere41. 
Briefly, children were eligible for inclusion if they were between the age of 4 and 18 years, 
did not use glucocorticoids 3 months prior to or during the study, and did not suffer a 
chronic disease. Healthy controls were recruited from primary and secondary schools in the 
Netherlands and among siblings of children attending the pediatric outpatient clinic41. For 
comparison with the current study, only data on Caucasian children between the age of 5 
and 15 years was used, resulting in 150 participants in the reference group. 
Data collection
Data collection during pregnancy
In the PARA-study participants were visited at their home address before pregnancy (if 
possible), three times during pregnancy and three times after the birth of the child (at 6, 
12 and 26 weeks). At all time-points data on mother and child was collected. RA disease 
activity was measured using the Disease Activity Score based upon 3 variables; swelling 
and tenderness by palpation in 28 joints and a C-Reactive Protein (DAS28-CRP(3)). For 
participants whose mother did not participate in the PARA-study, information on their 
disease activity and medication use during pregnancy, pregnancy course, and pregnancy 
outcome (from 1 year before delivery until 1 year after delivery) was obtained from their 
rheumatologist and gynecologist. 
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Hair collection
Participants were visited at their home address once during the study period. During this 
visit, a lock of 3 cm with approximately 100 hairs was cut from the posterior vertex of the 
child’s scalp, as close to the scalp as possible. There is a wide consensus that proximal parts 
of the hair reliably reflect chronic cortisol concentrations42. Exogenous environmental 
factors, such as frequent hair washing and cosmetic treatments could decrease cortisol 
levels in the more distal (older) segments of the hair31, 42-44. Additionally, sampling of hair 
that is taken from the posterior vertex is the most optimal, because the intra-individual 
variation is smallest at that site31, 34. Hair growth patterns vary across different regions of the 
scalp and the posterior vertex region shows the most uniform growth rates45. Because hair 
grows approximately 1 cm per month, a hair sample of 1 cm is thought to reflect the mean 
exposure of cortisol in 1 month30, 46.
The hair samples were taped to a piece of paper, and the proximal side was marked. The 
hair samples were stored at room temperature in an envelope until analysis. 
Parents were also asked to fill out a questionnaire on e.g. frequency of washing the hair, 
hair color, cosmetic hair treatments and medication/illness of their children. 
Anthropometry
During the visit, blood pressure, growth and body composition were also measured 
(height, weight, hip and waist circumference,  and skin folds using Holtain caliper). All 
measurements, except for weight, were performed 3 times. Blood pressure was measured 
3 times in rest with an automatic device (Omron M6 AC; Omron Healthcare, Hoofddorp, the 
Netherlands), using a cuff appropriate to the size of the child’s upper arm. The mean of the 3 
measurements were used in the analysis. Fat percentage was calculated using the skin folds 
(biceps, triceps, subscapular, and suprailiacal) with the Durnin and Womersley formula47. 
Body mass index (BMI) was calculated using the formula weight (kg)/height2(m2). Systolic and 
diastolic blood pressure/height ratios were calculated, since those ratios have been shown to 
correlate with the corresponding blood pressure percentiles in both male and female children48. 
All other child-related values were transformed into standard deviation scores (SDS) for age and 
gender according to the 2010 Dutch reference values49, using the Growth Analyser(version 4.0; 
Growth analyser BV, Rotterdam, the Netherlands, www.growthanalyser.org). Birth weight was 
expressed as birth weight SDS, corrected for gestational age and gender50. 
Data collection reference population
Hair samples and data on anthropometrics were collected during school visitation. 
Demographic information, data on general health, the use of medication, and hair care 
were collected through questionnaires41. Hair collection was performed with a similar 
method as in the current study. 
Cortisol and cortisone analysis in hair
The hair samples were processed and analysed, by liquid chromatography–tandem mass 
spectrometry (LC-MS/MS) as described previously44, at the department of Clinical Chemistry, 
Erasmus University Medical Center, Rotterdam, The Netherlands. 
Statistical Analysis
For all subjects descriptive statistics were calculated as numbers, percentages, means, medians, 
standard deviation scores (SDSs) and interquartile ranges (IQRs). For comparing baseline 
characteristics, Student t tests were used for normally distributed continuous variables, 
Wilcoxon rank-sum tests for not normally distributed continuous variables, and Chi squared 
and Fisher’s exact tests for categorical variables. Cortisol and cortisone were logarithmically 
(log10) transformed to achieve a normal distribution. Linear regression models were built to 
analyse associations between cortisol and cortisone, and antenatal prednisone exposure. 
Factors associated in other studies24, 51 with hair cortisol and cortisone concentrations (age, 
sex, socioeconomic status[SES] based on the educational level of the mother, season of hair 
collection, hair color, washing frequency), were used as independent covariables. Similarly, 
a regression model was built to analyse the association between maternal DAS28-CRP(3) 
during pregnancy and cortisol and cortisone concentrations. Furthermore, associations 
between cortisol, cortisone, DAS28-CRP(3) and the anthropometric measurements (BMI 
SDS, fat percentage SDS based on skinfolds, waist and hip circumference SDS, systolic and 
diastolic bloodpressure SDS, ratio waist-hip circumference, and ratio skinfolds trunk to 
skinfolds peripheral) were analysed using linear regression. 
In addition, a linear regression analysis was performed to compare the cortisol 
concentrations children born to mothers with RA, with the reference population using 
stepwise backwards selection of relevant covariates (age, sex, weight SDS, height SDS, BMI 
SDS, waist circumference SDS, height circumference SDS, SES, washing frequency, and hair 
color). 
P-values ≤0.05 were considered statistically significant. All statistical analysis were 
performed using STATA software version 15.1 for Windows. 
Ethics
This study is in  compliance with the Helsinki Declaration. The Medical Ethics Committee 
at the Erasmus MC University Medical Center Rotterdam, the Netherlands, approved the 
current study (MEC-2014-395) and the PARA-study (MEC-214.320/2002/117). Parents(and 
children) received oral and written information about the study. Informed consent was 
signed by both parents, and their children if they were aged ≥12 years. 
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RESULTS
Participants 
In total, 252 children born to mothers with RA and both of their parents were invited to 
participate in this study (figure 1). From these, 58 (23.0%) did not respond to the invitation 
and could not be reached by mail or phone. From the 72 invited subjects who refused 
participation, 35 (48.6%) did not provide a reason, 16 (22.2%) explained that they had 
participated in too many studies, and 12 (16.7%) were not interested in participation due to 
the fact that this study had to be performed in their children. After exclusion of 5 children 
with antenatal prednisone exposure <5mg/day and/or less than during 2 trimesters, in 
total 117 children were included in this study. From these, we included 56 children who 
had antenatally been exposed to prednisone (prednisone dose ≥5mg/day, during at least 2 
trimesters of pregnancy) and 61 children who had not been exposed. 
Participants and non-participants were compared. There were no statistically significant 
differences in maternal DAS28-CRP(3) in 3rd trimester, maternal age at delivery, presence 
of autoantibodies in mother, SES based on educational level of the mother, sex of the 
offspring, and birth weight. Gestational age was borderline significant (p=0.05), with a 
median gestational age of 277.9 days (IQR 270.9 – 286.0) in participants and 275.0 days (IQR 
268.0 – 282.5) in non-participants. 
Descriptive statistics of the study population are shown in table 1. Overall, the baseline 
characteristics were comparable in the prednisone and the non-prednisone group. Birth 
weight and gestational age were both significantly lower in the group with prednisone 
exposure compared with children without prednisone exposure. Mean birth weight was 
3167.5g (sd=691.9) in the prednisone group vs 3435.4g (sd=584.2) in the non-prednisone 
group, p-value 0.01. The median gestational age was 273.0 days (IQR 258.0 – 281) in the 
prednisone vs 281.0 days (IQR 274.0 – 287.0) in the non-prednisone group, p-value<0.001. 
Birth weight corrected for gestational age and sex was not different between the two 
groups. Maternal characteristics were also comparable in both groups, except for the 
DAS28-CRP(3), which was higher in the prednisone group, 3.7 (sd=1.1) vs 2.8 (sd=0.9) in the 
non-prednisone group, p-value <0.001. Detailed information on descriptive statistics of the 
children are provided in supplemental table 1. 
Figure 1. Flow-chart of the study population and inclusion of study participants. 
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Table 1. Descriptive statistics of study population 
Prednisone 
(N=56)
Non-prednisone 
(N=61)
Reference population 
(n=150)
Age child, yrs, mean (sd) 10.0 (2.5) 9.6 (2.2) 9.8 (3.1)
Male 36 (64.3) 34 (55.7) 68 (45.3)*
Birth weight g, mean (sd) 3167.5 (691.9)* 3435.4 (584.2)* -
Birth weigth sds, mean (sd) -0.1 (1.0) -0.2 (1.2) -
Gestational age days, median(IQR) 273.0  
(258.0 – 281)**
281.0  
(274.0 – 287.0)**
-
SES based on educational level of the mother
  middle
  high
15 (26.8)
35 (62.5)
23 (38.3)
33 (55.0)
21 (14.0)
99 (66.0)
Black/brown hair color 16 (28.6) 15 (24.6) 47 (31.3)**
Washing frequency (per week) ≥3 25 (44.6) 25 (41.0)  52 (34.7)**
Season hair collection winter & fall 39 (69.6) 37 (60.7)
Maternal DAS28-CRP(3) in 3rd trim, mean (sd) 3.7 (1.1)** 2.8 (0.9)**
Maternal age at delivery, yrs, mean (sd) 32.9 (3.8) 32.9 (3.9)
Maternal autoantibodies
  Present
  Absent
  Unknown
33 (58.9)
8 (14.3)
14 (25.0)
35 (57.4)
17 (27.9)
9  (14.8)
* p-values <0.05 **p-values <0.001, statistics were performed comparing the prednisone and non-prednisone 
group, and the prednisone and non-prednisone group together versus the reference population. sd=standard 
deviation; sds=standard deviation scores; IQR=interquartile range; SES=socioeconomic status; BP=blood pressure; 
DAS28-CRP(3)=disease activity score in 28 joints using C-reactive protein levels
Associations between antenatal prednisone exposure and cortisol and 
cortisone concentrations in scalp hair
The median hair cortisol concentration was 1.14 pg/mg (IQR 0.67 -1.75) in the children with 
antenatal prednisone exposure, and  1.15 pg/mg (IQR 0.65 – 2.21) in the children without 
antenatal prednisone exposure. The median hair cortisone concentration was 6.76 pg/
mg (IQR 5.42 – 8.86) in the prednisone group, and  7.40 pg/mg (IQR 5.39 – 10.73) in the 
non-prednisone group. After log-transformation, cortisol and cortisone were normally 
distributed. Hair cortisol and cortisone concentrations were not significantly different 
between the two groups. 
In our study population 17 children were exposed to prednisone with a mean dose per 
day ≥10.0 mg. Repeating the analyses in these children compared with the children 
without antenatal prednisone exposure did not result in significant associations between 
prednisone exposure and hair cortisol and cortisone concentrations (p-value>0.30). The 
median cortisol and cortisone concentrations were 0.97 pg/mg (IQR 0.68 – 1.57) and 6.26 
(IQR 4.80-8.49) in the prednisone group (≥10.0mg daily), and 1.15 (IQR 0.65 – 2.21) and 7.40 
(IQR 5.39 – 10.73) in the non-prednisone group, respectively. 
In univariable analysis, a higher SES (based on the educational level of the mother) was 
associated with higher hair cortisol and cortisone concentrations, and a washing frequency 
≥3 times with lower cortisol concentrations (Table 3). Children born to mothers with a 
higher SES had a lower washing frequency of their hair. The association between SES and 
levels of cortisol and cortisone was not present in the multivariable model. 
In the multivariable linear regression models, prednisone exposure was not associated 
with hair cortisol and cortisone concentrations. The median of the mean prednisone 
dose per day during pregnancy was 7.5mg/day (IQR 5.0 -10.0). The mean prednisone 
dose and prednisone exposure in the first trimester were also not associated with these 
concentrations. In the multivariable models, only washing frequency was significantly 
associated with the levels of cortisone in hair. A washing frequency ≥3 times per week 
was associated with lower cortisone concentrations (p-values<0.05). Age, sex, season of hair 
collection, and hair color were not associated with hair cortisol and cortisone in the uni- and 
multivariable models. 
Associations between antenatal prednisone exposure and anthropometric 
values 
Antenatal prednisone exposure was not associated with the anthropometric measurements 
(BMI SDS, fat percentage SDS, waist circumference SDS, hip circumference SDS, ratio waist-
hip, ratio systolic blood pressure/height, ratio diastolic blood pressure/height, and the ratio 
skinfolds trunk/peripheral), corrected for age, sex, and SES (based on the educational level 
of the mother). The anthropometric values were also not associated with the hair cortisol 
and cortisone concentrations. 
Associations with maternal RA disease activity 
Maternal RA disease activity in the third trimester was not associated with hair cortisol and 
cortisone concentrations in the children. Maternal DAS28-CRP(3) in the third trimester was 
also not associated with the anthropometric measurements.
Comparison with reference population
The median hair cortisol concentration in the reference population was 1.93 pg/mg (IQR 
1.18 -3.11). After log-transformation, cortisol was normally distributed. 
Hair cortisol concentrations were not different between children born to mothers with 
RA and the reference population, corrected for the relevant variables mentioned previously, 
in a multivariate linear regression model.  In this model, an older age of the child and higher 
weight SDS were significantly associated with higher cortisol levels (p-values <0.05). 
120
Chapter 6
6
121
Antenatal prednisone exposure
DISCUSSION 
Prednisone is an anti-inflammatory drug that is prescribed to patients with an autoimmune 
disease, e.g. RA, also during pregnancy. Research into the long-term side effects of 
prednisone use during pregnancy on the offspring has been limited. In this relatively large 
and unique nationwide study, we followed the majority of the mothers and their children 
prospectively during and after pregnancy. The results of our study show that children with 
low-dose antenatal prednisone exposure do not have chronically elevated cortisol and 
cortisone concentrations in hair, compared with children without antenatal prednisone 
exposure. This is the first study to show these results prospectively from the antenatal period 
onwards in a (for this design) large cohort using scalp hair, reflecting chronic cortisol and 
cortisone concentrations. Adjustment for confounders allowed an independent analysis of 
the effects of antenatal prednisone exposure in childhood. 
Prednisone exposure was also not associated with anthropometric measurements 
like BMI SDS, fat percentage SDS, waist circumference SDS, hip circumference SDS, ratio 
waist-hip, and the ratio skinfolds trunk/peripheral, or with ratio systolic blood pressure/
height and ratio diastolic blood pressure/height. Furthermore, maternal RA disease activity 
during pregnancy was not associated with cortisol and cortisone concentrations, and 
anthropometric measurements. Children born to mothers with RA had a similar cortisol 
concentration compared with the reference population. 
In general, antenatal exposure to glucocorticoids might result in chronically elevated 
cortisol and cortisone concentrations in the offspring1-4, 46. Previous studies, mostly animal but 
also in humans, demonstrated long-term effects of maternal stress8, maternal depression9, 
10, and maternal anxiety during pregnancy12-14 on cortisol concentrations or cortisol 
responses in offsprings. As mentioned before, adverse events during pregnancy have been 
shown to influence the development of the fetal HPA axis. The systemic inflammation in 
RA patients, and medication use during pregnancy are also considered as an adverse event 
during pregnancy. This is one of the few prospective studies in humans studying offspring 
antenatally exposed to synthetic glucocorticoids with the most reliable method to measure 
chronic cortisol and cortisone concentrations (in scalp hair)33. In our current study we did 
not find any association between antenatal exposure to low-dose prednisone, maternal RA 
disease activity during pregnancy and long-term cortisol and cortisone concentrations or 
with an altered body composition or higher blood pressure in childhood. 
In a previous study by de Steenwinkel et al.26, children born to mothers with RA with 
antenatal prednisone exposure had higher daytime cortisol levels (measured in saliva) 
compared with children without prednisone exposure. However, measuring cortisol in 
saliva is not a reliable method for long-term concentrations due to the circadian rhythm, 
pulsatile secretion, daily variation and reactivity to acute (transient) stress21, 29, 30. Measuring 
cortisol in hair reliably reflects chronic concentrations. The elevated salivary cortisol levels in 
children with antenatal prednisone exposure born to mothers with RA from the study by de 
Steenwinkel et al.26 could be a result of increased HPA axis reactivity. However, for studying 
HPA axis reactivity, cortisol concentrations should preferably be measured before and after 
administrating a stressor. In another study by de Steenwinkel et al.52, maternal RA disease 
activity during pregnancy and antenatal prednisone exposure had no influence on the 
body composition or on the risk for the metabolic syndrome of approximately 7-years-old 
offspring52. In concordance with this study, we did not find either any associations between 
maternal RA disease activity during pregnancy, antenatal prednisone exposure, and body 
composition in offspring aged approximately 10 years, which is reassuring. It is still possible 
that the consequences for these offsprings will emerge later in their life, therefore following 
these children until post-pubertal age is interesting for future research.  The chronic use of 
prednisone and high RA disease activity are associated with reduced bone mineral density 
(BMD)53, 54. In our study, we did not explore the effect of antenatal prednisone exposure 
on the BMD of the offspring. However, in a previous study by de Steenwinkel et al.55, they 
investigated the influence of medication use and disease activity of the mother during 
pregnancy on the offspring at the age of approximately 7 years. In that study, a dual x-ray 
absorptiometry scan was performed in 108 children born to women with RA. They did 
not find any association between BMD and prednisone use or RA disease activity during 
pregnancy, even after correcting for all known associated variables, which is reassuring.
Currently, the treatment options for RA during pregnancy are prednisone, sulfasalazine, 
hydroxychloroquine and TNF inhibitors56. Most patients start with sulfasalazine or 
hydroxychloroquine, and when they do not respond to this therapy, prednisone or 
TNF-inhibitors are added. Compared with prednisone, TNF inhibitors are expensive and 
worldwide not easily available for all patients with RA. Therefore, it is important that this 
study showed the long-term safety of maternal prednisone use during pregnancy. 
Certain limitations should be taken into account when interpreting the results of this 
study. First, from the 252 invited children (and their parents), 122 (48.4%) were willing to 
participate in this study. In total, 72 (28.6%) refused participation. Baseline characteristics 
were comparable between participants and non-participants. These findings decrease the 
likelihood that selection bias influenced the results of this study. 
Second, in this study, the median of the mean prednisone dose per day during pregnancy 
was 7.5 mg (IQR 5.0 -10.0). The use of prednisone concentrations above 7.5 mg/day or 
even 10 mg/day might be more likely to influence the long-term cortisol and cortisone 
concentrations in the offspring. However, repeating the analyses in the children who were 
antenatally exposed to higher prednisone dosages (mean dose per day ≥10.0 mg), did not 
lead to different results. In addition, lower concentrations of prednisone are often sufficient 
for the treatment of RA during pregnancy. Unfortunately, we did not have information on 
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maternal weight during pregnancy for the majority of the participants. Maternal weight 
during the visit when the children’s hair was collected (child age approximately 10 years) 
was measured. However, since that would not be completely representative of the weight 
during pregnancy, prednisone dosages could not be corrected for maternal weight.
In conclusion, our study demonstrates that low-dose antenatal prednisone exposure and 
maternal RA disease activity during pregnancy are not associated with long-term elevated 
cortisol and cortisone concentrations, an altered body composition, or higher blood 
pressure in prepubertal childhood. Prednisone is an effective, low-priced antirheumatic 
drug that is considered safe to use during pregnancy. The findings of this study support 
the assumption that maternal prednisone use during pregnancy is safe for the offspring, 
at least until the age of approximately 10 years, which is reassuring for mothers who use 
prednisone and their physicians. 
REFERENCES
1. Levitt NS, Lindsay RS, Holmes MC, Seckl JR. Dexamethasone in the last week of pregnancy attenuates 
hippocampal glucocorticoid receptor gene expression and elevates blood pressure in the adult offspring in 
the rat. Neuroendocrinology 1996;64:412-8.
2. Cottrell EC, Seckl JR. Prenatal stress, glucocorticoids and the programming of adult disease. Front Behav 
Neurosci 2009;3:19.
3. Singh RR, Cuffe JS, Moritz KM. Short- and long-term effects of exposure to natural and synthetic glucocorticoids 
during development. Clin Exp Pharmacol Physiol 2012;39:979-89.
4. Seckl JR. Prenatal glucocorticoids and long-term programming. Eur J Endocrinol 2004;151 Suppl 3:U49-62.
5. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, et al. A transgenic model of visceral 
obesity and the metabolic syndrome. Science 2001;294:2166-70.
6. Desai M, Jellyman JK, Han G, Beall M, Lane RH, Ross MG. Maternal obesity and high-fat diet program offspring 
metabolic syndrome. American journal of obstetrics and gynecology 2014;211:237.e1-.e13.
7. Zambrano E, Nathanielsz PW. Mechanisms by which maternal obesity programs offspring for obesity: 
evidence from animal studies. Nutr Rev 2013;71 Suppl 1:S42-54.
8. O’Connor TG, Bergman K, Sarkar P, Glover V. Prenatal cortisol exposure predicts infant cortisol response to 
acute stress. Dev Psychobiol 2013;55:145-55.
9. Diego MA, Field T, Hernandez-Reif M, Cullen C, Schanberg S, Kuhn C. Prepartum, postpartum, and chronic 
depression effects on newborns. Psychiatry 2004;67:63-80.
10. Brennan PA, Pargas R, Walker EF, Green P, Newport DJ, Stowe Z. Maternal depression and infant cortisol: 
influences of timing, comorbidity and treatment. J Child Psychol Psychiatry 2008;49:1099-107.
11. Osborne S, Biaggi A, Chua TE, Du Preez A, Hazelgrove K, Nikkheslat N, et al. Antenatal depression programs 
cortisol stress reactivity in offspring through increased maternal inflammation and cortisol in pregnancy: 
The Psychiatry Research and Motherhood - Depression (PRAM-D) Study. Psychoneuroendocrinology 2018;in 
press.
12. Grant KA, McMahon C, Austin MP, Reilly N, Leader L, Ali S. Maternal prenatal anxiety, postnatal caregiving and 
infants’ cortisol responses to the still-face procedure. Dev Psychobiol 2009;51:625-37.
13. Gutteling BM, de Weerth C, Buitelaar JK. Prenatal stress and children’s cortisol reaction to the first day of 
school. Psychoneuroendocrinology 2005;30:541-9.
14. O’Connor TG, Ben-Shlomo Y, Heron J, Golding J, Adams D, Glover V. Prenatal anxiety predicts individual 
differences in cortisol in pre-adolescent children. Biol Psychiatry 2005;58:211-7.
15. Bjorntorp P, Rosmond R. Obesity and cortisol. Nutrition 2000;16:924-36.
16. Kelly JJ, Mangos G, Williamson PM, Whitworth JA. Cortisol and hypertension. Clin Exp Pharmacol Physiol 
Suppl 1998;25:S51-6.
17. Gillman MW, Rich-Edwards JW, Huh S, Majzoub JA, Oken E, Taveras EM, et al. Maternal corticotropin-releasing 
hormone levels during pregnancy and offspring adiposity. Obesity (Silver Spring, Md ) 2006;14:1647-53.
18. Rondo PH, Lemos JO, Pereira JA, Souza JM. The relationship between cortisol concentrations in pregnancy 
and systemic vascular resistance in childhood. Early Hum Dev 2010;86:127-31.
19. Sen S, Carpenter AH, Hochstadt J, Huddleston JY, Kustanovich V, Reynolds AA, et al. Nutrition, weight gain and 
eating behavior in pregnancy: a review of experimental evidence for long-term effects on the risk of obesity 
in offspring. Physiol Behav 2012;107:138-45.
20. Aubuchon-Endsley NL, Bublitz MH, Stroud LR. Pre-pregnancy obesity and maternal circadian cortisol 
regulation: Moderation by gestational weight gain. Biological psychology 2014;102:38-43.
21. D’Anna-Hernandez KL, Ross RG, Natvig CL, Laudenslager ML. Hair cortisol levels as a retrospective marker of 
hypothalamic-pituitary axis activity throughout pregnancy: comparison to salivary cortisol. Physiol Behav 
2011;104:348-53.
22. Benediktsson R, Calder AA, Edwards CR, Seckl JR. Placental 11 beta-hydroxysteroid dehydrogenase: a key 
regulator of fetal glucocorticoid exposure. Clin Endocrinol (Oxf ) 1997;46:161-6.
124
Chapter 6
6
125
Antenatal prednisone exposure
23. Kieviet N, de Groot S, Noppe G, de Rijke YB, van Rossum EF, van den Akker EL, et al. Is poor neonatal adaptation 
after exposure to antidepressant medication related to fetal cortisol levels? An explorative study. Early Hum 
Dev 2016;98:37-43.
24. Rippe RC, Noppe G, Windhorst DA, Tiemeier H, van Rossum EF, Jaddoe VW, et al. Splitting hair for cortisol? 
Associations of socio-economic status, ethnicity, hair color, gender and other child characteristics with hair 
cortisol and cortisone. Psychoneuroendocrinology 2016;66:56-64.
25. Burton PJ, Waddell BJ. Dual function of 11beta-hydroxysteroid dehydrogenase in placenta: modulating 
placental glucocorticoid passage and local steroid action. Biol Reprod 1999;60:234-40.
26. de Steenwinkel FD, Hokken-Koelega AC, Hazes JM, Dolhain RJ. The influence of foetal prednisone exposure 
on the cortisol levels in the offspring. Clin Endocrinol (Oxf ) 2014;80:804-10.
27. Edwards CR, Benediktsson R, Lindsay RS, Seckl JR. Dysfunction of placental glucocorticoid barrier: link 
between fetal environment and adult hypertension? Lancet 1993;341:355-7.
28. Kossintseva I, Wong S, Johnstone E, Guilbert L, Olson DM, Mitchell BF. Proinflammatory cytokines inhibit 
human placental 11beta-hydroxysteroid dehydrogenase type 2 activity through Ca2+ and cAMP pathways. 
Am J Physiol Endocrinol Metab 2006;290:E282-8.
29. Staufenbiel SM, Penninx BW, Spijker AT, Elzinga BM, van Rossum EF. Hair cortisol, stress exposure, and mental 
health in humans: a systematic review. Psychoneuroendocrinology 2013;38:1220-35.
30. Veldhorst MA, Noppe G, Jongejan MH, Kok CB, Mekic S, Koper JW, et al. Increased scalp hair cortisol 
concentrations in obese children. J Clin Endocrinol Metab 2014;99:285-90.
31. Russell E, Koren G, Rieder M, Van Uum S. Hair cortisol as a biological marker of chronic stress: current status, 
future directions and unanswered questions. Psychoneuroendocrinology 2012;37:589-601.
32. Short SJ, Stalder T, Marceau K, Entringer S, Moog NK, Shirtcliff EA, et al. Correspondence between hair 
cortisol concentrations and 30-day integrated daily salivary and weekly urinary cortisol measures. 
Psychoneuroendocrinology 2016;71:12-8.
33. Gow R, Thomson S, Rieder M, Van Uum S, Koren G. An assessment of cortisol analysis in hair and its clinical 
applications. Forensic Sci Int 2010;196:32-7.
34. Sauve B, Koren G, Walsh G, Tokmakejian S, Van Uum SH. Measurement of cortisol in human hair as a biomarker 
of systemic exposure. Clin Invest Med 2007;30:E183-91.
35. Xie Q, Gao W, Li J, Qiao T, Jin J, Deng H, et al. Correlation of cortisol in 1-cm hair segment with salivary cortisol 
in human: hair cortisol as an endogenous biomarker. Clin Chem Lab Med 2011;49:2013-9.
36. Noppe G, Van Rossum EF, Koper JW, Manenschijn L, Bruining GJ, de Rijke YB, et al. Validation and reference 
ranges of hair cortisol measurement in healthy children. Horm Res Paediatr 2014;82:97-102.
37. Groeneveld MG, Vermeer HJ, Linting M, Noppe G, van Rossum EF, van IMH. Children’s hair cortisol as a 
biomarker of stress at school entry. Stress 2013;16:711-5.
38. Noppe G, van den Akker EL, de Rijke YB, Koper JW, Jaddoe VW, van Rossum EF. Long-term glucocorticoid 
concentrations as a risk factor for childhood obesity and adverse body-fat distribution. Int J Obes (Lond) 
2016;40:1503-9.
39. de Man YA, Dolhain RJ, van de Geijn FE, Willemsen SP, Hazes JM. Disease activity of rheumatoid arthritis during 
pregnancy: results from a nationwide prospective study. Arthritis Rheum 2008;59:1241-8.
40. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism 
Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
41. Smit MP, van Leer EHG, Noppe G, de Rijke YB, Kramer van Driel D, van den Akker ELT. Long-Term Cortisol 
Concentration in Scalp Hair of Asthmatic Children Using Inhaled Corticosteroids: A Case-Control Study. 
Hormone Research in Pædiatrics 2017;88:231-6.
42. Manenschijn L, Koper JW, Lamberts SW, van Rossum EF. Evaluation of a method to measure long term cortisol 
levels. Steroids 2011;76:1032-6.
43. Dettenborn L, Tietze A, Kirschbaum C, Stalder T. The assessment of cortisol in human hair: associations with 
sociodemographic variables and potential confounders. Stress 2012;15:578-88.
44. Noppe G, de Rijke YB, Dorst K, van den Akker EL, van Rossum EF. LC-MS/MS-based method for long-term 
steroid profiling in human scalp hair. Clin Endocrinol (Oxf ) 2015;83:162-6.
45. Pragst F, Balikova MA. State of the art in hair analysis for detection of drug and alcohol abuse. Clin Chim Acta 
2006;370:17-49.
46. Karlen J, Frostell A, Theodorsson E, Faresjo T, Ludvigsson J. Maternal influence on child HPA axis: a prospective 
study of cortisol levels in hair. Pediatrics 2013;132:e1333-40.
47. Durnin JV, Womersley J. Body fat assessed from total body density and its estimation from skinfold thickness: 
measurements on 481 men and women aged from 16 to 72 years. Br J Nutr 1974;32:77-97.
48. Galescu O, George M, Basetty S, Predescu I, Mongia A, Ten S, et al. Blood Pressure over Height Ratios: Simple 
and Accurate Method of Detecting Elevated Blood Pressure in Children. Int J Pediatr 2012;2012:253497.
49. Talma H., Bakker B., HiraSing R.A., S. vB. Groeidiagrammen 2010. Handleiding bij het meten en wegen van 
kinderen en het invullen van groeidiagrammen. . TNO Kwaliteit van Leven, Leiden 2010;ISBN:978-90-5986-
347-7.
50. Niklasson A, Ericson A, Fryer JG, Karlberg J, Lawrence C, Karlberg P. An update of the Swedish reference 
standards for weight, length and head circumference at birth for given gestational age (1977-1981). Acta 
Paediatr Scand 1991;80:756-62.
51. Staufenbiel SM, Penninx BW, de Rijke YB, van den Akker EL, van Rossum EF. Determinants of hair cortisol and 
hair cortisone concentrations in adults. Psychoneuroendocrinology 2015;60:182-94.
52. de Steenwinkel FDO, Dolhain R, Hazes JMW, Hokken-Koelega ACS. Does prednisone use or disease activity 
in pregnant women with rheumatoid arthritis influence the body composition of their offspring? Reprod 
Toxicol 2017;71:118-23.
53. Tengstrand B, Hafstrom I. Bone mineral density in men with rheumatoid arthritis is associated with erosive 
disease and sulfasalazine treatment but not with sex hormones. J Rheumatol 2002;29:2299-305.
54. Majumdar SR, Morin SN, Lix LM, Leslie WD. Influence of recency and duration of glucocorticoid use on bone 
mineral density and risk of fractures: population-based cohort study. Osteoporos Int 2013;24:2493-8.
55. de Steenwinkel FD, Hokken-Koelega AC, Hazes JM, Dolhain RJ. Brief report: does medication use or disease 
activity during pregnancy in patients with rheumatoid arthritis affect bone density in their prepubertal 
offspring? Arthritis Rheumatol 2014;66:533-7.
56. Gotestam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, et al. The EULAR points 
to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann 
Rheum Dis 2016;75:795-810.
126
Chapter 6
Supplemental table 1. Detailed descriptive statistics of study population 
Prednisone (N=56) Non-prednisone 
(N=61)
Reference population 
(n=150)
Weight kg, mean (sd) 36.7 (12.5) 35.6 (12.0) 36.5 (14.1)
Weight sds, mean (sd) 0.4 (1.0) 0.5 (1.1) 0.3 (0.9)
Height cm, mean (sd) 143.2 (16.7) 142.2 (16.0) 143.6 (19.5)
Height sds, mean (sd) -0.1 (1.0) 0.1 (1.1) 0.3 (0.8)*
BMI child, mean (sd) 17.4 (2.3) 17.1 (2.7) 16.9 (2.6)
BMI child sds, mean (sd) 0.4 (0.9) 0.3 (1.2) 0.0 (1.1)*
Overweight 7 (12.5) 7 (11.5) 14 (9.3)
Systolic BP mmHg, mean (sd) 107.2 (11.5) 106.0 (11.2) -
Ratio systolic BP/height, mean (sd) 0.8 (0.1) 0.7 (0.1) -
Diastolic BP mmHg, mean (sd) 63.5 (6.8) 65.8 (8.5) -
Ratio systolic BP/height, median (sd) 0.4 (0.1) 0.5 (0.1) -
Waist circumference cm, mean (sd) 59.0 (6.8) 58.0 (8.2) 64.4 (9.2)**
Waist circumference sds, mean (sd) -0.3 (1.1) -0.5 (1.3) 0.8 (0.8)**
Hip circumference cm, mean (sd) 69.3 (9.9) 67.9 (9.6) 73.0 (10.3)**
Hip circumference sds, mean (sd) -0.4 (1.0) -0.5 (1.1) 0.3 (1.1)**
Waist-hip ratio, mean (sd) 0.9 (0.1) 0.9 (0.1) 0.9 (0.1)
Fat percentage, mean (sd) 18.5 (5.7) 19.2 (5.7) -
Fat percentage sds, mean (sd) -0.1 (1.1) 0.0 (1.1) -
Skinfolds, mm
  Biceps, mean (sd)
  Triceps, mean (sd)
  Subscapulair, median (IQR)
  Suprailiac, median (IQR)
6.2 (2.9)
9.4 (3.4)
6.0 (4.3 – 7.3) 
6.6 (5.0 – 9.3)
7.0 (3.9)
9.6 (4.0)
5.7 (5.0 – 7.7)
6.3 (4.7 – 10.0)
-
Skinfolds sds
  Biceps, mean (sd)
  Triceps, mean (sd)
  Subscapulair, median (IQR)
  Suprailiac, median (IQR)
0.4 (1.5)
0.2 (1.2) 
0.1 (-1.1 – 0.9)
-0.9 (-1.6 - -0.2)
0.8 (2.3)
0.3 (1.6)
0.0 (-0.7 – 0.7)
-1.0 (-1.6 – 0.1)
Ratio skinfolds trunk to peripheral, mean (sd) 0.9 (0.3) 1.0 (0.4) -
* p-values <0.05 **p-values <0.001, statistics were performed comparing the prednisone and non-prednisone 
group, and the prednisone and non-prednisone group together versus the reference population.
sd=standard deviation; sds=standard deviation scores; IQR=interquartile range; SES=socioeconomic status; 
BP=blood pressure; DAS28-CRP (3)=disease activity score in 28 joints using C-reactive protein levels
Journal of Rheumatology. 2018. Accepted 7
In rheumatoid arthritis fewer women 
breastfeed their off spring compared 
with women from the general 
population; results from a nationwide 
prospective cohort study
Hilal Ince-Aşkan
Johanna M.W. Hazes
Radboud J.E.M. Dolhain
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ABSTRACT
Objectives. The World Health Organization recommends to exclusively breastfeed infants 
until the age of six months. The first objective was to compare breastfeeding frequencies 
and time of cessation between women with rheumatoid arthritis (RA) and the general 
population. Second, to identify why patients with RA discontinue breastfeeding. 
Methods. This study was embedded in the Pregnancy induced Amelioration of Rheumatoid 
Arthritis study, a nationwide prospective cohort study. From 2002–2008 in total 249 
pregnancies were followed from pregnancy until 6 months postpartum. Data on lactation 
and medication use were collected. Proportion tests were used to compare percentages of 
breastfeeding between the study population and the general/reference population. 
Results. At 4-6, 12 and 26 weeks postpartum 43%, 26% and 9% of the patients with RA 
breastfed their offsprings respectively, compared with 63%, 46% and 41% in the general 
population (p-values<0.001). The main reason for women to discontinue breastfeeding was 
the restart of medication (n=129, 58.6%). Nevertheless, more than 40% of these patients 
restarted medication that was considered compatible with breastfeeding. 
Conclusions. This large prospective study demonstrates that RA is associated with lower 
proportions of women breastfeeding their offspring and earlier cessation compared with 
the general population. A considerable amount of patients discontinue breastfeeding 
so that they could start medication, despite the fact that many of the medications are 
considered safe to use during lactation. Using the results of this study, intervention strategies 
supporting patients with RA who wish to breastfeed may be developed. 
Research on the impact of pregnancy on rheumatoid arthritis (RA) and the consequences 
of RA on pregnancy has gained more and more interest in the last years. However, 
breastfeeding in patients with RA is a neglected area, since there are limited numbers of 
studies on this subject. There are no studies available that compare breastfeeding frequency 
and duration in RA with the general population Considering lactation in patients with RA, 
one prospective study, that focused on disease activity in relation with breastfeeding, 
showed worse disease activity 6 months postpartum in first-time breastfeeding women 
compared with non-breastfeeding women1. 
The World Health Organization (WHO) recommends to exclusively breastfeed infants 
until the age of six months, and to continue breastfeeding until the age of two years (or 
beyond) alongside complementary foods2. Besides being the most optimal infant nutrition 
and improving the bond between mother and child3, 4, breast milk also has other long-
term benefits2. Breastfed children have lower risk of infectious diseases5, sudden infant 
death syndrome6, asthma7, 8 obesity, high cholesterol or high blood pressure later in life9, 
10. Breastfeeding especially has major benefits for high-risk infants born prematurely5. Since 
RA may have a negative impact on pregnancy outcome11, breastfeeding might be utmost 
important for their offsprings. 
In view of the increased risk of a flare of RA within 3 months postpartum, medication is 
often restarted after delivery12. Safety data on the use of most antirheumatic drugs during 
lactation are absent or limited13. At the time this study was conducted, medication that 
was considered safe during lactation included conventional synthetic Disease Modifying 
AntiRheumatic Drugs (DMARDs) like hydroxychloroquine, sulfasalazine, and anti-
inflammatory drugs like prednisone and non-selective NSAIDs14. Drugs that were advised to 
be avoided during lactation included methotrexate (MTX) and leflunomide. Biologicals, all 
selective COX II inhibitors and azathioprine were also not recommended to be prescribed 
during lactation (at the time this study was conducted)14. 
The aims of the current prospective study were firstly to compare the frequency and 
duration of breastfeeding in women with RA with the general population. Secondly, 
to identify reasons why patients with RA discontinue breastfeeding. Finally, to identify 
clinical factors in the 3rd trimester during pregnancy associated with discontinuation of 
breastfeeding within three months postpartum. This study will help us to understand the 
impact of RA on lactation, and to develop intervention strategies to support patients with 
RA who wish to breastfeed. 
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PATIENTS AND METHODS
Study Population
The study cohort consisted of women who participated in the Pregnancy induced 
Amelioration of Rheumatoid Arthritis (PARA) study, a nationwide prospective cohort 
study from the Netherlands with an inclusion period from 2002 to 2008 (last visit in 2010), 
described in detail previously15. Patients were recruited by their rheumatologist if they met 
the American College of Rheumatology 1987 revised criteria for RA16. Inclusion was possible 
if patients had a wish to conceive, or when they were already pregnant, preferably in the 
first trimester. In total, 249 pregnancies were available for the current analysis17. 
The reference group consists of 3009 women recruited throughout the Netherlands in 
2005 for a population-based study on breastfeeding and infant formula, representative of 
the general population at that time18. Women were eligible for inclusion if their infant was 
aged 6 months or younger. 
Data collection
In the PARA-study, patients were visited by a research nurse at home preferably before 
pregnancy, three times during pregnancy and three times after the birth of the child (6, 12 
and 26 weeks). At first visit, data on demographics was collected. At all time-points a physical 
examination was performed and information on mother (e.g. disease activity, functionality, 
presence of erosions, medication) and child was collected. At the postpartum visits, data 
on child feeding was collected using questionnaires. These included questions on the start 
and duration of breastfeeding, on exclusive breastfeeding or combined with infant formula, 
or exclusively infant formula, and on the reason for discontinuing breastfeeding (restart 
of medication, maternal reasons, child related reasons, or a combination). Maternal reason 
were: no desire to, mastitis, work, too much effort, not enough milk, breast surgery. Child 
related reasons were: struggle to latch, failure to thrive, illness.
The Disease Activity Score based upon 3 variables; swelling and tenderness by palpation 
in 28 joints and a C-Reactive Protein (DAS28-CRP(3)) was used to measure RA disease 
activity19, 20. Remission was defined as a DAS28-CRP(3) <2.6, low disease activity as ≥2.6 to 
<3.2, intermediate disease activity as ≥3.2 to ≤5.1, and high disease activity as >5.115. In 
10 patients, the DAS28-CRP(3) from the third trimester was missing. Since the correlation 
between the DAS28-CRP(3) between second and third trimester was high (0.7), the DAS28-
CRP(3) was substituted with the DAS28-CRP(3) from the second trimester in these 10 
patients. 
As a measure for functionality, the conventional health assessment questionnaire (HAQ) 
score was determined using the validated Dutch translation of the Stanford HAQ, which 
considers the use of devices and aids20-22. Rheumatoid Factor (RF) and anti-citrullinated 
protein antibody (ACPA) were measured in the 3rd trimester. 
In the reference group questionnaires were used to determine among others frequency 
and duration of breastfeeding, frequency of exclusive breastfeeding or combined with 
infant formula, or exclusively infant formula. In addition, data on demographics, and labor 
and postnatal care was collected. 
Statistical Analysis
Descriptive statistics were calculated as numbers, percentages, means, medians, standard 
deviation scores (SDSs) and interquartile ranges (IQRs). Proportion tests were used to 
compare percentages of breastfeeding between the study population and the general/
reference population. Chi squared tests were used to compare frequencies between 
groups. Student’s t-tests were used to compare DAS28-CRP(3) between breastfeeding and 
non-breastfeeding patients. 
Subgroups based on birthweight were created (birthweight <2500g and ≥2500g) in 
children born to women who participated in the PARA-study. Chi squared tests were used 
to compare breastfeeding frequencies between low and normal birthweight infants. 
A multivariable logistic regression model was built for the analysis of the association 
of clinical factors in the 3rd trimester with cessation of breastfeeding within 12 weeks. 
Covariables with a p-value<0.2 in the univariable analysis were used in the multivariable 
model. After that, the model was fitted step-by-step using backwards selection of variables 
with p-values>0.2. The dependent variable was discontinuation of breastfeeding before 12 
weeks postpartum. Independent variables were the HAQ in the 3rd trimester, the autoantibody 
status, use of MTX in the past, the socioeconomic status (SES) based on education level, 
prednisone use in the 3rd trimester, sulfasalazine use in the 3rd trimester, the presence of 
erosions, the DAS28-CRP(3) in the 3rd trimester, maternal smoking periconceptional and/or 
during pregnancy, the visual analogue scale for global health (VAS GH) in the 3rd trimester, 
maternal age and parity. 
A subgroup analysis was performed including only the first participation of the patients 
in the PARA-study. Breastfeeding frequencies were once again analyzed using Chi squares 
tests, and the regression model was repeated in this group. 
Statistical significance was defined as p ≤0.05. All statistics were performed using STATA 
software version 15.1 for Windows. 
Ethics
This study is in compliance with the Helsinki Declaration. The Medical Ethics Committee at 
the Erasmus Medical Center Rotterdam, the Netherlands, approved the PARA-study (MEC-
214.320/2002/117). All participants provided written informed consent.
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RESULTS
Participants
In the PARA-study, in total 369 patients were included, which resulted in 256 successful 
pregnancies. The DAS28-CRP(3) in the second and third trimester was missing in 7 
pregnancies. After exclusion of these, in total data on 249 pregnancies from 216 women was 
available for the current analysis. Descriptive statistics of the study population are shown in 
table 1. The mean maternal age at delivery was 32.8 years and the median duration of RA 
was 4.9 years. The mean DAS28-CRP(3) was 3.4 in the third trimester. In total, 134 patients 
(53.8%) had a DAS28-CRP(3) ≥3.2 (intermediate to high disease activity) in the third trimester. 
Since the median HAQ in the third trimester was 0.75 (IQR= 0.25 – 1.25), the HAQ was 
dichotomized to a lower (<0.75) and higher (≥0.75) HAQ. This resulted in 114 patients 
(45.8%) with a lower, and 135 patients (54.2%) with a higher HAQ. 
In total, 186 (74.7%) were classified as RF and/or ACPA positive. Erosions were present in 
150 patients (60.2%). Approximately half of the patients had a high SES based on educational 
level (university of applied sciences and academic university education). In total 22 patients 
(8.8%) smoked periconceptional or during pregnancy. 
Breastfeeding during pregnancy
In total (exclusive and partial breastfeeding combined), 108 patients (43%) breastfed their 
offspring until at least 4-6 weeks, 65 (26%) until at least 12 weeks and 23 (9%) until at least 
26 weeks postpartum compared with 63%, 46%, and 41% respectively in the reference 
population (all p-values<0.001) (Table 2). In our study, breastfeeding frequency and duration 
was not different between nulliparous and multiparous patients with RA. 
Since breastmilk especially has benefits for infants with a low birth weight5, subgroups 
based on birthweight were created in the offsprings born to women with RA from the 
PARA-study, resulting in 23 infants with a birthweight <2500g and 226 ≥2500g. Only 26.1%, 
17.4% and 4.4% of the offsprings <2500g were breastfed at 4-6 weeks, 12 weeks and 26 
weeks respectively compared with 45.1%, 27.0% and 9.7% respectively in the offsprings 
with a birthweight ≥2500g (not significant). 
In total, 33 women participated more than once in this study. To exclude possible selection 
bias in the obtained results, a subgroup analysis, including only the first participation of the 
patients (n=216) was performed. Similar results in breastfeeding frequency and duration 
were obtained (data not shown). 
Table 1. Descriptive statistics of study population.*
Baseline characteristics (n=249 pregnancies)
Maternal age at delivery, mean (sd) years 32.8 (3.8)
Duration RA at baseline, median (IQR) years 4.9 (2.2 – 9.8)
DAS28 3rd trimester, mean (sd) 3.4 (1.1) 
3rd trimester DAS28-CRP# 
<2.6 72 (28.9)
≥2.6 to <3.2 43 (17.2)
≥3.2 to ≤5.1 118 (47.4)
>5.1 16 (6.4)
HAQ in 3rd trimester, median (IQR) 0.75 (0.25 – 1.25)
Parity
Nulliparous (no previous offsprings) 124 (51.5)
Multiparous (≥1 previous offspring) 117 (48.5)
RA-associated autoantibodies
Either RF or ACPA positive, or both positive 186 (74.7)
Both negative 63 (25.3)
RF positive 172 (69.1)
ACPA positive 153 (61.5)
Presence of erosions 150 (60.2)
Methotrexate use in the past 143 (57.4)
Biological agent use in the past 44 (17.7)
Medication use during 3rd trimester
Prednisone only 63 (25.3)
Sulfasalazine only 37 (14.9)
Both prednisone and sulfasalazine 22 (8.8)
Hydroxychloroquine (either alone or in combination) 4 (1.6)
No medication during 3rd trimester 123 (49.4)
SES based on educational level
Low 16 (6.4)
Middle 79 (31.7)
High 131 (52.6)
Unknown 23 (9.2)
Smoking$ 22 (8.8)
*Values are number (%) unless indicated otherwise. Normally distributed data is presented with mean (sd), not 
normally distributed data is presented with median (IQR). RA= rheumatoid arthritis; IQR= interquartile range; RF= 
rheumatoid factor; ACPA= anti-citrullinated protein antibody; DAS28-CRP(3)= disease activity score in 28 joints 
using C-reactive protein levels. 
# Disease activity groups are defined according to the European League Against Rheumatism criteria. $ Smoking 
periconceptional or during pregnancy
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Table 2. Numbers and percentages of breastfeeding women 4-6 weeks, 12 weeks and 26 weeks 
postpartum in the PARA-study and in the general population (Netherlands, 2005 18)*.
RA, PARA-study (n=249) General population (n=3009)
Total Exclusive Partial Total Exclusive Partial
4-6 weeks 108 (43)# 91 (36) 17 (7) 1896 (63)# 1625 (54) 271 (9)
12 weeks 65 (26)# 47 (19) 18 (7) 1384 (46)# 1053 (35) 331 (11)
26 weeks 23 (9)# 11 (4) 12 (5) 1233 (41)# 752 (25) 481 (16)
*Values are number (%) unless indicated otherwise. # p-value <0.001 between RA and general population
RA= rheumatoid arthritis
Table 3. Reasons for discontinuation of breastfeeding reported by the patients*.
Discontinuation < 6 
weeks postpartum 
(n=141)
Discontinuation 6 - 12 
weeks postpartum 
(n=43)
Discontinuation 
12 - 26 weeks 
postpartum (n=39)
Total 
(n=223)
Restart of medication
Total 86 (61.0) 28 (65.1) 15 (38.5) 129 (57.8)
Not compatible 51 17 8 76
Compatible 35 11 7 53
Maternal reasons 44 (31.2) 14 (32.6) 19 (48.7) 77 (34.5)
No desire to 15 . 1 16
Not enough milk 13 8 12 33
Work related . 4 3 7 
Too much effort 7 . 2 9 
Mastitis 4 1 . 5 
Breast surgery 3 . . 3 
Unknown . 1 1 2 
Child related reasons 11 (7.8) 1 (2.3) 3 (7.7) 15 (6.7)
Struggle to latch 6 . 1 7 
Failure to thrive 4 1 1 6 
Illness 1 . 1 2 
Combination of 
maternal and child 
related reasons
. . 1 (2.6) 1 (0.4)
Unknown . . 1 1
Unknown . . 1 (2.6) 1 (0.4)
*Values are number (%) unless indicated otherwise. 
Reasons for discontinuation of breastfeeding
In total, 223 patients discontinued breastfeeding over the course of 26 weeks. In 129 patients 
(58.6%), the reason for discontinuation of breastfeeding was the restart of medication 
(Table 3). From these 129 patients, in total 86 patients (61.0%) reported that the reason 
for cessation was the restart of medication before 6 weeks, 28 patients (65.1%) between 
6-12 weeks and 15 patients (41.7%) between 12-26 weeks postpartum. In 76/129 patients 
(58.9%) medication that was considered not compatible with lactation (at that time this 
study was conducted) was initiated. The other 53 patients (41.1%) received (a combination 
of ) prednisone (49.1%), sulfasalazine (39.6%), hydroxychloroquine (18.9%), and/or non-
selective NSAIDs (37.7%), all considered safe to use during lactation. 
In total, 94 patients (42.2%) reported reasons for cessation, other than the restart of 
medication. From these, the majority (n=77, 81.9%) included maternal reasons, e.g. “not 
enough milk” (35.1%) and “no desire to” (17.0%). As for child related reasons (n=15, 16.0%), 
the majority included “struggle to latch” (7.4%) and “failure to thrive” (6.4%), (see Table 3). 
In the general population (Netherlands 2000-200323), cessation due to “not enough milk” 
(including concern about the amount of milk), “problems relating to breasts and/or nipples”, 
and “health problems in the infant” were comparable with the results from this study. Work 
related cessation was reported in 7.4% of the patients in this study (in patients with reasons 
other than the restart of medication) compared with 13.9% in the general population 
(p-value<0.05)23.
As for the subgroups based on birth weight, approximately half of the patients with an 
offspring <2500g reported discontinuation due to maternal reasons and the other half due 
to restart of medication. These patients received MTX or a combination (54.5%), sulfasalazine 
or a combination (27.3%), prednisone or a combination (63.6%), hydroxychloroquine or a 
combination (18.2%), and non-selective NSAIDs or a combination (27.3%). 
Disease activity and medication use postpartum in breastfeeding and non-
breastfeeding patients
The DAS28-CRP(3) changed from 3.1 to 3.4 to 3.0 at 6, 12, and 26 weeks after delivery in 
breastfeeding and from 3.5 to 3.7 to 3.5 in non-breastfeeding patients (p value at all time 
points between the two groups < 0.05). 
Medication use postpartum is shown in table 4. Overall, patients who were not 
breastfeeding received more medication compared with patients who were breastfeeding. 
MTX and leflunomide were exclusively prescribed to non-breastfeeding patients.
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Factors in 3rd trimester associated with discontinuation of breastfeeding
within 12 weeks
For clinical purposes the HAQ in the third trimester was dichotomized at the median for 
easier interpretation (<0.75 and ≥0.75). In the univariable analyses, the HAQ, the presence 
of autoantibodies, smoking periconceptional or during pregnancy, MTX use in the past, SES 
based on educational level, prednisone use in the third trimester, the presence of erosions 
and the DAS28-CRP(3) in the third trimester were associated with discontinuation within12 
weeks (p-values<0.20) (Table 5). 
In the multivariable model, the HAQ in the 3rd trimester, the presence of autoantibodies and 
smoking were statistically significant (OR 3.7, 3.2, and 5.9 respectively, and p-values<0.001, 
0.003, and 0.032 respectively). Patients with a higher HAQ, patients who were autoantibody 
positive and patients who smoked periconceptional or during pregnancy were more 
likely to discontinue breastfeeding within 12 weeks postpartum. A lower SES based on 
educational level, prednisone use in the third trimester, MTX use in the past, the presence 
of erosions, and the DAS28-CRP(3) in the third trimester were not significantly associated 
with discontinuation within 12 weeks in the multivariable model (see Table 5). 
Patients with a HAQ ≥0.75 were more likely to restart MTX, leflunomide and biologicals at 
6 or 12 weeks postpartum compared with patients with a HAQ <0.75 (p=0.001). In addition, 
in patients with a HAQ ≥0.75 the disease activity postpartum was higher compared with 
patients with a HAQ<0.75 (DAS28-CRP(3) 3.8 vs 3.3, p-value=0.001). 
Also, patients who were autoantibody positive were more likely to restart MTX, 
leflunomide and biologicals at 6 or 12 weeks postpartum compared with patients who 
were autoantibody negative (p= 0.019). The autoantibody positive patients had higher 
disease activity postpartum compared with autoantibody negative patients (DAS28-CRP(3) 
3.7 vs 3.2, p-value<0.001). 
In the subgroup including only the first participation of the patients (n=216), similar 
results for the regression models were obtained (data not shown). 
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Table 5. 3rd trimester factors associated with discontinuation of breastfeeding within 12 weeks 
Discontinuation of breastfeeding within 12 weeks# 
Univariable Multivariable$ (n=226)
OR P- value OR P- value
HAQ 3rd trimester ≥0.75 3.121+ <0.001+ 3.669* <0.001*
Autoantibody status positive 2.649+ 0.002+ 3.210* 0.003*
Smoking% 3.841+ 0.075+ 5.902* 0.032*
MTX use in past 1.857+ 0.034+ 1.659 0.143
SES based on educational level 0.696+ 0.156+ 0.661 0.150
Prednisone use 3rd trimester 3.378+ 0.001+ 1.924 0.114
Presence of erosions 1.693+ 0.071+ - -
DAS28-CRP(3) 3rd trimester 1.305+ 0.052+ - -
Sulfasalazine use 3rd trimester 0.991 0.980
VAS GH 0.999 0.474
Maternal age 0.989 0.774
Parity ≥ 1 1.106 0.737
OR= Odds Ratio; HAQ= Health Assessment Questionnaire; MTX= methotrexate; SES= socioeconomic status; 
DAS28-CRP(3)= Disease Activity Score in 28 joints using C-reactive protein levels ; VAS GH= Visual Analogue Score 
Global Health. # Based on logistic regression $ Multivariable model after forward selection (limit for inclusion: P < 
0.20) and backward selection (limit for exclusion: P ≥ 0.20) % smoking periconceptional or during pregnancy, + 
Variables taken forward if p <0.20, * Statistically significant in the multivariable model
DISCUSSION 
In this large nationwide prospective study, we have shown that women with RA are less 
likely to breastfeed their offsprings compared with women from the reference population. 
More than half (57%) of the patients discontinue breastfeeding before 6 weeks. At 12 weeks 
only 26% of the patients were still breastfeeding (exclusively and partially combined) 
compared with 46% in the general (reference) population. At 6 months postpartum the 
difference is extremely large (9% vs 41% respectively). 
The majority of the patients reported that they had discontinued breastfeeding due to 
restart of medication. However, more than 40% of the patients ceased breastfeeding due to 
start of medication that was considered compatible with lactation, according to guidelines 
at the time this study was conducted. These drugs included prednisone, sulfasalazine, 
hydroxychloroquine, and/or non-selective NSAIDs. Cessation while using compatible 
medication was therefore not related to one specific antirheumatic drug. The only 
exception was hydroxychloroquine, which was prescribed to 4 women during pregnancy, 
and none during breastfeeding. However, due to the small numbers, a coincidence cannot 
be ruled out. This cessation of breastfeeding while using compatible medication could 
therefore perhaps be due to a general fear for taking medication when breastfeeding, a 
lack of knowledge, or generic preferences of women to not take any medication whilst 
breastfeeding. Unfortunately, in this study it was not assessed whether patients themselves 
did not feel comfortable to breastfeed when taking medication or whether this was 
discouraged by their physician. Retrospectively collecting data on this subject was not 
possible, since our study was a nationwide prospective study, and patients were recruited 
by rheumatologists from different hospitals, all over the country. In addition, we did not have 
informed consent from the patients to contact their rheumatologist to gather information 
on this subject. 
Other reasons for discontinuation included in maternal reasons, e.g. “not enough milk” 
and “no desire to”, and child related reasons e.g. “struggle to latch” and “failure to thrive”. 
Besides restart of medication, the reasons for cessation in this study were comparable 
with the general population23. Work related discontinuation of breastfeeding was reported 
in 7.7% of the patients in this study compared with 13.9% in the reference population 
(p-value=0.05). The most likely explanation for this difference is the lower proportion of 
paid employment in patients with RA24, 25. 
A higher HAQ in the third trimester, the presence of autoantibodies, and maternal 
smoking were significantly associated with discontinuation of breastfeeding within 12 
weeks. It is conceivable that the HAQ and autoantibody status is related with the severity 
of the disease. In our study population, patients with a higher HAQ and patients who were 
autoantibody positive, had a higher disease activity postpartum and were more likely to 
restart MTX, leflunomide and biologicals at 6 or 12 weeks postpartum. It makes therefore 
sense to conclude that both a high HAQ as well as autoantibody positivity identify patients 
that have a higher burden of disease and therefore are more likely to require additional 
medication postpartum, prohibiting them from breastfeeding. 
In addition, since the HAQ is a measure of functional status26 it is likely that patients 
with a higher HAQ discontinue breastfeeding due to functional impairment, either due 
to the physical difficulties associated with breastfeeding, or due to requirement of strong 
antirheumatic medications. 
Furthermore, maternal smoking was associated with early cessation of breastfeeding. 
Smoking was not related to medication use or disease activity postpartum. It is known that 
women with a lower SES are more likely to smoke during and after pregnancy, and less likely 
to breastfeed their offsprings27-31. Although breast milk loses many of its health promoting 
properties when the mother smokes during lactation, smoking mothers are advised not to 
discontinue breastfeeding32. Unfortunately, in our study the number of smoking mothers 
was too small to study associations with SES in subgroups. In addition, SES was included 
in the multivariable model, and maternal smoking was independently associated with 
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discontinuation of breastfeeding within 12 weeks, regardless of SES. Unfortunately, in our 
reference population, there was no data on smoking or SES, therefore we could not make a 
comparison with our reference group. 
In addition, RA patients with offsprings with a low birth weight also require additional 
awareness. It has been shown earlier that preterm born infants with (very) low birth 
weight benefit the most from breastmilk5. In our study cohort, 85% of the mothers with 
an offspring with a birthweight <2500g discontinued breastfeeding <6 weeks postpartum, 
while the mean DAS28-CRP(3) postpartum was comparable in both birthweight-groups 
(data not shown). Approximately half of the patients with an offspring <2500g reported 
discontinuation due to the restart of medication. According to the guidelines at the time 
this study was performed, sulfasalazine was considered not compatible with lactation in ill, 
stressed or premature infants13, 14. However, in that respect, patients receiving prednisone, 
hydroxychloroquine and non-selective NSAIDs could have continued breastfeeding. 
Unfortunately, in our reference population, there was no data on low birthweight infants, 
therefore we could not compare our data with our reference group. Limited publications 
on breastfeeding in low birth weight infants are available. In the Netherlands (2000-2003), 
50% of the infants with a birthweight ≤3000g were breastfed at 4 weeks postpartum23, 
compared with 38% in our study population (p-value=0.06). Outside the Netherlands, the 
results were not consistent. Some studies report similar numbers of lactation in low birth 
weight infants33, 34 compared with healthy infants, while others35, 36 report lower numbers. 
Another interesting finding from our study worth to mention is that, the DAS28-
CRP(3) postpartum was significantly lower in breastfeeding patients compared with non-
breastfeeding patients, despite taking less medication (when divided in breastfeeding and 
non-breastfeeding patients at every single time-point). This seems in contrast to the results 
of a previous study1 that reported that first-time breastfeeding, but not breastfeeding in 
subsequent pregnancies, was associated with significantly more increase in RA disease 
activity postpartum compared with non-breast feeders. In that study, the change in disease 
activity from third trimester to 6 months after delivery was compared and breastfeeding 
was defined as lactating for at least 4 weeks. When a similar analysis was performed in our 
study, no such association between first time breastfeeding and an increase of RA disease 
activity could be observed (data not shown). That we could not reproduce the data of 
that study might also be related to the fact that that study was performed in a different 
time period, in which one was more reluctant to treat pregnant and lactating women. In 
addition disease activity was assessed in a different way in that study compared to our 
study. Although women with less severe disease are more likely to start and continue 
breastfeeding, the results of our study do not support the hypothesis that breastfeeding 
itself causes an increase in RA disease activity1, e.g. by inducing high levels of prolactin, 
which is known to have pro-inflammatory properties. 
The results of this study will help to develop intervention strategies to support patients 
with RA who wish to breastfeed. First of all, since a large proportion of patients with RA 
do not start or continue breastfeeding for taking medication that in fact is compatible, 
education on medication use during lactation may be valuable for these patients and their 
doctors. Not only rheumatologists, but also specialized nurses, midwives, and lactation 
consultants should be trained to increase their knowledge on this subject. In addition, 
access to up-to date medication resources for patients and their clinicians (e.g. evidence 
based online databases) are required. 
Other patient groups that may benefit from targeted breastfeeding support include, 
patients with offsprings with a low birth weight, and patients who smoke. Furthermore, 
since functional impairment might influence the start and duration of breastfeeding, 
ergonomic recommendations should be provided especially to patients with a high HAQ. 
In addition, the results of this study clearly show that a substantial number of patients do 
not breastfeed because they are in need of medication that is considered not compatible 
with breastfeeding. In this respect it is important to realize that guidelines on antirheumatic 
drug prescription during lactation are often not based on proven side-effects or toxicity for 
the offspring, but based on the lack of safety data of those drugs, especially on transfer of 
medication into breastmilk13. This holds true for many medications, including methotrexate, 
one of the “cornerstones” of RA-treatment. In this respect the authors want to advocate that 
more research into his particular field is undertaken. That such research, although difficult 
to perform, is feasible, is shown by a recent study on the lack of transfer of certolizumab 
into breast milk37. 
This study has some limitations. Firstly, it was conducted approximately 10-16 years ago, 
and in time antirheumatic medication prescriptions have changed. However, we identified 
that there is a large group of patients that discontinue breastfeeding unnecessarily while 
using compatible antirheumatic drugs. This might reflect a lack of knowledge on this 
subject. It is questionable if the knowledge of doctors and nurses on this specific subject, 
and education of patients in the clinical practice has improved. Nevertheless, it would be 
interesting to perform a similar study on breastfeeding by patients with RA in this era of 
biologic therapies.
Secondly, in total, 33 women participated more than once in this study. To exclude 
possible selection bias in the obtained results, we performed a subgroup analysis, including 
only the first participation of the patients (n=216), and found comparable results in 
breastfeeding frequency and in the regression model.
In conclusion, our study demonstrates that RA is associated with lower proportions of 
women breastfeeding their offspring and earlier cessation compared with the general 
population. A considerable amount of patients discontinue breastfeeding (unnecessarily) 
so that they could start medication, despite the fact that many of the medications are 
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considered safe to use during lactation. Given the known benefits of breastfeeding on 
the offspring, more effort in education in the clinical practice and more research into the 
transfer of medication into breastmilk might enable more patients with RA to breastfeed. 
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This thesis provides more knowledge on the impact of maternal rheumatoid arthritis (RA) 
on pregnancy and outcome. Moreover, it offers useful new insights into the unresolved 
topics in patients with RA and their offsprings. In this general discussion, the findings of 
this thesis will be described as followed: new insights, clinical implications, strength and 
limitations of the studies described in this thesis, and the generalizability. This chapter ends 
with the recommendations for future research. 
NEW INSIGHTS 
RA disease activity
Although RA disease activity might improve during pregnancy, this improvement occurs less 
often and with less magnitude than previously thought 1. At the same time, female patients 
with RA (and their rheumatologists) often desire to taper medication during pregnancy. 
In addition, current guidelines advise to discontinue e.g. some biological agents during 
gestation 2, while clinical guidelines on tapering antirheumatic drugs during pregnancy 
are absent. Since RA disease activity improves in approximately half of the patients1, one 
of the aims of this thesis was to identify female RA patients who were more or less likely to 
improve during pregnancy. 
New insights on RA disease activity: 
-  The improvement of RA disease activity in one pregnancy is, in contrast to previous 
assumptions, not predictive for improvement in following pregnancies. However, a flare 
postpartum is predictive for a subsequent flare. 
-  Low RA disease activity in the first trimester, the absence of autoantibodies, and not 
using prednisone in the first trimester are associated with low disease activity and 
remission at the end of pregnancy. 
Short- and long-term consequences
It was already known that high RA disease activity might have an impact on the pregnancy 
outcome. Children born to women with active RA have a less fortunate start, with increased 
risk of lower birth weight and rapid catch-up growth in weight3, 4, both associated with an 
increased risk for cardiovascular and metabolic disease in later life5, 6. Epigenetic processes, 
like DNA methylation, are thought to be one of the mechanisms underlying the associations 
between lower birth weight and later-life health7, 8. Furthermore, animal studies have shown 
that an excess of maternal glucocorticoids during pregnancy, is associated with altered HPA 
axis activity with higher plasma cortisol levels in the offspring, higher blood pressure and 
hyperglycemia in later life9-12. Since RA may negatively impact the later-life health of the 
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offspring3, breastfeeding might be utmost important. Breastmilk is the most optimal infant 
nutrition13, 14, and has multiple benefits for the long-term health of the child15-21. 
The long-term health outcomes of children born to women with RA, were relatively 
unexplored and needed to be elucidated. Therefore, another aim of this study was to 
determine some of the short- (e.g. lactation) and long-term consequences of maternal RA, 
RA disease activity, and medication use during pregnancy on the offspring.
New insights on short- and long-term consequences: 
-  Children born to women with RA have a different DNA methylation profile compared 
with children born to mothers from the general population. The differentially methylated 
CpGs are associated with, or located near genes that are associated with cardiovascular 
and metabolic disease. 
-  Antenatal prednisone exposure and maternal RA disease activity are not associated with 
chronically elevated cortisol and cortisone concentrations, nor with an altered body 
composition or higher blood pressure in childhood. 
-  Women with RA breastfeed their offspring less and with a shorter duration compared to 
women from the general population. Notably, a considerable amount of patients with 
RA discontinue breastfeeding unnecessarily by incorrectly considering the use of some 
medication incompatible with breastfeeding.
CLINICAL IMPLICATIONS
With the findings of this thesis, new, valuable insights have been provided regarding the 
impact of RA during pregnancy on mother and child. Similar to healthy women, young 
female RA patients also desire to conceive. Nowadays, attention for care in patients with RA 
who wish to conceive is gradually increasing. 
RA disease activity
This thesis identified that there are predictive factors present before, and in early pregnancy, 
that are associated with lower disease activity at the end of pregnancy. The disease course 
in a previous pregnancy is, in contrast to previous assumptions22, not a predictor for a 
subsequent pregnancy. Therefore, it is not reasonable to rely on disease activity in a previous 
pregnancy. However it is possible to anticipate a flare after delivery based on a previous flare 
postpartum. 
This thesis did not study tapering in particular, and more research into this field is 
necessary. However, the combination of clinical factors before or in early pregnancy, that 
have been identified in this thesis, might be useful in the clinical practice for the adjustment 
of antirheumatic medication during pregnancy. Women with low disease activity in the 
first trimester are likely to maintain low disease activity or achieve remission in the third 
trimester, independent of their autoantibody status and prednisone use. In these patients 
careful tapering of antirheumatic drugs may be feasible. 
Short- and long-term consequences
This thesis has shown that offsprings born to women with RA during pregnancy have a 
different DNA methylation profile compared with children born to healthy women. Altered 
methylation is associated in other studies with cardiovascular and metabolic disease in 
adulthood 7, 8, 10, 23. In our study, some of the differentially methylated CpGs have directly been 
associated with, or are located near genes that have been associated with cardiovascular 
and metabolic disease. At the age of approximately 7, the DNA methylation profile was not 
associated with an altered body composition in our study. However, it is still possible that 
there will be consequences for these children in adulthood.
Although RA might impact the pregnancy outcome not only on short-term, but also on 
long-term, the clinical consequences for the offsprings on the long-term have not been 
demonstrated (yet). Therefore, patients may be reassured that the long-term consequences 
of maternal RA during pregnancy for their offspring are probably limited.
In addition, this study has revealed that low- dose antenatal prednisone exposure and 
maternal RA disease activity during pregnancy are not associated with chronically elevated 
cortisol and cortisone concentrations, an altered body composition, and/or a higher blood 
pressure in the offspring. Maternal prednisone use during pregnancy is associated in other 
studies with short-term effects on the pregnancy outcome, as reviewed in chapter 2 of 
this thesis. In our study we have shown that the long-term impact of low-dose antenatal 
prednisone exposure is limited. Especially in patients for whom TNF inhibitors are not 
available or not desired, treatment strategies including low-dose prednisone should be 
preferred. In addition, patients using low-dose prednisone should be reassured concerning 
the long-term consequences for their offspring. 
Regarding lactation, the results of this study revealed a largely neglected area that requires 
additional attention, where there is a considerable amount of profit that can be gained. 
In RA fewer women breastfeed their offspring compared with women from the general 
population. A significant number of patients reported discontinuation of lactation due to 
the restart of medication, while they restarted medication that was considered compatible 
with lactation at the time our study was conducted24. Breastmilk might particularly be 
beneficial for offsprings born to women with RA since breastfeeding in infancy is associated 
with e.g. a lower occurrence of cardiovascular risk factors in adulthood25. Education of RA 
patients on the safety of using various antirheumatic medication during lactation may be 
valuable and may encourage patients breastfeeding their infant for a longer period of time.
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STRENGTH AND LIMITATIONS
This thesis is based on the PARA-, FEPRA-, and HAIR-study, all nationwide prospective cohort 
studies from the Netherlands (described in more detail in the general introduction). In this 
part of the general discussion, the strength and limitations of these three studies will be 
discussed. 
General limitations 
As for all observational studies, certain limitations regarding internal and external validity 
might also apply to the studies described in this thesis. Internal validity refers to the 
strength of inferences from a study, and external validity refers to the generalizability of 
the results26. In prospective cohort studies, problems in internal validation include random 
errors, systematic errors (e.g. selection bias, information bias), and confounding. Random 
errors were strived to be limited by collecting relatively large sample sizes. Selection bias 
might have multiple causes, like a healthy worker effect or loss to follow-up. Testing the 
baseline characteristics between participants and non-participants resulted in no statistical 
differences. Information bias, for example due to interviewer or recall bias, was strived to be 
limited by using standardized protocols for data collection, standardized questionnaires, and 
trained researchers. Confounding may occur when baseline characteristics or prognostic 
factors differ between the compared groups. Even though it is difficult to eliminate all 
confounders, using a comparable control group, and correcting for possible confounders 
in the statistical models improve the internal validation of a study27. Finally, in prospective 
cohort studies exposures precede the outcome, proving a temporal sequence. However, 
this does not automatically prove a causal relationship. Therefore, careful interpretation of 
the results is important. 
PARA-study
The PARA-study was the first large nationwide prospective cohort study on the impact of 
pregnancy on RA, and the impact of RA on the pregnancy outcome.
The main strength of the PARA-study is that all pregnancies in this large cohort were 
prospectively followed from conception (if possible) until 26 weeks postpartum. Patients 
were visited at their home address, increasing the compliance, resulting that in majority 
of the patients all visits were completed. The visits were performed by the same research 
assistants, limiting variations in measurements. Another strength is that in the PARA-study the 
RA disease activity was calculated using the DAS28-CRP with 3 variables, which is considered 
to be the most reliable scoring method for RA disease activity during pregnancy 28. 
The main limitation of the PARA-study is that the study was conducted a decade ago, 
when TNF inhibitors were not prescribed during pregnancy. Participants of the PARA-study 
only used prednisone, sulfasalazine, and hydroxychloroquine during pregnancy. Another 
limitation was that, in the PARA-study, patients were enrolled between 2002 and 2008, 
when American College of Rheumatology (ACR) 1987 revised criteria for RA29 applied. 
However, in the past decade, the ACR/ European League Against Rheumatism (EULAR) 
2010 classification criteria for RA were introduced 30, resulting in earlier diagnosis. The 2010 
criteria have a higher sensitivity and a lower specificity compared with the 1987 criteria31, 32, 
and approximately 90% of the patients of the patients that fulfill the 1987 criteria, also fulfill 
the 2010 criteria32. Therefore, the vast majority of the PARA-participants will probably fulfill 
the 2010 criteria. 
FEPRA-study
For the FEPRA-study, a few years later, patients were asked to visit the Sophia Children’s 
Hospital in Rotterdam once with their children. This study focused on the long-term 
consequences of maternal RA during pregnancy on the offspring. During this visit, in all 
children, anthropometrics were measured and a Dual-Energy X-ray Absorptiometry (DXA)-
scan was performed. In addition, saliva and fasting blood samples were collected.
The main strength of the FEPRA-study was that the study population was a relatively 
large and unique cohort of children born to women with RA, who were followed in a large 
prospective study before, during and after their pregnancy. 
The main limitation of the FEPRA-study was that only 55% of the PARA-study participants 
agreed to participate with the FEPRA-study. The majority of the patients declined 
participation due to the distance to the hospital. Nevertheless, there was no statistical 
difference in independent variables between the participating and non-participating 
group, decreasing the likelihood of selection bias. 
HAIR-study
A few years later, PARA- study participants were approached once more to participate in 
another follow-up study with their children, the HAIR-study. In this study, children between 
the age of 5 and 16 were included to study the effects of antenatal prednisone exposure. 
Participants throughout the Netherlands were visited at their home address where a tuft of 
hair from the children and anthropometric data from children were collected. 
The main strength of the HAIR-study was that this was again a relatively large follow-
up study of a previous large prospective cohort study. In addition, in this study, scalp hair 
was used to measure long-term steroid levels, which is considered to be the most reliable 
method. 
The main limitation of the HAIR-study was that only 117 (46.4%) from the invited patients 
agreed to participate with their child. The main reason for refusing participation was that 
the parents were “tired” of participating in studies, and that they felt that the investigations 
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were too much of a burden for their child. However, there were nog significant differences 
in baseline characteristics between participants and non-participants. Therefore it is unlikely 
that selection bias influenced the results of this study. 
GENERALIZABILITY
After summarizing the most important findings of this thesis and discussing the 
strength and limitations of our studies in the preceding sections, it is necessary to look 
into the generalizability of our results. Medical research is mostly performed to increase 
knowledge about a disease and to improve patient care by using the results. Research 
findings should be implemented into the daily practice to improve patient care. In order 
to achieve implementation, the generalizability of the results is essential. As for our study, 
not only the generalizability of the results to RA patients from the general population, but 
also generalizability of the results to patients with other autoimmune diseases is utmost 
important. 
Since our studies were nationwide, and patients were included from both urban and 
rural areas, and from every socioeconomic status, we think that the majority of the results 
are generalizable to female patients with RA in the Netherlands. 
However, there are some differences between our study and the current practice. First, 
our study population consisted of female RA patients who fulfilled the ACR 1987 revised 
criteria, while currently the ACR/EULAR 2010 criteria are applied. Nevertheless, as mentioned 
before, this probably did not influence the results of this thesis. 
Second, at the time our study was conducted, TNF inhibitors were not prescribed to 
RA patients during pregnancy, and TNF inhibitors were not considered compatible 
with lactation. Therefore, we cannot draw any conclusions on the short-and long-term 
consequences of TNF inhibitors on the offspring.
This study does not only provide useful insights for female patients with RA, but also for 
female patients with other rheumatic diseases who wish to conceive. Juvenile idiopathic 
arthritis (JIA) is a pediatric rheumatic disease with an onset in childhood33. In majority of these 
patients, the disease remains active until adulthood34. Although JIA is a more heterogeneous 
autoimmune disease than RA, the pathological basis of these two disease share similarities 
(especially with polyarticular JIA)35. Psoriatic arthritis (PsA) has a peak prevalence between 
the age of 40 and 50 years, however, the disease may also occur in younger patients36. 
Even though there are substantial differences in the pathogenesis of PsA and RA37, in 
both diseases the pathophysiology involves a chronic inflammation mediated by pro-
inflammatory cytokines38. As both JIA and PsA patients share common pathophysiological 
mechanisms and have comparable treatment options during pregnancy, it is plausible that 
the results of our study on short-and long-term consequences for the offspring are also 
useful for these patients. 
In addition, the generalizability of our study is not limited for patients with rheumatic 
diseases, but extends to female patients with other autoimmune diseases who wish to 
conceive, and for patients who use corticosteroids during pregnancy. Female patients with 
an inflammatory bowel disease (IBD) are an excellent example of patients that can also 
benefit from this research. IBD has a high prevalence in women of childbearing age39, and 
shares common pathogenic mechanisms with rheumatic diseases. IBD treatment during 
pregnancy is also comparable with the treatment of RA during pregnancy, including the 
use of corticosteroids. Therefore, the results of our studies may also be valuable for IBD 
patients. 
RECOMMENDATIONS FOR FUTURE RESEARCH BASED ON THIS THESIS
This thesis has revealed several important associations between maternal RA during 
pregnancy and short- and long-term consequences for mother and child. However, there 
still is a lack of prospective studies on this subject. The results from this thesis highlight the 
importance of conducting more studies to evaluate the impact of RA during pregnancy on 
mother and child. Several recommendations for future research, that are derived from our 
results, are discussed below. 
In the current era, treat-to-target approaches are applied for the treatment of RA (not 
necessarily during pregnancy) 40. Furthermore, treatment guidelines for patients with RA 
during pregnancy include the use of TNF inhibitors 2. Prospective follow-up studies of 
pregnant patients using TNF inhibitors during pregnancy and their offsprings are upcoming. 
However, studies on long-term consequences for the offspring are lacking. First of all, future 
studies could reveal whether more intensive antirheumatic treatment before and during 
pregnancy may lead to improved pregnancy outcomes. Another recommendation for 
future research include studying the long-term consequences of antenatal exposure to TNF 
inhibitors, such as differential DNA methylation.
In 2016, a EULAR task force has reported points to consider for use of antirheumatic drugs 
before pregnancy, during pregnancy, and during lactation2. However, clinical guidelines on 
tapering medication during pregnancy in patients with RA are lacking. This thesis provides 
clinical characteristics at the beginning of pregnancy that are associated with low disease 
activity or remission in the third trimester. It will be interesting to perform a prospective 
study on tapering medication in pregnant patients with RA, using the characteristics that 
have been defined in this thesis. With the results of that prospective study, guidelines on 
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tapering antirheumatic drugs during pregnancy may be developed. Subsequently, it would 
be interesting to observe the results of these guidelines.
Educating physicians in the most optimal way into the subject of pregnancy and lactation 
in patients with RA will be challenging. More research is necessary in order to develop 
guidelines for the management of RA during pregnancy that are applicable in different 
countries around the world. To guarantee successful implementation of these guidelines, it 
is also recommended to study the most optimal implementation technique. Subsequently, 
it would be interesting to observe the results of these guidelines.
Although our study on DNA methylation in children born to women with RA was in its 
kind a relatively large study, an epigenetic study in 80 children (and 354 controls) is still 
small. Nevertheless, we did find 147 CpGs that were significantly different between children 
born to women with RA and children born to women from the general population. A 
recommendation for future research is to replicate our findings in another cohort of children 
born to women with RA. In addition, even though we had enough power to find differences 
between the two groups, our study did not have enough power to relate the differences 
to RA disease activity and/or medication use. An international collaboration will result in a 
study with a larger population of children born to women with RA (or other autoimmune 
disease). 
This thesis has revealed that maternal prednisone use and maternal RA disease 
activity is not associated with impaired HPA axis activity or an altered body composition 
in approximately 10-years-old offsprings. However, it might very well be possible that 
at this age the children are too young to draw any definite conclusions on their risk of 
cardiovascular disease in adulthood. This thesis has shown that children born to women 
with RA have significant differences in the methylation of CpGs that are located near genes 
associated with cardiovascular and metabolic disease. Therefore, another suggestion for 
further research is to continue the follow-up of these children until early adulthood to 
assess their risk of cardiovascular and metabolic disease, preferably in relation to the disease 
activity during pregnancy and medication use.  
Finally, although somewhat outside of the scope of this thesis, studies on male patients 
with RAin the fertile age are lacking. Studies on RA disease activity and medication use in 
male RA patients who try to conceive may elucidate the impact of paternal RA on pregnancy 
and the pregnancy outcome. 
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Summary
Rheumatoid arthritis (RA) is a common disease, also affecting women in the childbearing 
age. It was already known that high RA disease activity and prednisone use influence 
the pregnancy outcome. However, it was not known which women were prone to have 
high disease activity during pregnancy and what kind of impact this might have on the 
offsprings. Therefore, the aims of this thesis were to identify clinical factors associated 
with improvement of the disease activity during pregnancy, and to identify the possible 
short- and long-term consequences of RA, RA disease activity and prednisone use on the 
offsprings. 
Chapter 1
This chapter introduces the topics explored in this thesis. It provides an overview of 
RA in general, during pregnancy, and during lactation. Furthermore, it describes the 
developmental origins of health and disease (DOHaD) hypothesis, explaining the lifelong 
consequences of adverse circumstances during pregnancy on the offspring. In addition, 
it gives an overview of the role of cortisol and the importance of epigenetics within this 
subject. Finally the designs of the PARA, FEPRA, and HAIR-study are described. 
Chapter 2
In this chapter, multiple aspects on RA and pregnancy are reviewed. It describes among 
others, fertility in patients with RA, the RA disease course during and after pregnancy, 
pregnancy outcomes, effects on the offspring. In addition, it reviews the pathogenic 
mechanism underlying the improvement of RA during pregnancy, and the treatment of RA 
during pregnancy. Finally, it provides practical approaches to patients with RA who wish to 
conceive. 
Chapter 3
This chapter illustrates the RA disease activity during and after two subsequent pregnancies. 
The course of the RA disease activity (improvement, deterioration, or a combination) during 
a first pregnancy was not associated with the disease course in a second pregnancy. 
However, a flare postpartum after a first pregnancy was associated with a subsequent 
flare. Therefore, in a subsequent pregnancy, treatment should not be based on the disease 
course in a previous pregnancy. However, a deterioration of the disease activity postpartum 
may be anticipated based on a previous flare. 
Chapter 4
The objective of this chapter was to determine a combination of clinical factors at the 
beginning of pregnancy, associated with low disease activity and remission of RA in the 
third trimester during pregnancy. RA patients who had a low disease activity in the first 
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trimester (irrespective of autoantibody status or prednisone use) were likely to have low 
disease activity or remission in the third trimester. Women with higher disease activity in the 
first trimester who were taking prednisone and/or expressed autoantibodies were less likely 
to have low disease activity and remission in the last trimester. In addition, RA patients with 
higher disease activity who were not taking prednisone and did not express autoantibodies, 
still had a fair chance for low disease activity in the third trimester. These findings may be 
useful for daily clinical practice, or for future studies. 
Chapter 5
Epigenetics are thought to be one of the mechanisms underlying the earlier mentioned 
DOHaD hypothesis. DNA methylation is an epigenetic modification, which can be defined 
as tissue specific changes in DNA without changing the underlying DNA sequence. Changes 
in DNA methylation may result in altered gene expression. DNA methylation occurs at 
cytosine (C) bases where they are located near guanine (G) bases with a phosphate (p) 
group in the middle. These sites where methylation is measured are called CpGs. 
This chapter investigates the influence of maternal RA during pregnancy on the DNA 
methylation profile of their offspring. Children born to women with RA had a different DNA 
methylation profile compared with children born to mothers from the general population. 
In total 147 CpGs were significantly different between these groups. From the top 5 CpGs, 
2 were associated in another study with myocardial infarction. Other significant CpGs were 
located near genes that are associated with e.g. cardiovascular and metabolic disease. 
These findings support the hypothesis that RA during pregnancy might have life-long 
consequences for the offspring. 
Chapter 6
In this chapter the long-term consequences for children of maternal prednisone use and 
RA disease activity during pregnancy were studied. Antenatal prednisone exposure and RA 
disease activity were not associated with chronically elevated cortisol and cortisone levels 
in children born to women with RA. In addition, antenatal prednisone exposure and RA 
disease activity were not associated with an altered body composition or a higher blood 
pressure in childhood. These findings are reassuring for women who use prednisone during 
pregnancy and their doctors. 
Chapter 7
This chapter focusses on lactation in female patients with RA. Women with RA breastfeed 
their offspring less often and with a shorter duration compared with women from the 
general population. The main reason of discontinuation was the restart of medication, 
however half of these patients discontinued unnecessarily since they restarted medication 
that was considered compatible with lactation. In addition, a worse functional status 
expressed by a higher HAQ, the presence of autoantibodies, and smoking were associated 
with discontinuation of breastfeeding within 12 weeks postpartum. Education of patients, 
doctors, and nurses on the use of medication during lactation might enable more patients 
to breastfeed their offspring for a longer period of time. 
Chapter 8
Finally, in this chapter, the general discussion, the new insights based on the findings in this 
thesis, and the clinical implications are described. Furthermore, the strength and limitations 
of the PARA, FEPRA, and HAIR-study, and the generalizability of the results are discussed. 
This chapter ends with the recommendations for future research, based on the findings in 
this thesis.
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Reumatoïde artritis (RA) is een veelvoorkomende ziekte, waar ook vrouwen in de vruchtbare 
leeftijd al aan kunnen lijden. Uit eerder onderzoek is gebleken dat een hoge ziekteactiviteit 
van RA en het gebruik van prednison door de moeder tijdens de zwangerschap invloed 
hebben op de zwangerschapsuitkomsten. Echter, is het nog niet onderzocht welke vrouwen 
meer kans hebben op lage of hoge ziekteactiviteit gedurende de zwangerschap en wat 
de impact hiervan kan zijn op hun kinderen. Daarom heeft dit proefschrift als doelen: het 
identificeren van klinische factoren die geassocieerd zijn met de activiteit van RA tijdens de 
zwangerschap en het identificeren van de mogelijke korte en lange termijn gevolgen van 
het hebben van RA, de ziekteactiviteit van RA en het effect van het gebruik van prednison 
tijdens de zwangerschap op de kinderen. 
Hoofdstuk 1
Dit hoofdstuk introduceert de onderwerpen die onderzocht zijn in dit proefschrift. Het 
geeft een overzicht van RA in het algemeen, RA gedurende de zwangerschap en RA tijdens 
het geven van borstvoeding. Daarnaast worden in dit hoofdstuk de behandelopties van RA 
tijdens de zwangerschap en tijdens het geven van borstvoeding besproken. Vervolgens 
wordt in hoofdstuk 1 de “developmental origins of health and disease” (DOHaD) hypothese 
beschreven, welke een verklaring geeft voor de levenslange gevolgen op de kinderen van 
bepaalde omstandigheden gedurende de zwangerschap . Volgens deze hypothese, kan 
blootstelling aan meerdere ongunstige omstandigheden in de baarmoeder leiden tot 
hart- en vaatziekten en metabole ziektes (zoals bijvoorbeeld diabetes mellitus type 2) in 
het latere leven. Hoofdstuk 1 licht ook de rol van het stress-hormoon cortisol en het belang 
van epigenetica als mogelijke verklaring voor de DOHaD hypothese toe. Tenslotte wordt de 
opzet van de PARA, FEPRA en HAIR studie beschreven. 
Hoofdstuk 2
In dit hoofdstuk worden meerdere aspecten van RA en zwangerschap besproken. Het 
beschrijft onder andere de vruchtbaarheid van patiënten met RA, vrouwen met RA 
doen er langer over om zwanger te worden dan gezonde vrouwen. Daarnaast wordt het 
beloop van de RA ziekteactiviteit gedurende en na de zwangerschap besproken. Tijdens 
de zwangerschap verbetert de ziekteactiviteit, maar in minder vrouwen en in mindere 
mate dan op basis van eerder onderzoek werd gedacht. Na de bevalling verslechtert de 
ziekteactiviteit in de meerderheid van de RA patiënten. In hoofdstuk 2 worden ook de 
zwangerschapsuitkomsten van vrouwen met RA beschreven. Volgens sommige studies 
hebben vrouwen met RA een iets verhoogde kans op zwangerschapsvergiftiging tijdens 
de zwangerschap. Ook is een hoge ziekteactiviteit van de RA geassocieerd met een grotere 
kans op een keizersnede en is het gebruik van prednison geassocieerd met vroeggeboorte 
van het kind. Verder hebben kinderen van moeders met RA een lager geboortegewicht, 
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ook wanneer dit gewicht gecorrigeerd wordt voor de duur van de zwangerschap. 
Hoofdstuk 2 geeft ook een overzicht van de pathogenetische mechanismen die ten grondslag 
liggen aan de verbetering van RA gedurende de zwangerschap, zoals veranderingen in de 
hormonen, de aanwezigheid van autoantilichamen en de samenstelling van afweercellen. 
Vervolgens beschrijft het de behandelopties van RA tijdens de zwangerschap. Tot slot 
geeft het praktische tips voor de behandeling en begeleiding van vrouwen met RA die een 
zwangerschapswens hebben. 
Hoofdstuk 3
Dit hoofdstuk beschrijft het beloop van de ziekteactiviteit van vrouwen met RA die 
tijdens twee opeenvolgende zwangerschappen zijn vervolgd. Tijdens de zwangerschap 
kan de ziekteactiviteit van RA spontaan verbeteren. In oudere studies is aangetoond dat 
verbetering van de ziekteactiviteit in een eerste zwangerschap voorspellend is voor de 
verbetering in een volgende zwangerschap. Echter, is de informatie over de ziekteactiviteit 
in deze studies retrospectief verzameld en zijn subjectievere maten gebruikt om de 
ziekteactiviteit te meten. Hoofdstuk 3 geeft de resultaten weer van onderzoek naar 27 
vrouwen die tijdens en na 2 zwangerschappen prospectief gevolgd zijn en waarbij de 
ziekteactiviteit objectief is gemeten. De resultaten laten zien dat het beloop van de 
ziekteactiviteit van RA (dat wil zeggen een verbetering, verslechtering of een combinatie 
hiervan) gedurende een eerste zwangerschap niet voorspellend is voor het ziektebeloop in 
een tweede zwangerschap. Echter, een opvlamming van de ziekteactiviteit na een eerste 
zwangerschap is wel gerelateerd aan een opvlamming na een volgende zwangerschap. In 
een volgende zwangerschap moet de behandeling daarom niet gebaseerd worden op het 
ziektebeloop in een eerdere zwangerschap. Echter, er kan wel geanticipeerd worden op een 
verslechtering van de ziekteactiviteit na de bevalling op basis van een eerder opvlamming. 
Hoofdstuk 4
Het doel van dit hoofdstuk is om te bepalen of een combinatie van klinische factoren in 
het begin van de zwangerschap, geassocieerd is met een lage ziekteactiviteit of remissie 
van RA in het derde trimester van de zwangerschap. Zoals eerder beschreven, verbetert de 
ziekteactiviteit van RA in een deel van de patiënten spontaan tijdens de zwangerschap. Het 
is echter nog niet bekend in welke vrouwen de kans het grootst is dat de ziekteactiviteit 
verbetert. In hoofdstuk 4 beschrijft vrouwen die tijdens en na 190 zwangerschappen zijn 
gevolgd. De volgende klinische factoren zijn onderzocht in de statistische analyses: de 
ziekteactiviteit van RA in het 1ste trimester, het gebruik van prednison in het 1ste trimester, 
het gebruik van sulfasalazine in het 1ste trimester, pariteit, het gebruik van methotrexaat in 
het verleden, de aanwezigheid van autoantilichamen, de aanwezigheid van erosies en de 
duur van de RA.
De resultaten laten zien dat RA patiënten met een lage ziekteactiviteit in het eerste trimester 
meer kans hebben op lage ziekteactiviteit of remissie in het derde trimester. Dit effect is 
onafhankelijk van de aanwezigheid van autoantilichamen en het gebruik van prednison. 
Bovendien, vrouwen met een hogere ziekteactiviteit in het eerste trimester die prednison 
gebruiken en/of autoantilichamen in het bloed hebben, hebben minder kans op een lage 
ziekteactiviteit of remissie in het derde trimester. Daarentegen, vrouwen met een hogere 
ziekteactiviteit die geen prednison gebruiken en geen autoantilichamen in het bloed 
hebben, hebben toch een redelijke kans op een lage ziekteactiviteit of remissie in het derde 
trimester. Deze bevindingen kunnen nuttig zijn in de dagelijkse praktijk en in toekomstige 
onderzoeken. 
Hoofdstuk 5
Dit hoofdstuk onderzoekt de invloed van RA van de moeder op de epigenetische 
veranderingen in het kind. Epigenetica wordt beschouwd als één van de onderliggende 
mechanismen van de eerder genoemde DOHaD hypothese. DNAmethylatie is een 
epigenetische verandering, welke beschreven kan worden als weefsel specifieke 
aanpassingen in het DNA zonder daarbij aanpassingen te doen in de onderliggende 
DNA code. Hierdoor kunnen modificaties in de DNAmethylatie leiden tot een veranderde 
genexpressie. DNAmethylatie vindt plaats in cytosine (C) basen, daar waar ze gelokaliseerd 
zijn naast guanine (G) basen met een fosfaat (p) groep tussenin. Deze locaties worden CpGs 
genoemd en op deze locaties kan de hoeveelheid methylatie gemeten worden. 
In dit hoofdstuk zijn 80 kinderen, op een leeftijd van ongeveer 6-7 jaar, van moeders met 
RA vergeleken met 345 kinderen van moeders uit de algemene populatie. Dit onderzoek 
werd prospectief uitgevoerd. De resultaten van dit onderzoek laten zien dat kinderen van 
moeders met RA een ander methylatie profiel hebben dan kinderen van moeders uit de 
algemene populatie. In totaal zijn 147 CpGs significant anders tussen de 2 vergeleken 
groepen. Van de 5 meest significante CpGs zijn er 2 die in een andere studie geassocieerd 
zijn met het optreden van een hartinfarct. Andere significante CpGs zijn gelokaliseerd in 
of nabij genen die geassocieerd zijn met hart- en vaatziekten en metabole ziektes (zoals 
bijvoorbeeld diabetes mellitus type 2). Deze bevindingen ondersteunen de hypothese dat 
RA tijdens de zwangerschap levenslange gevolgen zou kunnen hebben op de gezondheid 
van het kind. 
Hoofdstuk 6
In dit hoofdstuk worden de lange termijn gevolgen van het gebruik van prednison door 
de moeder en de ziekteactiviteit van RA tijdens de zwangerschap voor hun kinderen 
bestudeerd. Het gebruik van prednison werd geobjectiveerd door gebruik te maken van 
cortisol en cortison concentraties (cortison is de inactieve vorm van cortisol). Cortisol heeft 
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een belangrijke rol in de DOHaD hypothese. Voor dit onderzoek zijn in totaal 56 kinderen 
met blootstelling aan prednison en 61 kinderen zonder blootstelling aan prednison tijdens 
de zwangerschap geïncludeerd. Cortisol en cortison zijn gemeten in het haar, dit is een 
betrouwbare methode voor het meten van lange termijn concentraties. De resultaten laten 
zien dat blootstelling aan prednison in de baarmoeder (dit wordt antenatale blootstelling 
genoemd) en de ziekteactiviteit van RA van de moeder tijdens de zwangerschap niet 
geassocieerd zijn met chronisch verhoogde waardes van cortisol en cortison concentraties 
in het haar van kinderen van moeders met RA. De cortisolwaardes in het haar van kinderen 
van moeders met RA zijn vergelijkbaar met haar cortisolwaardes in kinderen uit de algemene 
populatie. 
Bovendien zijn antenatale blootstelling aan prednison en ziekteactiviteit van RA niet 
geassocieerd met een andere lichaamssamenstelling (bijvoorbeeld een hoger BMI of een 
hoger vetpercentage) of een verhoogde bloeddruk op kinderleeftijd. Deze bevindingen 
zijn geruststellend voor vrouwen die prednison gebruiken tijdens de zwangerschap en hun 
behandelende artsen. 
Hoofstuk 7
Dit hoofdstuk focust op het geven van borstvoeding in vrouwen met RA. De World Health 
Organisation (WHO) adviseert moeders om hun kind minimaal 6 maanden uitsluitend 
borstvoeding te geven en borstvoeding te blijven geven tot minimaal het 2e levensjaar. 
Borstvoeding heeft vele voordelen voor zowel moeder als kind. Moedermelk is het optimale 
voedingsmiddel voor zuigelingen en het versterkt de band tussen moeder en kind. Daarnaast 
heeft moedermelk meerdere immunologische en metabole voordelen voor het kind. Deze 
voordelen zijn het grootst bij kinderen met een laag geboortegewicht. Bij moeders met RA 
worden baby’s vaker met een lager gewicht geboren, dus in deze groep zou borstvoeding 
een toegevoegde waarde kunnen hebben. Uit hoofdstuk 7 blijkt dat moeders met RA minder 
vaak beginnen met het geven van borstvoeding aan hun kind. Bovendien geven zij minder 
lang borstvoeding dan vrouwen uit de algemene populatie. Eén maand na de bevalling 
geeft 43% van de vrouwen met RA borstvoeding tegenover 63% van de vrouwen uit de 
algemene populatie. Na 3 maanden geeft 26% van de moeders met RA nog borstvoeding 
versus 46% van de moeders uit de algemene bevolking. Na 6 maanden is dit gedaald tot 
9% van de moeders met RA versus 41% van de moeders uit de algemene bevolking. Een 
andere belangrijke bevinding is dat ongeveer 60% van de moeders met RA aangeeft dat ze 
zijn gestopt met het geven van borstvoeding om te kunnen starten met het gebruik van 
RA medicatie. Echter, bleek dat bijna de helft van deze vrouwen onnodig de borstvoeding 
had gestaakt, omdat de medicatie die zij herstartten veilig wordt geacht tijdens het geven 
van borstvoeding. Andere mogelijke redenen van staken van borstvoeding, zoals “geen zin”, 
“niet genoeg melk”, “moeite met aanleggen” zijn vergelijkbaar met de algemene populatie. 
Gezien de voordelen van borstvoeding is er dus gezondheidswinst te boeken door artsen, 
verpleegkundigen en door patiënten meer educatie aan te bieden ten aanzien van het 
geven van borstvoeding in combinatie met het gebruik van medicatie. 
Hoofdstuk 8
Tot slot worden in dit hoofdstuk, de algemene discussie, de nieuwe inzichten gebaseerd 
op dit proefschrift en de klinische implicaties hiervan beschreven. Bovendien worden de 
krachten en beperkingen van de PARA, FEPRA en HAIR-studie besproken. Daarnaast wordt 
de generaliseerbaarheid van de bevindingen bediscussieerd. Dit hoofdstuk eindigt met 
de aanbevelingen toekomstig onderzoek welke gebaseerd zijn op de bevindingen uit dit 
proefschrift.
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Starting strong is good, finishing strong is epic - R. Sharma
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grote passie begon ik aan dit project en met grote voldoening ben ik dit dankwoord aan 
het schrijven. Een promotietraject doorloop je niet alleen. Dit is dan ook het gedeelte van 
mijn proefschrift waarin ik iedereen die betrokken is geweest mag bedanken. Het schrijven 
van mijn dankwoord was bijna net zo moeilijk als het uitleggen aan familie en vrienden dat 
promoveren toch echt iets anders is dan studeren.
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Allereerst wil ik graag alle patiënten en hun kinderen bedanken voor het deelnemen aan 
onze studies. Jullie bijdrage was essentieel. Bedankt voor jullie tijd, moeite, interesse en 
vertrouwen in onze onderzoeken.
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supervisie, hulp en geduld gedurende dit project. Ik heb heel veel van jou geleerd. Ik 
bewonder je passie voor je werk en je expertise in zwangerschap en reumatische ziekten. 
Je had een duidelijke visie voor mijn promotietraject en daar week je niet van af. Dankzij 
jouw leuke en grappige verhalen waren onze werkbesprekingen altijd gezellig. Je had altijd 
tijd voor me en soms luisterde je ook echt naar me. Je was betrokkenen en toch gaf je mij 
voldoende ruimte om mijn eigen gang te gaan. Bedankt dat je vertrouwen in mij had en 
bedankt dat je zo geduldig bleef toen ik je onder druk zette om mijn promotietraject af te 
ronden.
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Jullie oprechte liefde voor mij, Sebati en Milhan is onmiskenbaar. 
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alle offers die jullie hebben gebracht. Jullie mogen heel trots zijn op jullie zelf, nog trotser 
dan dat jullie op mij zijn! Het is daarom ook vanzelfsprekend dat ik mijn proefschrift aan 
jullie heb opgedragen. 
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Mijn speciale dank gaat uit naar mijn dierbare zusje, mijn allerbeste vriendin. Je hebt mij 
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mijn presentaties. Niets was teveel voor je. Er zijn niet genoeg woorden om mijn liefde en 
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And when I’m losing all my energy
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Sebati, sevdiceğim, canyoldaşım. Ik kan me niet voorstellen dat ik zoveel had kunnen bereiken 
in mijn carrière zonder jouw steun en aanmoediging. Jouw bijdrage aan dit proefschrift is 
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jaren veel werk uit mijn handen en gaf mij de ruimte om in alle rust mijn promotietraject af 
te ronden. Naast dat je een geweldige partner bent, ben je een fantastische vader voor ons 
wondertje en een groot voorbeeld voor de rest van zijn leven. Ik kijk uit naar onze toekomst 
en kan niet wachten om de hele wereld samen met jou te ontdekken. SSÇ!
Your little hands wrapped around my finger
And it’s so quiet in the world tonight
Milhan Elyesa, en değerlim, kıymetlim, can parçam, gözümün nuru, kabul olmuş duam, 
Rabbimin en güzel hediyesi, cennet kokulum. Dankzij jou weet ik wat onvoorwaardelijke 
liefde betekent. Ik hou oneindig veel van jou! Na een dag hard werken verdwijnt al mijn 
vermoeidheid bij het zien van jouw mooie lach en voel ik me weer helemaal goed. Bedankt 
dat je bent zoals je bent; vrolijk, lief en dol op mij! Ik hoop dat je later heel trots op je mama 
kan zijn. Ik ben nu al heel trots op jou.

